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Mitochondria continuously undergo changes in their morphology by two dynamic 
processes called mitochondrial fusion and mitochondrial fission. Mitochondrial fusion 
results in longer mitochondria and is important for the complementation of mtDNA and 
intermixing of essential mitochondrial proteins and nutrients to maintain healthy 
mitochondrial population. Mfn1 and Mfn2 are involved in outer mitochondrial 
memebrane fusion while OPA1 mediates inner mitochondrial membrane fusion. On the 
other hand, mitochondria are broken into smaller units for easy transport and removal of 
damaged mitochondria by Drp1. Defective mitochondrial dynamics has been linked 
with various common neuropathies and neurodegenerative diseases. Charcot Marie 
Tooth Type 2A (CMT2A) and its subtype Hereditary motor and sensory neuropathy 
type VI (HMSNVI) are caused by mutations in Mfn2 and result in progressive loss of 
distal motor and sensory neurons of peripheral nervous system. However, the 
pathomechanism of Mfn2 mutations and specific degeneration of peripheral motor and 
sensory neurons is still unclear. In the PhD, I studied the mitochondrial morphology in 





showed fragmented mitochondria with reduced 
mitochondrial aspect ratio, length, branching and networks. However, CMT2A patients 
carrying Mfn2
Q674P
 mutation showed normal mitochondrial morphology. The second 
part of project involved characterising the effect of mitochondrial fusion inducing 
compound Ethacrynic acid (EA) in various cellular assays. Our results showed that EA 
increases mitochondrial fusion in PEG fusion assay and in CV14A cells overexpressing 
Fis1. EA also showed reduced number of fragmented mitochondrial morphology in 
Mfn2
R364W
 patient fibroblasts. Third part of project involved the characterisation of 
Drosophila melanogaster mitochondrial assembly regulatory factor (Marf) and its role 
in fly development, locomotion and mitochondrial morphology in motor neurons. Our 
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Mitochondria are crucial for numerous cellular processes including energy metabolism, 
programmed cell death, cell signalling and metabolic pathways involving iron, lipids 
and amino acids. Over 1.5 billion years ago mitochondria evolved from a symbiotic 
relationship between free living aerobic α-proteobacteria and primitive eukaryotic cell 
(Bereiter-Hahn, 1990; de Duve, 2007). Majority of bacterial chromosome got 
incorporated in the genome of host eukaryotic cell but each mitochondrion also contains 
a few copies of the remnant chromosomes known as mtDNA (de Duve, 2007). 
Mitochondria are double membranous organelles consisting of the outer membrane and 
the inner membrane (Bereiter-Hahn and Voth, 1994). Mitochondrial inner membrane 
forms folding structures known as cristae that hold two aqueous compartments, the 
intermembrane space and the matrix. Mitochondria being the power house of the cell 
generate ATP through the Kreb’s cycle in the matrix and oxidative phosphorylation 
across the inner mitochondrial membrane (Bereiter-Hahn, 1990; Bereiter-Hahn and 
Voth, 1994).  
1.1 Mitochondrial dynamics 
Initially, mitochondria were described as isolated membranous granular 
cytoplasmic compartments, however later it was found that mitochondria have a 
dynamic nature and show distinct morphologies (Lewis and Lewis 1914). However, the 
visualization of mitochondrial dynamics in live cells became possible by late 20
th
 
century, with the development of live imaging and mitochondrially targeted fluorescent 
proteins and dyes (Bereiter-Hahn et al., 1994; Nunnari et al., 1997). The dynamic 
behaviour of mitochondria involves mitochondrial shape changes and distribution of 
mitochondria in the cells. In mitochondrial fusion, an individual mitochondrion moving 
along the cytoskeleton meets another mitochondrion and undergoes merging of lipid 
bilayers and mixing of mitochondrial contents (Parone et al., 2008). Fusion allows 
mixing of heterogeneous mitochondrial components which contribute towards the 
maintenance and/or inter-complementation of mtDNA and distribution of proteins, 
nutrients and reorganization of membranes (Chen et al., 2005; Detmer and Chen, 2007b; 
Parone et al., 2008) (Figure 1.1). In contrast, an individual mitochondrion divides by 
fission producing smaller mitochondrial units separating out the damaged mitochondria 
which are removed from cell by mitophagy (Twig et al., 2008) (Figure 1.1). A balance 
of fusion and fission is important for varying physiological conditions of any cell 












Figure 1.1: Mitochondrial Dynamics. Schematic of mitochondrial fusion and fission (adapted 
from Twig et al., 2008). Under normal conditions mitochondrial fusion and fission events 
depend on mitochondrial membrane potential. Mitochondrial fusion results in long 
mitochondria and mitochondrial networks with electrically coupled polarised mitochondria. 
Mitochondrial fusion is mediated by Mfn1, Mfn2 and OPA1. Mitochondrial fusion results in 
complementation of mtDNA, intermixing of mitochondrial proteins and nutrients and 
membrane reorganisation. Upon loss of mitochondrial membrane potential mitochondrial 
networks are broken down into smaller mitochondria. Mitochondrial fission is mediated by 
Drp1, Fis1 and Mff. The depolarised and damaged mitochondrial population is eliminated from 
the healthy mitochondrial population by mitophagy. Smaller mitochondria with intact 





1.2 Mitochondrial Fusion 
Mitochondrial fusion occurs in multiple steps. It involves tethering of 
mitochondrial membranes of adjacent mitochondria resulting in outer membrane fusion 
following the tethering of inner membranes and mixing of the matrix contents. 
Mitochondrial fusion provides a mechanism to maintain homogeneity with in the 
organelle (Detmer and Chen, 2007b). The main fusion proteins are Mitofusins (Mfn1 
and Mfn2) and Optic atrophy 1 (OPA1). Mfn1 and Mfn2 are outer mitochondrial 
membrane GTPases and shares 63% amino acid identity (Koshiba et al., 2004). Both 
mediate fusion forming homodimers and heterodimers on adjoining mitochondria 
(Koshiba et al., 2004). Inner membrane fusion is primarily mediated by another 
GTPase, Opa1 (Cipolat et al., 2004). 
1.2.1 Mfn1 and Mfn2 
Drosophila melanogaster fuzzy onions (Fzo), was identified as the first fusion 
gene (Hales and Fuller, 1997). Fzo belongs to the family of dynamin-like GTPases that 
have homologues in eukaryotes from yeast to humans. During Drosophila 
spermatogenesis, Fzo initiates mitochondrial fusion forming giant mitochondrial 
structure known as Nebenkern, essential for sperm motility (Hales and Fuller, 1997). 
Fzo expression is restricted to the testes, however, a ubiquitously expressed Drosophila 
fusion mediator known as mitochondrial assembly regulatory factor (Marf), was later 
identified as Fzo homologue in Drosophila (Hwa et al., 2002). Marf has more general 
role in controlling mitochondrial outer membrane fusion in flies (Hwa et al., 2002). The 
expression and functional restrictions of fusion proteins as seen in flies has not been 
reported in yeast or higher eukaryotes. Fzo1p is the only factor for outer mitochondrial 
membrane fusion in yeast. Vertebrate orthologue for Fzo and Marf are two homologues 
Mitofusin 1 and Mitofusin 2 (Mfn1 and Mfn2) (Santel and Fuller, 2001). Human Mfn1 
and Mfn2 share 46% amino acid identity with Drosophila Marf and 31% amino acid 
identity with Fzo. A cladogram depicting the most parsimonious evolutionary 
relationship between mitofusin genes in species from Drosophila to man is available
1
. 
The evolutionary distance between fly and man is too great to infer any meaningful 
evolutionary relationships between Mfn homologues and orthologues. Drosophila Fzo 
                                               
1







and Marf are the result of a gene duplication event, but Ciona species apparently only 
have a single Mfn gene. All higher vertebrates including fish have at least two 
homologues. Thus based on this phylogenetic data we are able to deduce that Mfn1 and 
Mfn2 arose by a gene duplication event in the vertebrate lineage prior to the 
evolutionary branch leading to the fishes. 
Mitofusins are present on the outer mitochondrial membrane and contain amino 
terminal GTPase domain, a coiled coil or heptad repeat domain 1 (HR1), a bi-partite 
transmembrane domain and a second coiled coil or heptad repeat domain 2 (HR2) in 
carboxy terminal (Figure 1.2). Bi-partite transmembrane domain of Mfn2 helps in 
anchoring the protein to the outer mitochondrial membrane with a small loop hanging in 
the middle in intermembrane space. The bi-partite transmembrane domain gives U-
shape to the protein resulting in most of the protein facing cytosol. The topology of 
mitofusins is identical from yeast to higher eukaryotic cells indicating that the 
mitochondrial fusion remained conserved throughout evolution (Rojo et al., 2002). 
Fusion is mediated by tethering two opposing outer mitochondrial membranes of 
adjacent mitochondria through the formation of hairpin like structure by the HR2 
domains of neighbouring mitochondria (Koshiba et al., 2004). These interactions are 
both homo dimeric (Mfn1-Mfn1 or Mfn2-Mfn2) and hetero-dimeric (Mfn1-Mfn2) in 
trans between two mitochondria (Detmer and Chen, 2007a). It is believed that 
mitofusins (Mfns) work similar to that of SNAREs proteins (soluble N-ethylmaleimide-
sensitive fusion protein attachment protein receptors) and form inter or intra molecular 
interactions to tether the adjacent membranes followed by lipid bilayer destabilization 
by their hydrophobic domains and biochemical energy provided by GTP hydrolysis 
from GTPase domain (Chen and Scheller, 2001; Ishihara et al., 2004). 
 
Figure 1.2: Schematic of Mfn1 and Mfn2 domain structures. GTPase: GTPase domain, 
HR1: Heptad repeat domain 1, TM: Bi-partite transmembrane domain, HR2: Heptad repeat 
domain 2. aa: amino acid residues. 
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The GTPase domain has catalytic regions and GTP binding regions (Santel et 
al., 2003). Mfn1 exhibits approximately 8 folds higher GTPase activity than Mfn2 
(Ishihara et al., 2004). It is suggested that Mfn1 might be principally involved in 
mitochondrial tethering while Mfn2 participates only in the subsequent steps of outer 
membrane fusion (Ishihara et al., 2004). Cells lacking Mfn1 show smaller fragmented 
mitochondria that are unable to fuse, however Mfn2 deficient cells have larger and 
thicker mitochondrial fragments (Chen et al., 2003). Mfn1 overexpression showed 
enhanced mitochondrial networks while GTPase truncated Mfn1 or GTPase inactive 
Mfn1 expression showed mitochondria as trapped in a tethered state lacking 
mitochondrial fusion (Santel et al., 2003; Koshiba et al., 2004). GTPase dead mutant of 
Mfn2 displayed accumulation of docked mitochondrial intermediates (Eura et al., 2003). 
In contrast, mutations in HR2 domain of Mfn1 showed fragmented mitochondria 
(Koshiba et al., 2004). This suggests that GTPase domain and HR2 domains plays 
sequential steps during the fusion process. Additionally, Mfn2 is also present on 
endoplasmic reticulum (ER) and is involved in maintaining mitochondria-ER contact 
sites (de Brito and Scorrano, 2008). Silencing Mfn2 affects both mitochondrial and ER 
morphologies (de Brito and Scorrano, 2008). Interestingly, besides their functional 
redundancy, the tissue expression patterns for Mfn1 and Mfn2 are different. Mfn1 is 
ubiquitously expressed and Mfn2 is a also ubiquitous protein but expressed at higher 
rates in brain, heart and skeletal muscles (Santel et al., 2003). Furthermore, Mfn2 
reduced expression levels were found in obese and type 2 diabetic individuals and Mfn2 
mutations are associated with Charcot-Marie-Tooth 2A and Hereditary motor and 
sensory neuropathy type VI (Zuchner et al., 2004; Bach et al., 2005). 
1.2.2 OPA1 
Optical Atrophy 1 (OPA1), a large GTPase, allows mitochondrial inner 
membrane fusion and involved in mitochondrial cristae remodelling (Cipolat et al., 
2004; Ishihara et al., 2006). Mutations in OPA1 are associated with autosomal dominant 
optic atrophy (ADOA), a neuropathy of optic nerve (Alexander et al., 2000; Delettre et 
al., 2000). Additionally, in mammalian cells, knockdown of OPA1 showed fragmented 
mitochondria and aberrant inner membrane structures and were sensitive to apoptosis 
(Olichon et al., 2003; Griparic et al., 2004). OPA1 has a mitochondrial import sequence 
(MIS), protein anchoring transmembrane, first heptad repeat domain 1 (HR1), a GTPase 





In mammalian cells, alternative splicing results in eight OPA1 isoforms (Satoh 




Figure 1.3: Schematic of OPA1 domain structure. MIS: Mitochondrial import sequence, 
MPP: Matrix-processing peptidase, TM: Transmembrane domain, HR1: Heptad repeat domain 
1, GTPase: GTPase domain, Middle domain, GED: GTPase effector domain, HR2: Heptad 
repeat domain 2. aa: amino acid residues. 
 
Matrix-processing peptidases (MPP) cleave MIS and imports OPA1 into the 
matrix. This cleavage results in mature or long-OPA1 isoform (L-OPA1). L-OPA1 is 
attached to the inner membrane by the tansmembrane domain, hence, most of the 
protein protrudes in the intermembrane space. L-OPA1 is further processed into 
soluble-OPA1 (S-OPA1) by m-AAA proteases, i-AAA protease and presenilin-
associated rhomboid-like protease (PARL) (Cipolat et al., 2006; Song et al., 2007). 
Under normal conditions both isoforms are present (Griparic et al., 2007). In Mgm1p, 
yeast orthologue of OPA1, L-Mgm1p isoform forms homodimeric complexes in trans 
by the heptad repeats and tether opposing inner membranes and the mechanical energy 
to initiate lipid bilayer mixing is provided only by S-Mgm1p which is GTPase active 
(DeVay et al., 2009). Furthermore, apoptosis and mitochondrial depolarization results in 
enhanced proteolysis of L-OPA1 in to S-OPA1 which leads to cytochrome c release and 








1.2.3 Other proteins involved in mitochondrial fusion 
In yeast, an outer mitochondrial membrane protein Ugo1p, is also required for 
the mitochondrial fusion (Sesaki and Jensen, 2001). Ugo1p links Fzo1p and Mgm1p 
through its carboxy-terminal exposed to the intermembrane space (Sesaki and Jensen, 
2004). However, based on amino acid sequences no mammalian homolog of Ugo1p has 
been found yet. In mammalian cells Mfn1 interacts with OPA1 to facilitate the progress 
of outer membrane to inner membrane fusion therefore, it is still speculated that a 
functional homologue of Ugo1p may be involved (Cipolat et al., 2004). 
Furthermore, a mitochondrial inner membrane protein; Prohibitin 2 is important 
for the maintenance of L-OPA1 (Merkwirth et al., 2008). Prohibitin 2 deficient cells 
showed fragmented mitochondria with disorganised cristae and introduction of L-OPA1 
rescues the defect (Merkwirth et al., 2008). Another inner membrane scaffolding protein 
stomatin like protein-2 (SLP-2) regulates L-OPA1 stabilization and involved in stress 
induced cellular protective phenomenon of mitochondrial hyperfused morphology 
(Tondera et al., 2009). Additionally, SLP-2 also interacts with Mfn1 and Mfn2 and 
prohibitins to regulate outer and inner mitochondrial fusion during stress (Da Cruz et 
al., 2008; Tondera et al., 2009). 
1.3 Regulation of mitochondrial fusion 
Mitochondrial fusion is a well coordinated process initiating with outer 
membrane fusion and subsequently inner membrane fusion takes place. Mutations in the 
intermembrane loop present between two transmembrane domains of yeast Fzo1p 
showed loss of interaction of protein with the inner membrane leading to complete 
mitochondrial fusion failure (Fritz et al., 2001). In contrast, mutations in mitochondrial 
inner membrane proteins such as Opa1 and Mgm1p result into loss of mitochondrial 
inner membrane fusion only (Meeusen et al., 2006). Mitochondrial fusion is a 
synchronised process regulated by various factors and cellular signalling pathways or 
events as discussed below. Figure 1.4 summaries various fusion regulating components. 
1.3.1 Ubiquitination of Mfns 
Regulating expression levels of fusion machinery is critical to maintain 





motif protein Mdm30 regulates the levels of Fzo1p by promoting its ubiquitylation 
(Escobar-Henriques et al., 2006). The modified ubiquitinated Fzo1p is then targeted by 
26S proteasome for degradation (Cohen et al., 2008). Mdm30p mutants displayed 
fragmented mitochondria and suggest that it is essential for the normal mitochondrial 
morphology in yeast (Fritz et al., 2003). Various studies have shown that Mfn1 and 
Mfn2 levels are regulated by E3 ubiquitin ligase known as Parkin (Poole et al., 2010; 
Ziviani et al., 2010). It has been shown in Drosophila cells and mammalian cells that 
upon dissipation of membrane potential, Mfn1 and Mfn2 are polyubiquitinated and 
degraded in response to Parkin activation prior to mitophagy (Poole et al., 2010; Tanaka 
et al., 2010; Ziviani et al., 2010). Cells deficient with Parkin or PINK1; a mitochondrial 
kinase, resulted in elongated mitochondria. Furthermore, in PINK1 and parkin mutant 
flies the steady-state levels of Marf is increased in contrast to decreased levels in PINK1 
and Parkin-overexpressing flies (Poole et al., 2010; Ziviani et al., 2010). It suggests that 
PINK1/Parkin pathway prevents or delays fusion as PINK1 acts via its kinase activity to 
activate either Parkin and its recruitment to the depolarised mitochondria to process 
Mfns ubiquitylation or PINK1 may directly act on Mfn to signal its removal via Parkin 
mediated ubiquitination and proteosomal degradation. 
1.3.2 Bcl-2 family members 
Bax and Bak, the two Bcl-2 family members, regulate mitochondrial fusion in 
both positive and negative manner. In healthy cells, cytosolic Bax and its homologue 
Bak interacts with Mfn1/Mfn2 and regulates the assembly of large complexes at the 
sites of mitochondrial fusion, thus positively progressing mitochondrial fusion 
(Karbowski et al., 2002; Karbowski et al., 2006; Hoppins et al., 2011). Bax interacts 
physically with Mfn2 (392-602 region of Mfn2) in yeast two-hybrid analysis. However, 
during apoptosis Bax dissociates from Mfn2, undergoes conformational changes to form 
apoptotic active form and translocates to the mitochondrial outer membrane (Karbowski 
et al., 2002). Bax/Bak double knockout cells showed short mitochondrial rods 
suggesting incompetency for efficient fusion (Karbowski et al., 2006). Additionally, 
Bcl-xL and Ced-9 also interact physically with mitochondrial fusion machinery by 
promoting mitochondrial fusion (Delivani et al., 2006; Hoppins et al., 2011). Together 
these findings propose a defined role for Bcl-2 family members as negative and positive 










Figure 1.4: Schematic for the localization of fusion and fission machinery and various 
regulatory components. Mfn1 and Mfn2 are present on the outer mitochondrial membrane and 
mediate the outer membrane fusion by forming homo and heterodimers assembled in trans. 
PINK1/Parkin pathway influences mitochondrial fusion by Mfn ubiquitination and proteosomal 
degradation. Mitofusin binding protein (MIB) is a negative regulator of mitochondrial fusion by 
interacting with Mfn1. Bcl-2 family members Bax and Bak regulates Mfn1/Mfn2 both 
positively and negatively in response to cellular signals. Mitochondrial phospholipase D 
(mitoPLD) hydrolyses cardiolipin to produce fusogenic phosphatidic acid. Inner membrane 
fusion is mediated by long-OPA1 isoform (L-OPA1). L-OPA1 is anchored in inner membrane 
and forms homotypic complexes in trans to mediate fusion. L-OPA1 is cleaved to short-OPA1 
isoform (S-OPA1) by pcp1 (in yeast) and proteases mAAA, iAAA, presenilin-associated 
rhomboid-like protease (PARL) and OMA1. Prohibitin-2 and SLP-2 are the inner membrane 
scaffolding proteins stabilising OPA1. Mitochondrial fission is facilitated by Drp1, a soluble 
cytosolic protein which is recruited by mitochondrial outer membrane anchored proteins Fis1 
and Mff to oligomerise at the fission sites. Mdv1 and Caf4 are the adaptor proteins that enable 
Fis1 mediated Drp1 assembly on mitochondria in yeast. Drp1 undergoes various post-
translational modifications such as phosphorylation, ubiquitination, sumoylation and S-
nitrosylation for activation and recruited to mitochondria to induce fission. GDAP1 acts as a 






1.3.3 Mitofusin binding protein 
Mitofusin binding protein (MIB) acts as the negative regulator of Mfn1 activity. 
It belongs to a family of medium-chain dehydrogenase/reductase proteins carrying 
conserved coenzyme-binding domain. MIB functionally interacts with Mfns as Mfn1 
expression rescues increased mitochondrial fission due to MIB overexpression in the 
cells (Eura et al., 2006). On the other hand, MIB knockdown leads to the formation of 
elongated mitochondria (Eura et al., 2006). 
1.3.4 OPA1 proteases 
Proteolytic processing of OPA1 by various proteases are also major regulatory 
mechanisms that control mitochondrial fusion and cristae morphology. As discussed in 
section 1.2.2 various mitochondrial proteases are responsible for maintaining the 
balance of OPA1 isoforms (Figure 1.4). In response to various cellular cues as mtDNA 
loss, low membrane potential, reduced ATP synthesis or apoptosis, L-OPA1 is 
processed to S-OPA1 by specific proteases (Ishihara et al; 2006; Griparic et al., 2007). 
L-OPA1 is processed by presenilin-associated rhomboid-like protein (PARL) to 
generate S-OPA1 in the intermembrane space which is important for maintaining close 
uniform cristae junctions (Cipolat et al., 2006). PARL indirectly regulates mitochondrial 
morphology as loss of PARL results in reduced levels of S-OPA1, cristae deformation 
and cytochrome c release. In addition three AAA-proteases; AFG3L2, Paraplegin and 
YmeL1 constitutively process OPA1 in the matrix and the inner membrane under 
various cellular responses and shift the balance towards S-OPA1 and resulting in 
enhanced mitochondrial fission (Duvezin-Caubet et al., 2007; Song et al., 2007). Also, 
in impaired mitochondria with low membrane potential Oma1 (overlapping activity 
with m-AAA protease), processes L-OPA1 to S-OPA1 and shuts down the fusion 
machinery of dysfunctional mitochondria (Ehses et al., 2009; Head et al., 2009). It 
suggests that such processing of OPA1 by Oma1 is a part of mitophagy process and 
works in concordance with Mfn ubiquitination and degradation, thus acting as quality 
control regulation of healthy mitochondrial population. 
1.3.5 Lipids 
Mitochondrial fusion involves tethering of adjacent mitochondria by Mfn1/Mfn2 





phospholipase D (MitoPLD) is lipid modifying enzyme and a member of phospholipase 
D super family. It promotes mitochondrial fusion by the generation of phosphatidic acid 
at the outer mitochondrial membrane by hydrolysing mitochondria-enriched lipid 
known as cardiolipin (Choi et al., 2006). Phosphatidic acid is a fusogenic lipid which 
facilitates outer membrane proteins anchorage and membrane bending for fusion (Choi 
et al., 2006). These changes thermodynamically favour deformation and bilayer mixing. 
Additionally, cardiolipin is located in the inner membrane therefore it is suggested that 
phosphatidic acid promotes fusion where outer mitochondrial membrane is in close 
opposition to inner membrane. However, increased levels of phosphatidic acid acts as 
negative regulator of mitochondrial fusion and promotes mitochondrial fission (Huang 
et al., 2011). Increased levels of phospatidic acid recruit phosphatase Lipin 1b to 
mitochondrial outer membrane. Phosphatase Lipin 1b then converts fusogenic 
phospatidic acid into diacylglycerol which is not fusion efficient (Huang et al., 2011). 
1.4 Mitochondrial Fission 
To keep the balance between the dynamic behaviour of mitochondrial 
population, loner mitochondria and mitochondrial networks are broken into smaller 
units, by process know as mitochondrial fission. Firstly, mitochondrial fission is 
important for growth and proliferation of mitochondria as mitochondria can not be 
generated de-novo. Secondly, during mitosis fission allows segregation of pre-existing 
mitochondria to the daughter cells. Thirdly, fission generates small mitochondria that 
are easily transported to the distant regions of the cell. Last but not least fission is a 
quality control mechanism by which cell can get rid of old or damaged mitochondria 
(Twig et al., 2008). However, uncontrolled mitochondrial fission can result in mtDNA 
loss, impaired oxidative phosphorylation and increased susceptibility of cells to undergo 
apoptosis. Mitochondrial fission is mediated by Dynamin-related protein1 (Drp1) 
(Otsuga et al., 1998; Smirnova et al., 2001). Drp1 is a soluble cytosolic protein, 
however during fission Drp1 is recruited from cytosol by mitochondrial outer 
membrane anchored proteins Fis1/Mff to the fission sites (Otera et al., 2010). At the 
fission sites Drp1 assembles as oligomeric complexes enfolding around the fission spots 
to form a collar like structure (Smirnova et al., 2001). Such structure is maintained to 
constrict the lipid bilayer thus facilitating Drp1 to sever the membranes. Assembly of 
Drp1 from cytoplasm to the mitochondria is regulated by various post-translation 





the membranes by GTP hydrolysis (Smirnova et al., 2001). After the completion of 
fission Drp1 complexes are dissolved. 
1.4.1 Dynamin-related protein1 (Drp1)  
Drp1 is a member of the conserved dynamin superfamily and contains a GTPase 
domain, a middle domain (MID), variable domain (VD) and a GTPase effector domain 
(Otsuga et al., 1998; Mozdy et al., 2000; Smirnova et al., 2001) (Figure 1.5). MID is 
region for Drp1 oligomerization. Post translation modification sites are present in VD 
region of the protein. GED domain acts as GTPase activity regulator and is necessary 
for various protein interactions. Interestingly, GED folds back to interact in cis as well 
as in trans with the MID (Zhu et al., 2004). Cells lacking Drp1 lack mitochondrial 
fission and contain highly interconnected mitochondrial networks. Drp1
K38A
 GTPase 
mutant (inhibiting GTP binding) acts as dominant negative mutants by sequestering 
endogenous cytosolic Drp1 into uncharacterized cytosolic aggregates and inhibits 
fission (Smirnova et al., 2001). Drp1 activation as fission factor is regulated by various 




Figure 1.5: Schematic of Drp1 domain structures. GTPase: GTPase domain, Middle domain, 
VB: Variable domain, GED: GTPase effector domain. aa: amino acid residues. 
 
Furthermore, various cellular stresses including treatment with the phorbol ester, 
increase of subcellular calcium and/or induction of apoptosis also results in enhanced 
Drp1 mitochondrial translocation and progression of mitochondrial fission (Labrousse 
et al., 1999; Frank et al., 2001; Breckenridge et al., 2003). A new born female with 
Drp1
A395D





development, microcephaly and optic atrophy and died post 37 days of birth (Waterham 
et al., 2007). 
1.4.2 Drp1 anchoring proteins: Fis1 and Mff 
Fis1 (Fis1p in yeast) is a small protein present on the outer mitochondrial 
membrane with a short C-terminal tail protruding into the intermembrane space and N-
terminal region containing multiple tetratricopeptide repeat (TPR) region facing the 
cytosol (Mozdy et al., 2000; Yoon et al., 2003) (Figure 1.6). In yeast, Dnm1p is 
recruited to the fission sites by Fis1p through WD-40 domain containing proteins: 
Mdv1p or Caf4p (Tieu et al., 2002; Griffin et al., 2005). Mdv1p and/or Caf4p are 
molecular adaptors. It has been suggested that in yeast Fis1p recruits Mdv1p from 
cytosol, where Mdv1p interacts with Dnm1p effector domains and stabilises Dnm1p 
oligomerization on the fission sites (Lackner et al., 2009). Caf4 also acts in similar 
manner, however in the presence of Mdv1p it has a dispensable role as it maintains 
residual levels of fission in yeast cells lacking Mdv1p (Griffin et al., 2005). In 
mammalian cells, Fis1 overexpression results in enhanced mitochondrial fragmentation 
(James et al., 2003; Yoon et al., 2003). Expression of Fis1 does not rescue Fis1p mutant 
phenotype in yeast (Stojanovski et al., 2004). Furthermore, in Fis1 knockdown cells 
Drp1 is still recruited to the fission sites suggesting another anchoring factor present in 
mitochondrial outer membrane (Lee et al., 2004). RNAi screen done in Drosophila cells 
to isolate novel proteins affecting mitochondrial morphology identified mitochondrial 
fission factor (Mff) (Gandre-Babbe and van der Bliek, 2008). Mff have N-terminus 
heptad repeats exposed into the cytoplasm and a C-terminal transmembrane domain 
projecting into the intermembrane space of mitochondria and interacts transiently to 
Drp1 via cytoplasmic domain  (Gandre-Babbe and van der Bliek, 2008; Otera et al., 
2010) (Figure 1.6). Mff is unable to initiate fission in Drp1 deficient mouse embryonic 
cells (MEFs) (Otera et al., 2010). Otera and colleagues have also shown Mff-dependent 
Drp1 recruitment in Fis1 knockdown HeLa cells (Otera et al., 2010). Furthermore, 
overexpression of Mff produced stronger mitochondrial fragmentation as compared to 
Fis1-induced fragmentation (Otera et al., 2010). These findings indicate that, Mff has a 
major role in Drp1 recruitment and fission initiation and Fis1 is functionally dispensable 








Figure 1.6: Schematic of Fis1 and Mff domain structures. TPR: Tetratricopeptide repeats, 
TM: Transmembrane domain, Cc: Coiled coil domain. aa: amino acid residues. 
1.5 Regulation of mitochondrial fission 
1.5.1 Post translational modifications of Drp1 
Drp1-phosphorylation at two different conserved sites, serine 616 and 637 
regulates the mitochondrial fission in an opposing manner. During cell cycle 
mitochondrial fission occurs at the early mitotic phase. Drp1 undergoes phosphorylation 
at serine 616 in the GED domain by CDK1/cyclin B at the initiation of S phase during 
mitosis (Taguchi et al., 2007). This enhances Drp1 activity and facilitates the 
segregation of mitochondria in new daughter cells as a result of mitochondrial division. 
Additionally, phosphorylation at Ser637 by Ca
2+
/calmodulin-dependent protein kinase 
1α (PK1α) increases transfer of Drp1 from cytosol to the mitochondria (Han et al., 
2008). Ca
2+
/calmodulin PK1α is activated by intracellular calcium (Ca
2+
) (Han et al., 
2008). In contrast, Ser637 phosphorylation by cyclic adenosine monophosphate 
dependent protein kinase (PKA) inhibits the GTPase activity of Drp1 and restrains 
mitochondrial fission (Chang and Blackstone, 2007). Interestingly, increase in 
intracellular calcium levels activates the cytosolic phosphatase called calcineurin. 
Activated calcineurin dephosphorylates Drp1 at the Ser637, stimulates its translocation 
to the mitochondria and promotes mitochondrial fission (Cribbs and Strack, 2007). 
In addition, Drp1-nitrosylation at Cys644 residue in GED domain has been 
shown to enhance mitochondrial fission in response to nitric oxide in neurons 
expressing β-amyloid protein (Cho et al., 2009). This modification results in enhanced 
GTPase activity and oligomer formation. It has been shown that Drp1 is also a target for 
Parkin mediated ubiquitination and degradation (Wang et al., 2011). In contrast, Drp1 
sumoylation by small ubiquitin-like modifier (SUMO) protein promotes Drp1 assembly 
on mitochondria and protects Drp1 from ubiquitination and degradation (Harder et al., 





anchored protein ligase (MAPL) promotes mitochondrial fission (Braschi et al., 2009). 
However, sentrin/SUMO-specific protease 5 (SENP5) desumoylation of Drp1 is a 
negative regulator of mitochondrial fission (Zunino et al., 2007). 
1.5.2 Other proteins involved in fission regulation 
Endophilin B, a fatty acyl transferase belongs to endophilin protein family, 
containing amino-terminal BAR domain (Cuddeback et al., 2001). The BAR domain 
participates in the regulation of mitochondrial membrane curvature. Endophilin B 
knockdown displayed outer mitochondrial membrane abnormalities (Karbowski et al., 
2004). Also, endophilin B1 has also been shown to interact with Bax and co-localizes 
with Bax during apoptosis (Cuddeback et al., 2001; Karbowski et al., 2002) 
Ganglioside-induced differentiation activated protein 1 (GDAP1) is present on 
mitochondrial outer membrane and acts as a pro-fission factor (Niemann et al., 2005). 
GDAP1 RNAi showed reduced mitochondrial fission (Wagner et al., 2009). Mutations 
in GDAP1 are also associated with a subtype of Charcot-Marie-Tooth disease. It 
involves the degeneration of Schwann cells and neurons of the peripheral nervous 
system (Niemann et al., 2005). 
1.6 Biological significance of mitochondrial dynamics 
1.6.1 Mitochondrial dynamics and maintenance of mtDNA 
Mitochondrial fusion allows mitochondria to exchange lipid membranes and 
intra-mitochondrial content including mtDNA to maintain a healthy and relatively 
homogeneous mitochondrial population. The mtDNA genome encodes essential 
subunits of the respiratory complexes I, III and IV. In yeast, loss of the Fzo1p results in 
reduced mtDNA molecules and respiratory defects (Hermann et al., 1998). Likewise, 
Mgm1 mutant yeast also showed fewer mtDNA molecules (Jones and Fangman, 1992). 
Also, treating HeLa cells with carbonyl cyanide m-chlorophenylhydrazone (CCCP) 
showed mtDNA loss in 25% of cell population with fragmented mitochondria (Legros 
et al., 2004). MEFs deficient in either Mfn1 or Mfn2 exhibit reduced ATP levels and 
cell growth retardation (Chen et al., 2005; Chen et al., 2007). Also significantly large 
population of fragmented mitochondria contain fewer mtDNA nucleoids (Chen et al., 














 knockout in skeleton muscles) showed severe 
developmental and metabolic defects and died early at the age of 6-8 weeks (Chen et al., 
2010). These mice had 50%-70% low body weight as compared to control pups and 
increased serum lactate suggesting impaired oxidative phosphorylation. The skeletal 
muscles from these mice presented swollen fragmented mitochondria aggregated into 
clumps disrupting the alignment of myofibril arrays (Chen et al., 2010). These mice 
show a low copy number of mtDNA nucleoids (~250) as compared to age-matched 
controls (~3500) at 7-8 weeks age. They showed that mtDNA copy number decreases 
significantly with age in these mice. Mice with single allele of either Mfn1 or Mfn2 
showed normal body weight and normal mtDNA nucleoids per cell at the age of 7-8 
weeks (Chen et al., 2010). Additionally, MEFs lacking both Mfn1 and Mfn2 show lower 
mtDNA and this defect is restored by overexpression of either Mfn1 or Mfn2 (Chen et 
al., 2010). These findings emphasized that the defective mitochondrial fusion is 
responsible for the lower mtDNA copy number and respiratory defects probably due to 
loss of efficient oxidative phosphorylation. 
Reactive oxygen species (ROS) generated as a by-product in oxidative 
phosphorylation can cause various kinds of mtDNA mutations and lesions (Rossignol et 
al., 2003). Mitochondrial fusion is a defence mechanism which allows mutations in 
different mtDNA genomes to complement each other and prevents respiratory 
dysfunction. As most of mtDNA mutations are recessive a cell can hold up to 60-90% 
of mtDNA mutations before being functionally compromised (Rossignol et al., 2003). A 
threshold level of pathogenic mtDNA is also a trait for mtDNA point mutations and 
deletions associated mitochondrial encephalomyopathies. It is suggested that a patient 
only shows the clinical signs of disease after the mutation threshold is crossed (Ono et 




 mutation in 
mitochondrial DNA polymerase resulted in neonatal death (Chen et al., 2010). 




 showed reduced respiratory 
capacity and ATP production due to reduced complex 1 activity (Chen et al., 2010). 
Complex 1 is more prone to mtDNA mutations as compared to other complexes because 







1.6.2 Mitochondrial dynamics and development 
Various studies carried out in-vivo from simple to complex organisms, has 
established that mitochondrial dynamics is important for normal development. 
Caenorhabditis elegans lacking either Fzo1(Mfn) or Eat-3(OPA1) present slow growth, 
reduced body size and high percentages of embryonic lethality (Breckenridge et al., 
2008). Marf ubiquitous knockdown in flies result in larval lethality (Dorn et al., 2011). 
Mfn1 and Mfn2 knockout mice die in midgestation due to placental defects. Mfn2
-/-
 
showed reduced number of trophoblast giant cells of placenta (Chen et al., 2003). To 





) were generated which express normal levels of 
Mfns in placenta. These mice were born viable. Meox-Cre/Mfn1
loxP 
mice displayed no 
physiological defects and were fertile. However, Meox-Cre/Mfn2
loxP 
showed severe 
movement defects and impaired cerebellar development (Chen et al., 2007). Similarly, 
OPA1 deficient mice (OPA1
-/-
) show embryonic lethality however heterozygous OPA1 
(OPA1
-/+
) mice were viable but showed age-dependent degeneration of retinal ganglion 
cells that develop into visual impairment (Davies et al., 2007). Perturbations in 
mitochondrial fission also results in developmental defects as Drp1 knocked down by 
RNAi in Caenorhabditis elegans showed embryos dying before reaching 100 cells stage 
(Labrousse et al., 1999). Homozygous Drp1 mutant flies were semi lethal. Escaper flies 
were uncoordinated and showed numerous neurological defects (Verstreken et al., 
2005). Drp1 knockout model mice showed brain hypoplasia due to enhanced apoptosis 
in neural cortex (Ishihara et al., 2009). 
1.6.3 Neurons and mitochondrial dynamics 
Mitochondria are required in neurons to generate ATP for various specialized 
functions such as active pumping of Ca
2+
 across the plasma membrane and Ca
2+
 
buffering in presynaptic and postsynaptic terminals (Hollenbeck and Saxton, 2005). 
Mitochondria usually concentrate in pre and post synaptic areas but are also evenly 
spaced in the remaining portions of axons and dendrites (Hollenbeck and Saxton, 2005; 
Saxton and Hollenbeck, 2012). Synaptic transmission requires active population of 
mitochondria to provide ample ATP for the maintenance of plasma membrane potential 
and recycling of neurotransmitters and vesicles (Saxton and Hollenbeck, 2012). 
Furthermore, sufficient mitochondrial content and mobility in dendrites is vital for 





protein translation, which are all high energy demanding processes. To meet the energy 
demand of various processes, mitochondria need to be placed near the sites of activity 
and it requires an active system for transport within the polarised neurons (Saxton and 
Hollenbeck, 2012). In neurons, mitochondria are distributed to various regions by active 
transport mediated by microtubules, actin filaments and motor proteins. Mitochondria 
travel by fast axonal transport at an average speed of 0.3–2.0 µm/sec (~20–70 mm/day) 
(Sheng and Cai, 2012). Mitochondria move bidirectionally with frequent pauses. One-
third of axonal mitochondria are found mobile in mature cultured neurons (Kang et al., 
2008). Mitochondria containing high membrane potential move from the cell body in 
anterograde direction to synaptic regions with high metabolic demand (anterograde 
movement) and low membrane potential carrying mitochondria are transported to the 
cell body for repair by fusion or destruction by mitophagy (retrograde movement) 
(Martin et al., 1999; Hollenbeck and Saxton, 2005). Both kinds of transport require 
molecular motor proteins which attach to mitochondrion and pull it along microtubules. 
Motor proteins such as kinesin superfamily proteins (KIFs) and cytoplasmic dynein are 
involved in directed anterograde and retrograde transport of mitochondria respectively 
in axons (Pilling et al., 2006). Members of the kinesin-1 family (KIF5) are the primary 
anterograde motor and kinesin-3 family members; KIF16 and KLP6 have also been 
identified as mitochondrial motors (Tanaka et al., 2011). KIF5 moves along 
microtubules by hydrolysing ATP taking steps of ~17nm (Yildiz et al., 2004). Short 
range transport of mitochondria primarily in dendritic spines, growth cones and synapse 
boutons is mediated by actin filaments and myosin motor proteins (Bridgman, 2004). 
Number of adaptor and linker proteins that bind the mitochondria to the motor proteins 
has been identified. Milton is an adaptor protein that binds to the KIF5 heavy chain to 
anchor mitochondria to the motor protein in Drosophila (Stowers et al., 2002). TRAK1 
and TRAK2 are mammalian orthologues of Milton. In addition Miro, a mitochondrial 
outer membrane protein, links mitochondria to Milton (Guo et al., 2005). Miro has two 
EF-hands which are the Ca
2+
-binding regions. These hands mediate the protein to 
regulate mitochondrial transport in the cell. Two mammalian orthologues for Miro are 
Miro1 and Miro2. Currently, there are two proposed models by which Miro exerts its 
effects on mitochondrial mobility. According to one model, in the absence of Ca
2+
 
Miro-Milton-KIF5 complex is involved in mitochondrial anterograde transport. 
However, in the presence of Ca
2+
 influx following synaptic activity, EF hands of Miro 
sequesters and binds Ca
2+
. This results in change in conformation of Miro and blocks 





mitochondrial movement and facilitates mitochondria to buffer local elevated levels of 
Ca
2+
 (Wang and Schwarz, 2009). The second model known as motor releasing model 
accounts that in presence of Ca
2+
 influx, Miro-Milton complex is released from KIF5 
binding and mitochondrial movement is halted (Macaskill et al., 2009). Furthermore, 
syntabulin, RAN-binding protein 2 (RANBP2) and fasciculation and elongation protein 
zeta-1 (FEZ1) are among other adaptor proteins identified as important for 
mitochondrial anterograde transport and synapse docking (Cai et al., 2005; Ikuta et al., 
2007; Cho et al., 2007). In contrast, retrograde transport machinery is less well 
characterised. Dynein binds to microtubules by its heavy chain and by its light chain 
protein TCTEX1, it binds to voltage-dependent anion-selective channel 1 (VDAC1) 
present at the outer mitochondrial membrane (Schwarzer et al., 2002). Dynactin, is 
another large complex that binds to both dynein and microtubules and facilitates 
retrograde transport of organelles including mitochondria (King and Schroer, 2000). 
Genetic interactions showed that anterograde motors and retrograde motors are also 
dependent on each other for effective bi-directional mitochondrial transport. Dynein has 
been found to be present on mitochondria moving in anterograde direction as well. Miro 
is also required along with dynein in Drosophila neurons for mitochondrial retrograde 
movement (Hirokawa et al., 1990; Russo et al., 2009). However, dynein-Miro 
association has not been demonstrated yet. 
1.6.3.1 Mitochondrial fusion, fission and transport in neurons 
The connections between mitochondrial dynamics and mitochondrial transport 
are becoming clear with recent research. It has been established that mitochondrial 
fusion and fission takes place in all parts of the neuron. Mitochondrial morphology is 
distinct in various regions of the neuron. Mitochondria mostly form loose networks in 
neuronal cell bodies, small rod shaped and spherical mitochondria are present in axons 
and neuromuscular junction (Li et al., 2004). These smaller discrete morphologies are 
important because transport machinery can easily carry smaller mitochondria as 
compared to large mitochondria. Perturbing mitochondrial dynamics in chick peripheral 
axons, either by overexpressing Mfn1 or inhibiting Drp1 by RNAi resulted in long 
immotile mitochondria (Amiri and Hollenbeck, 2008). In addition, Drosophila Drp1 
mutants result in neuromuscular junctions devoid of mitochondria (Verstreken et al., 
2005). Also, Drp1 mutant flies are unable to mobilize reserve pools of synaptic vesicles 
due to inadequate ATP supply from the few synaptic mitochondria present in boutons 





within a day of birth and showed brain hypoplasis due to enhanced apoptosis in the deep 
cortical neuronal cell layer (Ishihara et al., 2009). These neurons are the early-born cells 
but die due to apoptosis before maturing into neurites and synapses and showed 
aggregated mitochondria within cell body and neurite processes in cultures (Ishihara et 
al., 2009). Similarly, Miro and Milton deficient flies have shown fewer mitochondria in 
axons and synapses, inefficient Ca
2+
 buffering and diminished synaptic activity 
(Stowers et al., 2002; Guo et al., 2005). Thus, such inadequacies result in insufficient 
energy distribution, impaired local Ca
2+
 buffering and inefficient synaptic vesicle 
mobilization from reserve pool resulting in impaired synaptic activity. However, 
overexpression of Miro showed enhanced mitochondrial fusion and increased 
mitochondrial density in dendrites (Koutsopoulos et al., 2010). Dynein has been shown 
to interact with Drp1 as dynein disruption also resulted in enhanced mitochondrial 
fusion (Varadi et al., 2004). Additionally, actin is also involved in the employment of 
Drp1 to mitochondria for fission (De Vos et al., 2005). In comparison, mutations in 
Mfn2 have been linked to inherited peripheral neuropathy suggesting an important role 
of this pro-fusion protein in neurons (Verhoeven et al., 2006). Disease associated Mfn2 
mutations presented improper mitochondrial distribution in axons of motor neurons 
from transgenic mice (Detmer et al., 2008). Sensory neurons expressing CMT2A 
associated Mfn2 mutations and/or loss of Mfn2 (Mfn2
-/-
) showed mitochondrial 
clustering in proximal axonal segments, reduced density of mitochondria in distal 
regions, slower anterograde and retrograde mitochondrial mobility with prolonged 
pauses in axons (Baloh et al., 2007; Misko et al., 2010). On the other hand, a unique 
role of Mfn2 as mitochondrial transport mediator has also been reported by Misko and 
colleagues. Mfn2 interacts with Miro 2 and Milton 1 (Milton homolog 1) and mediates 
mitochondrial transport in axons (Misko et al., 2010). It is suggested that 





 neurons showed mitochondria spend increased time paused in the axons 
(Misko et al., 2010). However, this study has claimed that disruption in transport does 
not appear to be a consequence of attenuated fusion thus suggesting a fusion 
independent role for Mfn2 in the regulation of mitochondrial motility (Misko et al., 
2010). A recent paper by same group has shown axonal degeneration in neurons 
expressing disease associated Mfn2 mutations. They showed the improper distribution 
of mitochondria along the axons resulting in hypoxia leading to axonal degeneration 
and this defect was rescued by either expressing Mfn1 or treatment with tetrodotoxin 





selective degradation of damaged mitochondria has been found to influence 
mitochondrial mobility by modifying Miro. PINK1 phosphorylates Miro, facilitates its 
degradation in parkin dependent manner and promotes mitochondrial retrograde 
transport (Wang et al., 2011). Interestingly, Mfns have also shown to undergo parkin 
mediated ubiquitylation, thus promoting mitochondrial fission and possibly mitophagy 
(Poole et al., 2010; Ziviani et al., 2010).  
1.6.3.2 Mitochondrial dynamics and neurodegenerative diseases 
Several studies in past decade have linked impaired mitochondrial dynamics, 
mitochondrial transport defects, perturbation of mitochondrial quality control and 
mitochondrial dysfunction to the pathogenesis of various neurodegenerative and 
neurological disorders (Schon and Przedborski, 2011). Alzheimer’s disease (AD) is 
characterised by the neuronal death, neurofibrillary tau tangles and beta-amyloid (Aβ) 
plaques in cerebral cortex (Braak and Braak, 1991). Impaired axonal transport is 
involved in axonal degeneration in AD patients and is marked by the presence of axonal 
swellings containing aggregated mitochondria along with abnormal accumulation of 
other organelles, microtubules and motor proteins (Stokin et al., 2005). Additionally, 
mitochondrial dysfunction including decreased mitochondrial respiration, ROS 
generation, and decreased mitochondrial size with fragmented cristae structures are 
observed in brains of AD patients and AD mouse models (Spuch et al., 2012). 
Accumulation of soluble Aβ oligomers results in generation of nitric oxide by activating 
neuronal nitric oxide synthase due to increased intracellular Ca
2+
 via the pathological 
activation of NMDA receptors (Li et al., 2009). It has been shown that enhanced 
mitochondrial fragmentation in cultured cortical neurons and AD patient brains is due to 
activation of Drp1 GTPase activity by S-nitrosylation in the presence of nitric oxid (Cho 
et al., 2009). 
Parkinson’s disease (PD) is another common neurodegenerative disease, 
characterized by postural instability, resting tremor and walking difficulties caused by 
the loss of dopaminergic neurons in the substantia nigra and presence of Lewy bodies 
mainly consisting of α-Synuclein protein; a presynaptic protein (Abou-Sleiman et al., 
2006). Post-mortem PD brain tissues showed impaired complex I activity and an 
increase in markers of oxidative stress (Schapira et al., 1990). However, mitochondrial 
association with PD came from studies done on autosomal recessive familial PD 







cells, revealed that loss of PINK1 or Parkin results in increased mitochondrial fusion. In 
vivo PINK1 or Parkin mutant animals showed swollen and disrupted mitochondria in 
flight muscle while PINK1 RNAi or Parkin RNAi in S2R+ cells showed tubular 
networks (Greene et al., 2003; Poole et al., 2008; Ziviani et al., 2010). Importantly, the 
in vivo phenotypes can be rescued by the over expression of Drp1 or Fis1 or loss-of-
function mutations in Mfn(Marf) and OPA1 showing that the effects on mitochondrial 
morphology may at least partially be responsible for the organismal phenotypes (Poole 
et al., 2008; Yang et al., 2008). In fact, Mfn1 and Mfn2 are targets for Parkin-mediated 
ubiquitination and degradation which explains the enhanced mitochondrial fusion seen 
in Drosophila cells (Ziviani et al., 2010; Tanaka et al., 2010). However, the literature on 
the effects of PINK1 and parkin on mitochondrial morphology in vertebrates is 
conflicting. For example, while PINK1 knockdown in COS-7 cells showed increased 
number of cells with long tubular mitochondria and fibroblasts derived from PD 
patients carrying Parkin mutations showed increased mitochondrial branching 
(Mortiboys et al., 2008; Yang et al., 2008). Different groups have demonstrated that 
PINK1 or Parkin RNAi in HeLa cells or neuroblastoma cells results in mitochondrial 
fragmentation, which was enhanced by Drp1 overexpression and rescued by the 
expression of Drp1 dominant negative mutant (Exner et al., 2007; Lutz et al., 2009). 
While others have found no change in morphology in MEFs from PINK1 KO mouse 
(Morais et al., 2009).  
The possible reason for these discrepant findings are unclear but could likely 
reflect the greater complexity in regulation of cell biological processes found in higher 
organisms than in Drosophila. For instance, vertebrates may have additional 
compensatory or regulatory mechanisms that may further affect mitochondrial 
morphology in response to downstream effects of loss of PINK1 or Parkin. 
Additionally, some variation may derive from technical differences used between model 
systems; for example, the degree of RNAi knockdown versus genetic knock-out in 
mammalian cells, or the genetic heterogeneity and other ‘life history’ factors inherent in 
patient cells. Overall, several studies support that PINK1/Parkin pathway has an 
influencing effect on mitochondrial dynamics but the degree of influence may depend 
on subtle variation in cellular circumstances, such as basal stress level (e.g. oxidative 
stress, mitochondrial stress). 
Huntington's disease (HD) is gradually developing neurodegenerative disease 





expansion (PolyQ) in the Huntingtin (HTT) gene (Walker, 2007). HTT is involved in 
the trafficking of mitochondria, ER, Golgi vesicles and late endosomes by forming 
complexes with both retrograde and anterograde motor machinery of the cell (Caviston 
and Holzbaur, 2009). In cultured neurons, mutant HTT decreases mitochondrial bi-
directional transport (Trushina et al., 2004). This is due to the association between 
mitochondria and the N-terminal region of mutant HTT containing abnormal 
polyglutamate expansions, thus affecting the complex formation of mitochondria with 
transport machinery (Orr et al., 2008). In addition, fibroblast derived from juvenile and 
adult-onset HTT patient and neuronal cultures from HTT rat model showed increased 
fragmentation and abnormal cristae arrangement due to enhanced Drp1 
dephosphorylation by increased calcineurin activity in the presence of mutant HTT 
(Costa et al., 2010; Song et al., 2011). Furthermore, expression of mitochondrial fission 
proteins Drp1 and Fis1 increases as compared to pro-fusion proteins in the presence of 
mutant HTT (Shirendeb et al., 2011).  
Lastly, amyotrophic lateral sclerosis (ALS) is another late onset 
neurodegenerative disorder that involves gradual loss of motor neurons and demise of 
affected individual within 3-5 years of diagnosis (Tandan and Bradley, 1985). 
Mutations in the antioxidant enzyme Cu/Zn superoxide dismutase-1 (SOD1) are 
associated with familial ALS (Shaw, 2005). Neurons from ALS patients and transgenic 
mice expressing mutant SOD1 showed impaired axonal mitochondrial transport (De 
Vos et al., 2007; Shi et al., 2010). Furthermore, mouse models carrying SOD1 
pathogenic point mutation displayed low mitochondrial quantity as well as degenerating 
mitochondria in the axons and dendrites (Wong et al., 1995; Collard et al., 1995). TAR 
DNA-binding protein 43 (TDP43) is also associated with familial and sporadic cases of 
ALS and cytoplasmic inclusions composed of massive accumulation of mitochondria in 
the motor neuron cell bodies of transgenic mice overexpressing wild-type human 
TDP43 (Shan et al., 2010).  
1.7 Charcot-Marie Tooth (CMT) Diseases 
Charcot-Marie-Tooth diseases (CMT) are the group of most common inherited 
neuromuscular disorders, involving degeneration of peripheral motor and sensory 
neurons. CMT affects up to 1 in 1200 individuals and in Europe its prevalence is 40 in 
100,000 (Skre, 1974; Braathen et al., 2011). Based on clinical and pathological findings 





neuropathy (CMT1) and axonal neuropathy (CMT2). The pathological difference 
between these two forms is degeneration and loss of supporting Schwann cells with 
secondary axonal loss in peripheral nerves in CMT1 and degeneration of only axons in 
peripheral nerves in CMT2. However, some mixed forms of CMT also exists which 
show both demyelination and axonal defects. To date, around 30 genes have been linked 
to CMT (Bucci et al., 2012). The genetics of CMT1, CMT2 and intermediate forms and 
functions of the causative genes are summarised in Table 1.1. However, it is still 
unclear that how mutations in mostly ubiquitously expressed genes result in exclusive 
demyelination and axonal degeneration of motor and sensory neurons of peripheral 
nervous system. 
The clinical symptoms include distal limb weakness starting with lower 
extremities (leg and foot) and latter progresses in to distal upper extremities (hands and 
arms) as the disease advances, muscle atrophy, sensory loss, decreased reflexes, foot 
deformities including hammer toes and pes cavus with stepping gait and postural tremor 
(Zuchner et al., 2005; Verhoeven et al., 2006). Often mobility impairment and frequent 
falls lead to wheelchair dependency. As the clinical presentations for both types of 
CMTs are quite similar therefore they can be distinguished by electrophysiological 
criteria for nerve conduction analysis of the affected individuals. Patients with CMT1 
usually present motor nerve conduction velocity of less than 38 m/s and individuals 
presenting a mild decrease to normal motor nerve conduction velocity of more than 
38 m/s are characterised under CMT2 (Harding and Thomas, 1980). Moreover, various 
intermediate forms of CMT have been reported displaying intermediate and/or 
heterogeneous motor nerve conduction velocity readings ranging from 25 to 45 m/s. 
Although, CMTs are non-fatal neuropathies but no doubt they affect the quality of life 
of the affected individuals. There are no treatments available apart from orthopaedic 





















Table 1.1: Genetics of CMT 
 











1.7.1 Charcot-Marie Tooth type 2A2 and Hereditary motor and 
sensory neuropathy type VI 
Charcot-Marie Tooth type 2A (CMT2A/CMT2A2) is a subtypes of CMT2 
linked with mutations in mitofusin 2 (Mfn2) (Zuchner et al., 2004; Verhoeven et al., 
2006). Mutations in Mfn2 account for 20-40% of all CMT cases and ~20% of all CMT2 
cases (Zuchner et al., 2005; Verhoeven et al., 2006). More than 60 mutations in Mfn2 
have been reported to be linked with CMT2A (Cartoni and Martinou, 2009) (Table 
1.2). Mutations are spread throughout the protein (Zuchner et al., 2004; Verhoeven et 
al., 2006) (Table 1.2). Heterozygous missense mutations predominate, but nonsense 
mutations and small in-frame deletions have also been reported (Zuchner et al., 2004; 
Engelfried et al., 2006; Verhoeven et al., 2006; Zuchner et al., 2006; Polke et al., 2011) 
(Table 1.2). The mode of inheritance is mainly autosomal dominant (Zuchner et al., 
2005; Chung et al., 2006; Verhoeven et al., 2006). However, families with homozygous 
or compound heterozygous mutations have also been reported (Nicholson et al., 2008; 
Vallat et al., 2008; Calvo et al., 2009; Polke et al., 2011) (Table 1.2). The age at onset is 
diverse even within and among families ranging from 1 year of age to the 6
th
 decade of 
life (Zuchner et al., 2006) (Table 1.2). Most of the affected individuals present 




 decade of life, though; many remain mildly affected or non-
symptomatic indicating low disease penetrance (Zuchner et al., 2006). Early onset 
CMT2A with progressive optic nerve dysfunction results in visual impairment and is 
classified under Hereditary Motor and Sensory Neuropathy type VI (HMSNVI) 
(Verhoeven et al., 2006; Zuchner et al., 2006). Usually the visual impairment gets 
worse, however, a subset of HMSNVI patient have shown recovery of vision later in 
life (Zuchner et al., 2006).  
Biopsies taken from CMT2A patients sural nerves have shown loss of axons and 
thick myelinated nerve fibers (Vallat et al., 2008). One report has shown that early onset 
cases show 70% reduction in myelinated fibers as compared to the late onset CMT2A 
(Chung et al., 2006). Though onion bulb formations which are the layers of Schwann 
cell proliferation around a regenerating nerve fiber are not typical feature of CMT2A as 
compared to CMT1, however few patients have also shown some pseudo-onion bulbs in 
the clusters of regenerating nerve fibers (Chung et al., 2006; Vallat et al., 2008). Sural 
nerve biopsies have shown small spherical mitochondria aggregated abnormally near 




































1.7.2 Mitochondrial morphology in patient derived fibroblasts 
In recent year mitochondrial morphology has been analysed in fibroblasts 
derived from CMT2A patients. Loiseau et al studied mitochondrial morphology in 







reported normal mitochondrial network morphology. However, they reported energetic 
metabolic defects in patient fibroblasts. They showed reduced mitochondrial respiratory 
control ratio due to increased oligomycin-insensitive respiration, reduced membrane 
potential and reduced oxidative phosphorylation efficiency (ATP production/oxygen 
consumption) (Loiseau et al., 2007). In another report, fibroblasts from CMT2A patients 









and one mutation in the HR2 domain Mfn2
L734V
 were analysed for mitochondrial 
morphology and fusion capacity (Amiott et al., 2008). This report also showed normal 
mitochondrial morphology with efficient mitochondrial fusion occurring. Also they 
reported no difference in Mfn2 expression levels, mtDNA content and respiratory 
capacity.  
Recently, another group has shown that fibroblasts derived from CMT2A patient 
carrying Mfn2 heterozygous mutation Mfn2
R94Q
 displayed enhanced fusion with 
increased branching and mitochondrial networks (Chevrollier et al., 2012). This is the 
first time any group has quantified the mitochondrial morphology using a computerized 
analysis (in this case Imaris FilamentTracer software) for the CMT2A fibroblasts. This 
report is in opposition to what Chan and colleagues showed by expressing Mfn2
R94Q
 in 
Mfn2 null MEFs (Detmer and Chan, 2007a). It is also important to mention that 
MitoCharc mice carrying Mfn2
R94Q
 mutation has also shown no mitochondrial 
morphology defects in motor neuron soma and axon. 
Another recent report has shown fragmentation of mitochondrial networks in 
fibroblasts carrying novel Mfn2 heterozygous mutation Mfn2
D210V
, however this 
mutation is associated with Optic atrophy ‘plus’ phenotype (Rouzier et al., 2012). This 
report has shown reduced Mfn2 expression in patients carrying D120V mutation but not 
in patients carrying another classical mutation Mfn2
A166T
. In addition Mfn2
D120V
 patients 
also carry multiple mtDNA deletions in muscles, thus adding Mfn2 to the list of genes 
responsible for mitochondrial myopathy. Muscle biopsy showed enlarged swollen 





fibroblasts showed respiratory impairment due to complex IV deficiency. 
1.7.3 In-vitro analysis of CMT2A associated Mfn2 mutations 
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 have normal fusion activity (Detmer and Chan, 
2007a). As discussed earlier, either Mfn1 or Mfn2 knockout MEFs show fragmented and 
aggregated mitochondrial morphology. Interestingly Mfn2
R94Q
 expression rescued 
mitochondrial fragmentation in Mfn2 null MEFs but not in Mfn1 lacking MEFs. This 
indicates that CMT2A-associated Mfn2 alleles (here Mfn2
R94Q
 which is unable to initiate 
fusion on its own) are able to form fusion capable complexes with wild-type Mfn1 by 
forming Mfn1/Mfn1 and Mfn1/Mfn2 (CMT2A allele)
 
complexes and not with wild-type 
Mfn2 (Detmer and Chan, 2007a). Furthermore, overexpression of CMT2A-associated 
Mfn2 mutations in dorsal root ganglion neurons results in mitochondrial aggregation in 
cell body and reduced number of mitochondria in distal axons (Baloh et al., 2007). 
Also, Mfn1 overexpression in motor neurons rescues the deficient mitochondrial 
transport associated with Mfn2
CMT2A
 alleles (Misko et al., 2010). 
It is still not clear that how Mfn2 mutations cause axonal degeneration, it can 
also be presumed that low Mfn1 expression in peripheral neurons may result in 
defective mitochondrial fusion and/or transport that could potentially result in many 
structural and metabolic complications. 
1.7.4 Transgenic models for CMT2A 
Transgenic mouse expressing Mfn2 GTPase mutation T105M in motor neurons 
under the control of HB9 motor neuron promoter has been reported to show gait defects 
and severe muscle atrophy due to axonal degeneration (Detmer et al., 2008). Motor 
neurons showed improper mitochondrial distribution with few mitochondria in axons 
which also form occasional clumps. However, heterozygous Mfn2
T105M
 mice were 
asymptomatic with no muscle atrophy and motor neuron degeneration (Detmer et al., 
2008). This is also in contrast to human disease as only a single copy of Mfn2 mutants is 
sufficient to cause neuropathy in humans. Additionally, sural nerve biopsies from 







 homozygous mice have shown few mitochondria in distal axon regions 
(Vallat et al., 2008; Funalot et al., 2009). Also, transgenic mice expressing Mfn2
R94Q
 
mutation in neurons develop late-onset neuropathy showing locomotion impairments 
and gait defects. Histopathological analysis of sciatic nerves has shown an increased 
mitochondrial density in the distal part of axons in addition to decrease in axonal size 
(Cartoni et al., 2010). Likely explanations for increased density of mitochondria in 
distal axonal regions might be due to defective retrograde transport of mitochondria 
leading to accumulation of mitochondria in distal regions or an enhanced mitochondrial 
fission or both. In addition Mfn2 knockdown in zebrafish results in developmental 
defects and motility impairments (Vettori et al., 2011). Recently, our group has also 
reported that loss of function mutations in Mfn2 results in motor deficit in zebrafish 
probably due to impired mitochondrial axonal tarsnport (Chapman et al., 2013). 
In the prospect of all the major advancement in the understanding the 
pathogenesis of CMT2A and HMSNVI it is still not clear how mutations in Mfn2 result 
in the cell specific degeneration of peripheral motor and sensory neurons. There are 
many questions still needed to be answered for example is mitochondrial dynamics is 
disturbed in these patients, is mitochondrial axonal transport is altered, is mitochondrial 
quality control mechanisms are disturbed etc. Studying these mechanisms in-vivo in 
patient derived cells and animal models would aid in the better understanding of disease 
pathology and development of potential treatments. 
1.8. Drosophila melanogaster as a model system 
The fruit fly Drosophila melanogaster has been successfully used as a model 
organism in the fields of genetics, developmental biology, neurobiology and 
pathophysiology. As a result of collaboration between Berkley Drosophila Genome 
Project and Celera genomics Drosophila melanogaster genome sequence was 
completed in 2000 (Celniker, 2000). Genome size is approximately 180 Mb encoding 
approximately 13600 genes (Adams et al., 2000). Interestingly, 60% of human disease 
genes have orthologues in Drosophila making them a powerful system to study disease 
genetics and pathology in-vivo (Celniker, 2000; Rubin and Lewis, 2000).  
Drosophila melanogaster has only four pairs of chromosomes, three autosomes 
and one sex chromosome. Female flies are homozygous for X chromosome (X/X) with 





(X/Y) and the ratio 0.5. Y chromosome contains few genes that are required for sperm 
differentiation (Bridges, 1916). Furthermore, recombination during meiosis is absent in 
male flies thus proving useful for genetic studies (Greenspan, 2004). The important 
genetic tools available in Drosophila are balancer chromosomes and phenotypic 
markers. Balancer chromosomes carry the normal sequence in a jumbled up manner that 
is due to a lot of inversions, chromosomes are unable to cross over with their 
homologues during meiosis. In addition balancer chromosomes also carry an easily 
identifiable marker (Greenspan, 2004). This is helpful in maintaining the stocks of 
homozygous lethal alleles in a heterozygous state without recombination.  
Many molecular pathways and several aspects of cell biology including gene 
expression, neural connectivity, organogenesis, cell signalling and cell death are similar 
in both flies and humans. The main reason for studying human diseases using 
Drosophila as an in-vivo model is because unbiased genetic screens to identify and 
analyze the components of pathological pathways can be performed. Forward genetic 
screens and reverse genetic approaches are typical method to study disease pathology in 
flies. Large amount of screening is necessary in forward genetic approaches to isolate 
the mutant of interest and such screens are done easily using various standard protocols 
in small set up (Celotto and Palladino, 2005). In reverse genetic approach the human 
diseases are modelled in Drosophila either by making transgenic flies expressing human 
genes or by targeting loss of function in fly orthologues of respective gene. In this 
approach using transgenic flies with the help of UAS-GAL4 system one can down 
regulate or over-express any gene in tissue specific pattern to analyze the phenotype 
(Brand and Perrimon, 1993; Johnston, 2002). Furthermore, UAS-GAL4 system allows 
expression of fluorescent proteins to be expressed in various tissue compartments in 
addition to tagging cellular organelles and studying their physiology in live or fixed 
samples (Johnston, 2002). 
On further practical basis Drosophila rearing needs less care and maintenance as 
flies can easily be grown on yeast agar food in small plastic vials or bottles. Flies have 
short generation time normally 10 days at 25ºC and have easily recognizable 
morphology of all the developmental stages. Virgin adult females can be distinguished 
easily to collect and use in genetic crosses. People have successfully developed low 
cost, easily performed and highly informative various every day assays such as larval 





Over the past years Drosophila melanogaster has been used extensively and 
successfully to study neurodegeneration in various common neurodegenerative diseases 
such as Parkinson’s disease, Alzheimer’s disease and Huntington disease. 
1.9 Aims and Objectives of the PhD Project  
The aim of the PhD project was to further investigate the role of Mfn2 in 
mitochondrial morphology. CMT2A and HMSNVI patient fibroblasts and Drosophila 
melanogaster were used as in-vivo model systems to study this cellular phenomenon. 
We aimed to test the hypothesis that pathogenic mutations in Mfn2 could lead to 
alterations in mitochondrial morphology. Enhanced fusion leads to longer mitochondria 
often making connections with each other forming mitochondrial networks and 
increased fission results in fragmented mitochondria. This balance is maintained by 
mitochondrial fusion and fission factors which are tightly regulated, since mitochondrial 
dynamics is considered to be important for a plethora of cellular processes such as 
energy production, calcium signalling, calcium buffering and apoptosis. To examine the 
effects of mutant Mfn2 on mitochondrial morphology, skin fibroblasts derived from 
CMT2A and HMSNVI patients carrying Mfn2 heterozygous mutations were used. Mfn2 
is involved in mitochondrial outer membrane fusion, suggesting that mitochondrial 
fusion may be defective in CMT2A and HMSNVI; however this remains to be 
confirmed. There are a few studies reporting mitochondrial morphological abnormalities 
in sural nerve biopsies done for CMT2A and HMSNVI patients (Verhoeven et al., 2006; 
Vallat et al., 2008). However, these nerve cells are not easily and readily accessible and 
not ideal to study the mitochondrial morphology in a large number of patients to profile 
mitochondrial morphology defects in CMT2A and HMSNVI. In recent years, 
researchers have successfully used patient derived skin fibroblasts as cellular model to 
analyse mitochondrial morphology and bioenergetic defects for various 
neurodegenerative diseases (Auburger et al., 2012). These fibroblasts are also ideal cells 
to study mitochondrial morphology as they carry the genetic and environmental factors 
which the patients were exposed to in their lifetime. Thus these cells will help us to 
better understand the mitochondrial morphological defects if any present in CMT2A 
and HMSNVI patients and to carry out various cellular assays to quantify the defects.  
The second objective was to characterise ethacrynic acid (EA), a potent 
mitochondrial fusion-inducing compound identified previously by Soltys and Gupta 





my PhD. EA treatment results in increased mitochondrial length and mitochondrial 
networks in cultured cells. Soltys and Gupta suggested that the cysteine alkylating 
nature of EA might be responsible for the increased mitochondrial fusion. However, 
they did not characterise the cellular targets and mechanism through which EA 
promotes mitochondrial fusion. Therefore, in this project I wanted to extend this work 
by characterising EA and seeing its effect on mitochondrial morphology under 
increased mitochondrial fission. Also, as a part of on-going drug screen to identify the 
compounds affecting mitochondrial morphology and increasing mitochondrial fusion, 
we in the department wanted to develop a potential treatment for fusion defective 
disorders and/or a bench tool to study mitochondrial dynamics. Having such goals are 
important for commercial and economic growth of the department which is appreciated 
in SITraN. 
The third objective of the project was to characterise Drosophila Mitofusin 
(Marf). Drosophila Marf has been studied before in various genetic interaction studies 
relating to the PINK1/Parkin pathway involved in mitochondrial dynamics (Poole et al., 
2008; Ziviani et al., 2010). In the beginning of my PhD, involvement of Marf in fly 
development and locomotion was not characterised, therefore, we aimed to generate 
Marf transgenic and genetic mutants and study the effect on development and 
locomotion. Also, Drosophila provides an opportunity to study mitochondrial 
morphology in motor neurons easily, offering an additional opportunity to study cellular 


















































2.1 Maintenance of tissue culture cell lines 
2.1.1 Solutions 
Fetal Calf serum (FCS) 
10% FCS (Lonza), 10% FCS (Invitrogen) 
L-glutamine 
Stock concentration: 200mM L-glutamine (Lonza) 
Working concentration: 2mM L-glutamine 
1% Pen-Strep 
Stock concentration: 10,000UI Penicillin and 10,000μg/ml Streptomycin (Lonza) 
Working concentration: 100UI/ml penicillin, 100μg/ml streptomycin 
Sodium Pyruvate Solution 
Stock concentration: 100mM sodium Pyruvate Solution (Lonza) 
Working concentration: 1mM sodium Pyruvate Solution 
Minimum Essential Medium non essential amino acids 
Stock concentration: 10mM non-essential amino acids (Lonza) 
Working concentration: 0.1mM non essential amino acids 
Minimum essential medium vitamins 
Stock concentration: 10mM Minimum essential medium vitamins (Lonza) 
Working concentration: 0.1mM Minimum essential medium vitamins 
Minimum Essential Medium (MEM) for human fibroblasts culture 





glutamine (Invitrogen), 1% Pen-Strep, 1mM sodium pyruvate, 0.1mM non essential 
amino acids and 0.1mM minimum essential medium vitamins. 
Dulbecco’s modified Eagle’s medium (DMEM) media for CV14A cells culture 
DMEM (Lonza) supplemented with 10% FCS (Invitrogen), 2mM L-glutamine  
(Invitrogen) and 1% Pen-Strep. 
Ethylene diamine tetra acetate(EDTA) 
0.5M EDTA, pH 8.0 made up in deionised water and autoclaved 
Trypsin-EDTA 
trypsin 0.25% with EDTA 0.02% (Sigma) 
Poly-L-Lysin 
5X Stock Solution made up adding 50ml deionised water, 1X used as working 
concentration. 
Phosphate buffered saline (PBS) 
PBS tablets (Sigma): 1 tablet dissolved in 200ml of deionised water yields 0.01 M 
phosphate buffer. 
3.7% formaldehyde fixative 
3.7% formaldehyde was made up in PBS from 37% formaldehyde (Sigma) 
Cells freezing solution 








2.1.2 CV14A cells 
CV14A cells are green monkey fibroblasts stably transfected with 
mitochondrially targeted DsRed1 and were kindly provided by Dr. Kurt J. De Vos (De 
Vos et al., 2003). 
2.1.2.1 Culture of CV14A fibroblasts 




 flasks in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum 
(Invitrogen), 2mM L-glutamine (Invitrogen) and 1% Pen-Strep and maintained at 37°C, 
under 5% CO2 in air. Cultured CV14A cells show cytoplasmic prolongation (<60% 
confluency) scattered on the culture surface which would later show a fusiform 
morphology once the culture is confluent (>60% confluency). CV14A cells were 
passaged 1:8 twice a week. 
2.1.2.2 Subculture of CV14A fibroblasts 
Subculture (passage) of fibroblasts was done with 80% cellular confluency in 
the flask. After aspirating the culture medium, the cells were rinsed with phosphate 
buffered saline (PBS) twice and then 2ml of trypsin 0.25% with EDTA 0.02% (Sigma) 
was added and the flask is maintained in humidified incubator for 5 minutes or until the 
cells had fully detached. Cells detached from the plastic surface were observed with 
spherical morphology. 8ml complete medium was added to the flask to inhibit the 
enzymatic action of trypsin and 1/8 part of cells with media were split into a new flask. 
They were kept in an incubator at 37ºC with 5% CO2. 
2.1.3 Human fibroblasts 
The human fibroblasts used in this study were obtained from Prof. Frank Baas 
(Academic Medical Centre, Amsterdam, Netherlands) under informed consent. 
2.1.3.1 Primary culture of human fibroblasts 
Primary fibroblast cells were cultured continuously in minimum essential 
medium (MEM) with 10% fetal calf serum, 2mM L-glutamine, 1% PenStrep (100UI/ml 





acids and 0.1mM minimum essential medium vitamins. This glucose-containing culture 
medium was used for all measurements (both biochemical and morphological) unless 
otherwise stated. 
2.1.3.2 Subculture of human fibroblasts 
Subculture (passage) of fibroblasts was done with 80% cellular confluency in 
the flask. After aspirating the culture medium, the cells were rinsed with PBS twice and 
then 2ml of trypsin was added and the flask was maintained in humidified incubator for 
5 minutes. 8ml complete medium was added to the flask to inhibit the enzymatic action 
of trypsin and 1/5 part of cells with media were split into a new flask. They were kept in 
an incubator at 37ºC with 5% CO2. 
2.2. Quantification of mitochondrial morphology for human fibroblasts 
2.2.1. Plating fibroblasts on 6 well plate 
22mm coverslips were placed in 6 well plate and incubated at 37ºC for 20 
minutes in 0.1mg/ml poly-l-lysine (Sigma) prior to plating. Coverslips were washed 
twice in sterile H2O. Human fibroblasts were grown in a 75cm
2
 flask until they reached 
80% confluency and were trypsinised as in section 2.1.3.2. The cell suspension was 
mixed well by gentle agitation of the flask. Before the cells have a chance to settle, 10µl 
of cell suspension was carefully added to the haemocytometer by gently resting the end 
of the Gilson tip at the edge of the chambers. 10X objective of the microscope used and 
cells were counted in all 4 sets of 16 corner squares. The cell count was determined and 
3.2x10
4
cells/ml were plated per well of a 6-well plate. Cultures were kept in an 
incubator at 37ºC with 5% CO2 overnight to establish for further experiments. 
 2.2.2 Preparation of Staining Solution 
Human fibroblast mitochondria were ideally stained with thiol-reactive 
chloromethyl moiety containing cell permanent MitoTracker probes (Invitrogen). These 
probes passively diffuse across the plasma membrane and accumulate in active 
mitochondria and retain in the mitochondria even after fixation. The stock for 
MitoTracker Red CMXRos (Molecular Probes) was prepared by adding anhydrous 





1mM. This stock was always kept at -20ºC. 
2.2.3 Labelling mitochondria for visualisation with MitoTracker RED 
Once the cells reached the desired confluency, fibroblasts were stained with 
66nM MitoTracker Red CMXRos freshly prepared in prewarmed MEM media and 
incubated for 3 min at 37ºC. Cells were subsequently washed 3 times with prewarmed 
fresh media for 1 min each at 37ºC. 
2.2.4. Live image acquisition 
2.2.4.1. Mounting cells for live imaging 
A square smaller than the size of 22x22mm coverslip was made in the middle of 
a chamber glass slide with high vacuum grease using a syringe. 200µl of media in 
which fibroblasts were growing was added in the chamber and the coverslip with cells 
was placed on it with cells face down in contact with the warm media. The edges of the 
coverslip were coated in wax made up of equal parts lanolin, vaseline and paraffin wax 
to prevent any air escaping and liquid leakage. 
2.2.4.2 Image capture of cells for mitochondrial morphology analysis 
The mounted slides were then placed under a 63X/1.25NA oil Antiflex Plan-
Neofluar objective on an upright Manual Zeiss Axiophot microscope with phase 
contrast and DIC for transmitted light illumination. This microscope was equipped with 
DAPI, FITC and TRITC filter sets (Chroma Technology Corp) for conventional 
epifluorescence illumination with (100W HBO lamp), Lambda 10-2 filter wheel (Sutter 
Instrument Company) and a multiformat CCD camera C4880-80 (Hamamatsu). Images 
were taken using the modular imaging software Openlab (PerkinElmer). 566nm 
fluorescence (Dsred2mito/CMXRos) image was taken for approximately 50-60 cells per 
sample and per condition. The exposure time was set as low as possible whilst still 
maintaining visible MitoTracker staining. This was done to keep bleaching and 
phototoxicity to a minimum. Images were saved as 12-bit gray scale TIFF (tagged 
image file format) files. Prior to image acquisition, images of a graticule (Watson, UK) 






2.2.5 Post-Imaging analysis using ImageJ 
To study mitochondrial morphology in human fibroblasts mitochondrial aspect 
ratio, mitochondrial length, mitochondrial bifurcation ratio and mitochondrial network 
complexity were quantified using ImageJ software and following the procedure for 
mitochondrial morphology analysis as described by De Vos and Sheetz (De Vos and 
Sheetz, 2007) with some modifications which are described in the text. 
2.2.5.1 Image processing to calculate mitochondrial aspect ratio and 
length 
Mitochondrial aspect ratio is the ratio between the major and minor axis of the 
ellipse equivalent to the mitochondrion (De Vos and Sheetz, 2007). 
AR=lmajor/lminor 
Where major axis is the longitudinal length and minor axis is the equatorial 
length of the ellipse fitted to the mitochondrion. As the shape of mitochondria 
resembles an ellipse therefore aspect ratio is a reliable measurement of mitochondrial 
length, however aspect ratio is a parameter suitable for individual mitochondria. 
Mitochondrial length is a direct measurement of individual mitochondrion 
length with reference to its height and width. 
Images were transferred as TIFF files to a computer with ImageJ software (by 
W. Rasband (NIH, Bethsada, MD; http://rsbweb.nih.gov/Imagej) and plug-ins written 
by Kurt J. De Vos (De Vos and Sheetz, 2007). Each Image file was opened as a stack of 
30 images. Each individual image in one stack represents individual cells therefore 
stack was converted into 30 individual images. All the raw images were 16-bit images. 
In fibroblasts the mitochondria are organised in a large network near the centre 
of the cell, also touching the neighbouring mitochondria and can result in over 
estimated measurements. Therefore to analyse individual mitochondria, the networked 
mitochondria were removed to avoid these artifacts.  





i. Adjust Image Brightness/Contrast 
Each individual raw image was opened in the ImageJ and the brightness and contrast 
was set to ensure even pixel intensity values across the entire image. 




ii. Removing Networked Mitochondria 
 
Filter the original image with a 15x15 Gaussian filter: 
 
ImageJ: Process>Filters>Convolve>Gaus 15x15 
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Apply the threshold; mitochondria show up black. 
 
Select the networked mitochondria using the wand tool in ImageJ. 
 
Restore the selection on the original image: 
 
ImgaeJ: Edit>Selection>Restore Selection 
 




iii. Segmenting touching Mitochondria 
 






ImageJ >Process>Filters>Convolve>MHat 5x5 
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iv. Producing 8-bit binary image: 
Subtract the convolved image from the cleared image obtaining a 32-bit result: 
ImageJ: Process>Image Calculator 
Threshold the resulting image to include all mitochondria and apply. 
Convert the threshold image to 8-bit: 
ImageJ: Image>Type>8-bit 
Threshold the 8-bit image and apply. 
Using the resulting binary image, count the number of mitochondria, determine the area 
and the best fitting ellipse for each organelle per time point by particle analysis: 
ImageJ: Analyze>Analyze Particles 
v. Mitochondrial Aspect ratio calculation 
Calculate aspect ratio by dividing the major axes over minor axes and then get 
the average aspect ratio per cell. 
Aspect ratio=Major axis/Minor axis 
vi. Mitochondrial Length calculation 
Calculate the length of mitochondria by taking the bigger value from height and 






2.2.5.2 Image processing for mitochondrial branching and networks 
Fibroblasts commonly show enormous branching and large networks of 
mitochondria. Mitochondrial branching and networks are defined as the quantification 
of the form factor of mitochondrial dynamic morphology in a cell. To quantify 
branching and network morphology I followed the same procedure as described by De 
Vos and Sheetz, 2007. 
i. Creating a skeleton image 
The individual raw image was opened in the ImageJ and converted into binary 
image: 
ImageJ>Process>binary>make binary 
The binary image was then converted into skeleton: 
ImageJ>Process>binary>skeletonise 
The image skeleton allows quantification of mitochondrial branching and connectivity 
as it involves erosion of any foreground pixel touching the background pixels except 
where the foreground pixels have value above background pixels. This leaves behind a 
skeletal remnant that largely preserves the extent and connectivity of the original 
network.  
ii. Bifurcation ratio and network complexity ratio calculations 
Branching and networks can be estimated by counting the endpoints and the nodes of 
the mitochondrial network. For instance a single mitochondrion has two end points and 
single branch point. 
After creating a skeleton binary image, end point and branch points were calculated 
using the Binary Connectivity plug-in written by G. Landini 
(http://www.dentistry.bham.ac.uk/landining/software/software.html). 
ImageJ>Plugin>Morphology>Binary Connectivity 






Look up the histogram for the graphic output and numeric results. 
ImageJ>Process>Histogram>List 
Numeric results were imported into Excel file and Branching or bifurcations was 
calculated by: 
Bifurcation ratio=Bifurcations/Endpoints 
Finally, network complexity ratio is calculated by: 
Network complexity ratio = Sum(four-way+five-way+….)/endpoint 
2.2.5.3. Statistical Analysis 
All the statistical analyses were performed using Prism software. Normality of 
the data was tested with D'Agostino-Pearson omnibus K2 test. Then for normally 
distributed data sets one-way ANOVA was used to analyse the statistical difference 
with Tukey’s post test for multiple comparisons. For non-normally distributed data sets 
non-parametric Kruskal-Wallis test followed by Dunn’s multiple comparisons test was 
performed to determine the statistical significance. 
2.3 Screen for mitochondrial fusion inducing compounds 
2.3.1 Drug library for the screen 
The drugs used in the screen were either taken from the literature search with 
relevance to their role on mitochondrial dynamics and/or also from the Spectrum 
Collection library of compounds details in result section 4.2 and Table 4.1. 
2.3.1.1 Preparation of Drug Stocks 
1000X stocks for all the drugs were prepared in DMSO or chloroform. Stocks were then 
aliquoted and kept at -20ºC.  





13mm cover slips were placed in 24 well plates and incubated at 37ºC for 20 
minutes in 0.1mg/ml poly-l-lysine prior to plating. Coverslips were washed twice with 
sterile H2O. CV14A cells were grown in a 75cm
2
 flask until they reached 80% 
confluency and were trypsinised as in section 2.1.2.2. The cell count was determined 
and 4x10
4
cells/well was plated in 24-well plate. Cultures were kept in an incubator at 
37ºC with 5% CO2 overnight to establish for further experiments. 
2.3.1.3 Addition of Drugs 
The drugs were made up from stock solution in half fresh and half conditioned 
DMEM medium in which cells were growing at a range of concentrations mentioned in 
the text of result section 4.2.1 and Table 4.1 Drug treatments were for 15 minutes, 4 
hours and 24 hour at 37ºC with 5% CO2. 
2.3.1.4 Fixation and mounting of cells 
CV14A cells were fixed with an aldehyde-based fixative. 3.7% formaldehyde in 
PBS was used. Cells were washed with PBS and incubated for 20 min at room 
temperature in 3.7% formaldehyde in PBS (Sigma). They were washed 2 times in PBS. 
13mm coverslips carrying cells were then placed, cells face up on microscope slides. 
50μl 50% glycerol/PBS was added to the coverslip and a 22x22mm glass coverslip 
placed on top. The edges were sealed with wax made up of equal parts lanolin, vaseline 
and paraffin wax. 
2.3.1.5 Image capture of cells for mitochondrial morphology analysis 
Slides were placed on the microscope set up and images were taken as shown in section 
2.2.4.2 and later saved as stacks of TIFF files. 
2.4 Cell Viability Assay 
A widely used MTT colorimetric assay was performed to determine the effect of 
drugs on viability and growth of cells. MTT (3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) is a yellow tetrazole salt that enters the mitochondria and is 
reduced  by mitochondrial succinate dehydrogenase to an insoluble formazan (purple) 
(Mosmann, 1983). The cells are then solubilised or lysed with an organic lysis solvent 





reduction of MTT can only occur in metabolically active cells the level of activity is a 
measure of the viability of the cells. 
2.4.1 MTT reagents 
MTT solution was prepared at 5mg/ml in PBS and was filtered through a 0.2µm 
filter. The falcon was wrapped in aluminium foil as MTT is photosensitive and kept at 
4ºC. 
Lysis solution: 100g SDS was dissolved in 200ml of dH2O and stir overnight at 
60ºC. Next day 200ml of dimethyl formamide (DMF) was added to the solution and the 
pH was adjusted at 4.7 by adding few drops of 1M HCl: glacial acetic acid (1:1). The 
final volume was made up to 500ml by adding 50% DMF (DMF: H2O, 1:1). 
2.4.2 MTT Assay 
Human fibroblasts were cultured in MEM media at the density of 
4x10
4
cells/well in 96-well flat bottom plate and were grown overnight at 37ºC. On the 
following day 100µl of various drug concentrations were added to the cultures and 
incubated for 24 hours at 37ºC. After 24 hours drug incubation, 10µl of 5mg/ml MTT 
solution was added in each well and incubated at 37ºC for 2 hours. In the meantime 
lysis solution was warmed up to 37ºC. MTT solution and media was aspirated and 
replaced with 100µl lysis solution. The plate was left on bench top plate shaker for 1 
hour at room temperature. The optical density of the wells was read on 
spectrophotometer at a wavelength of 570nm. 
2.5 Quantification of mitochondrial fusion 
Poly-ethylene glycol (PEG) is a polyether and is an important reagent to study 
membrane fusion in-vitro (Lentz, 2007). In membrane fusion two initially distinct lipid 
bilayers merge their hydrophobic cores to form interconnected structure. These 
structures can be hemifused when only one leaflet of a bilayer is involved in fusion or 
fully fused where the internal contents of the two structures has completely mixed 
(Holopainen et al., 1999). PEG has shown its significance in promoting fusion via its 
ability to bind to a large number of water molecules present on lipid bilayer surfaces. 





in a dehydrated region and promotes cell-cell fusion (Arnold et al., 1990; Burgess et al., 
1992). Recently, PEG fusion assay has been used in several studies to measure 
mitochondrial fusion activity in cell hybrids (Chen et al., 2003; Chen et al., 2005; 
Detmer and Chen, 2007a). 
2.5.1 PEG reagents 
DMSO/PEG (Sigma) mix, DMEM +10%DMSO, 35mg/ml cycloheximide in DMSO, 
DMEM complete media+ 30μg/ml cycloheximide (made fresh every time). 
2.5.2 PEG Fusion Assay 
5x10
4
cell/well CV14A cells expressing mitochondrially targeted DsRED were 
co-cultured with 5x10
4
cells/well CV14A cells expressing mitochondrially targeted GFP, 
overnight on 13mm cover slips coated with poly-l-lysine in 24 well plates. The next 
day, media was removed and cells were fused for 1 minute with 200µl 10% DMSO/ 
50% PEG solution. The cells were washed 3 times with DMEM+10%DMSO solution 
followed by one wash with DMEM complete media. Cells were then incubated for 30 
minutes at 37ºC in the presence of DMEM complete media+30µg/ml cycloheximide. 
Cycloheximide was included to prevent synthesis of new mitochondrially targeted 
DsRed or GFP in the fused cells. After 30 minutes incubation freshly prepared drug 
dilutions in DMEM complete media+30µg/ml cycloheximide were added to the cells 
for 4 hours. At the end of 4 hours drug incubation cells were fixed as discussed in 
section 2.3.1.4. 
The cells were then scored for fusion under a 63X/1.25NA oil Antiflex Plan-Neofluar 
(Zeiss) objective on the upright Manual Zeiss Axiophot microscope. 
2.6. Fis1 overexpression in CV14A cells 
2.6.1 Plasmids used 
Human myc-tagged Fis1 plasmid (hFis1) was a kind gift from Dr. Yisang Yoon 
(University of Rochester, USA) (Yoon et al., 2003). pCI-NEO empty vector (Promega), 
EGFP-C2 empty vectors (Clontec) and EGFP-peroxisome (Clontec) were gift from Dr. 





2.6.2 DNA preparation and purification 
Bacterial cultures of all the plasmids used were prepared from glycerol stocks by 
dipping the end of a sterile 10μl pipette tip into the appropriate frozen glycerol stock 
and placing in 5ml of LB broth containing 50μg/ml (final concentration) of the 
appropriate antibiotic. For hFis1 and pCI-NEO empty vector cultures were grown in 
presence of carbenicillin (50µg/ml final concentration). EGFP-cyto and EGFP-peroxi 
were grown in presence of Kanamycin (50µg/ml final concentration). The inoculated 
LB broth 5ml cultures were incubated overnight in the shaking incubator (200rpm) at 
37°C. 
2.6.3 Plasmid isolation using QIAprep Kit Method (Silicon based) 
Overnight cultures were then centrifuged at 4000g for 10 minutes. The 
supernatant was discarded and the tubes were inverted on paper towels. 250μl of 
resupension buffer A1 (4°C) was added and the pellet was resuspended by pipetting up 
and down. The homogenised mixture was transferred to a 1.5ml eppendorf tube and 
250μl of lysis buffer A2 was added. The tubes were gently inverted 5-6 times in order to 
lyse the cells. 300μl of neutralising buffer A3 was added and mixed by inversion. The 
samples were centrifuged at 13000rpm for 10 minutes to pellet debris. The supernatant 
was loaded onto the spin column and a 2ml collection tube and centrifuged for 
13000rpm for 1 minute. The flow through was discarded. 500μl of AW buffer was 
added to enhance the binding of plasmid to the membrane of the spin column and 
centrifuged for 1 minute at 13000rpm and the flow through was discarded. The column 
was washed with 600μl buffer A4 and the flow through was discarded after spinning at 
13000rpm for 1 minute. Centrifugation was repeated for 2 minutes at 13000rpm to 
remove all traces of A4 solution. The column was placed in a clean 1.5 ml tube and 
50μl of AE (elution buffer) was loaded on the column. The column was centrifuged at 
13000rpm for 1 minute and the plasmid DNA eluted in the AE buffer was collected and 
stored at -20°C. 
2.6.4 Quantification of plasmid DNA 
Plasmid DNA was quantified using the Nanodrop Spectrophotometer ND-1000 
(NanoDrop Technologies, Wilmington, USA). The nanodrop was first initiated with 2μl 





DNA was then used to assess the concentration in ng/ml. 
2.6.5 Fis1 overexpression in CV14A cells for mitochondrial 
morphology analysis 
2.6.5.1 Qiagen Effectene transfection 
Effectene is a nonliposomal lipid reagent for DNA transfection into many 
sensitive cell lines and primary cells. CV14A cells were plated at 2.5x10
4
cells/well density 
on 13mm coverslips in 24 well plates as discussed in section 2.3.1.2. After 12-18 hours 
transfection was performed. 1µg DNA containing 3:1 ratio for gene of interest (hFis1 
plasmid or empty vector plasmid) and reporter gene (GFP-cytoplasmic) was added in 
EC buffer (provided in the kit), followed by the addition of 8µl of enhancer making the 
total volume 120µl. This solution was mixed and vortexed for 1-2 seconds and 
incubated at room temperature for 5 minutes. After incubation 5µl of effectene 
transfection reagent was added, vortexed for 10 seconds and pipetted up and down 
gently, avoiding bubble formation, and incubated for 10 minutes at room temperature.  
Lastly, serum free media was added making the volume 200µl. The transfection 
mix was vortexed for 10 seconds and incubated at room temperature for 10 minutes. In 
the meantime cells were washed with sterile PBS and 200µl fresh complete media was 
added. After incubation, 20µl of the transfection mix was added to each well of the plate 
and cells were kept in the 37ºC incubator for 4 hours. 
2.6.5.2 Drug addition 
After 4 hours the transfection mix was aspirated and cells were given a wash 
with sterile PBS followed by the addition of various concentration of ethacrynic acid 
and 0.1% DMSO made in pre-warmed complete media (for details see Table 4.1). The 
plates were then incubated in 37ºC incubator for 24 hours. 
2.6.5.3 Cell fixation, Hoechst staining and Mounting 
After 24 hours drug incubation CV14A cells were fixed as discussed in section 
2.3.1.4. The fixed cells were then stained with Hoechst stain for nuclear morphology. 
Hoechst dyes are bisbenzimidazole derivatives and are commonly used to stain genomic 





(Molecular Probes) at the concentration of 0.2µg/ml in PBS for 10 min at room 
temperature in dark. Afterwards cells were washed twice with PBS to remove unbound 
dye. After Hoechst staining cells were the mounted on the glass slides as discussed in 
section 2.3.1.4.  
2.6.5.4 Assessment of mitochondrial morphologies 
Assessment of mitochondrial morphology was conducted on samples which had 
been re-named/re-numbered so the investigator was blind to the experimental condition. 
For each condition 200 cells were scored under 63X/1.25NA oil Antiflex Plan-Neofluar 
(Zeiss) objective on upright Manual Zeiss Axiophot microscope. 
2.6.6 Fis1 overexpression in CV14A cells for peroxisome morphology 
analysis 
2.6.6.1 ExGen500 transfection 
2.5x10
4
cell/well CV14A cells were plated in 24-well plate as discussed in 
section 2.3.1.2. 1 µg of DNA containing 3:1 ratio for gene of interest (hFis1 plasmid or 
empty vector plasmid) and reporter gene (GFP-peroxisome plasmid) was diluted in 20µl 
of 150mM NaCl. The mixture was vortex gently, 3.3µl of ExGen 500 (Fermentas) was 
added and vortex the solution immediately for 10 seconds. The transfection mix was 
then incubated for 10 minutes at room temperature. 20µl of the transfection mix (ExGen 
500+DNA mixture) was added drop-wise to the cells in each well containing 200μl of 
culture media. Cells were incubated at 37ºC for 4 hours, then 800μl of pre-warmed 
culture media was added and transfections were monitored 24 hours later. 
2.6.6.2 Drug Addition 
After allowing the transfection for 24 hours different concentrations of 
Ethacrynic acid were added to the cells. Cells were then incubated for next 24 hours in 
37ºC incubator. 
2.6.6.3 Image Acquisition and Processing 
After 24 hours drug incubation CV14A cells were fixed and mounted on the 





on Olympus FV1000 confocal microscope. 30 Z-stack images were taken for each 
condition. 
2.6.6.4 Peroxisome count analysis using ImageJ 
The maximum intensity Z-stack tiff image file was opened in the ImageJ and converted 
into Z-projection. 
ImageJ>Image>Stacks>Z-project 
The 5x5 Mexican Hat filter was applied to the 16-bit image 
 
ImageJ >Process>Filters>Convolve>MHat 5x5 
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Number of peroxisome per cell was calculated by applying particle analysis  
 











2.7. Fly Stocks 
Fly stocks including wild type w
1118
 and balancer stocks (CyO/MKRS, 
Gla;TM6B, If/CyO;TM6B/MKRS, FM7.GFP) were used from already existing stocks in 
the department and were originally obtained from the Bloomington Drosophila stock 
centre. GAL4 expressing lines including da-GAL4, elav-GAL4, D42-GAL4 were 
obtained from the Bloomington Drosophila Stock. The UAS-RNAi lines; UAS-Marf-
IR(GD) and UAS-Marf-IR(KK) were purchased from Vienna Drosophila RNAi Centre 
(VDRC). 
The deficiency line Df(1)Exel6239 used in EMS genetic screen, was from the 
Exelixis library, molecularly mapped based on the known position of the P-elements 
that were used to make the lines. Df(1)G4e[L]H24i[R] used in complementation assay 
was cytologically mapped deletion of DrosDel collection from the Bloomington 
Drosophila Stock Center (http://www.drosdel.org.uk/coverage.php). The attached XX 
duplication stock C(1)DX y f/FM7h/Dp(1;Y)dx
+
 was generated by Dr. Alex Whitworth 
by combining compound X stock with Dp(1;Y)dx
+
 stock sourced from Bloomington 
Drosophila Stock Center (http://flystocks.bio.indiana.edu/). 
2.8 Fly Husbandry 
All the flies were maintained in a humidified chamber (20-40% humidity) at 
25ºC or 18ºC on 12 hour dark-light cycle. Flies were grown in 250ml bottles containing 
25% filled standard yeast, cornmeal and agar medium. Stocks were grown at 18ºC and 
the flies were transferred into fresh food every 3 weeks. The experimental crosses were 
kept at 25ºC and were turned over every 3 days for maximum progeny collection. An 
experimental cross usually consists of 2 males and 5 females in a 10ml vial. However, 
crosses set up in bottles consist of 8-10 males and 16-20 females. 
2.9 Behavioural Assays 
All the behavioural experiments were performed in a genotype-balanced 
manner. Flies were reared in bottles, kept as mixed genders to allow mating, and kept 
with standard food at all times prior to testing, unless noted otherwise in the text. On the 
day of experiment the flies were allowed to acclimatize to the testing room for 2 hours 





All behavioural assays except larval locomotion assay were carried out at 25°C. 
2.9.1 Larval locomotion assay 
Drosophila larval crawling involves repeated, rhythmic, peristaltic contraction. 
During each peristaltic stride, muscle contractions are propagated from rear end of the 
body to the mouth, passing through all 11 segments one by one and pushing the larvae 
one step forward (Berrigan and Pepin, 1995). The larval locomotion assay was 
performed as described previously (Feiguin et al., 2009). Wandering third instar larvae 
were used for the assay. Individual larva was placed on a 100mm plate containing a 
matrix of 1% agarose and allowed to adapt for 30 seconds. The larva was then allowed 
to crawl across the dish for 2 minutes and under the stereoscope the peristaltic waves 
were counted. 20 larvae for each genotype were counted individually. 
2.9.2 Climbing Assay 
The climbing behaviour was assessed in a counter-current apparatus consisting 
of 6 chambers for two 18x150mm Pyrex test tubes joined by a sliding bridge (Benzer, 
1967). Flies were set in a cohort of 20 adult flies and habituated for 2 hours in the 25ºC 
room. Normally, 5 cohorts of 20 flies were tested each time. To start the assay, flies 
were introduced in lower tube of the first chamber of the apparatus and allowing 
20seconds to reach the top of the chamber. With the help of sliding bridge the 
successful climbers were then shifted into the next chamber and the process repeated 
four times (making five in total). At the end the number of flies in each chamber was 
noted and climbing index was calculated based on the distribution of the flies across all 
the chambers (Greene et al., 2003). 
2.9.3 Flight Assay 
The same cohort of flies used in climbing assays were analysed in flight assays. 
Flight assays were usually carried out after climbing assays. Flies were dispensed 
downwards through a 64x465mm 1-litre graduated cylinder via funnel. The cylinder has 
been lined with an acetate sheet coated with vacuum grease. The sheet was divided 
vertically into 5 equal parts. During the free fall from the top the flies with the ability to 
fly adhere to the grease. Number of flies in each section was noted and given a score. 





score. The flight index was calculated based on the distribution of the flies across all the 
sections. 
2.9.4 Longevity Assay 
For longevity assay all the experimental flies were reared and the lifespan trials 
were conducted in a humidified chamber (20-40% humidity) at 25ºC on 12 hour dark–
light cycle. 0-24 hour’s old flies were collected and kept in food vial at the density of 20 
per vial with a proportion of 10 male and 10 female. 200 flies were used for each 
genotype. After every three days the flies were transferred to new vial containing fresh 
food and number of dead flies was scored. In experiments with Ethacrynic acid feeding 
the flies were kept in vials containing food and Ethacrynic acid or DMSO. The 
mortality was recorded daily for 30 days. 
2.10 Neuromuscular Junction study 
2.10.1 NMJ dissection 
3
rd
 instar wandering larvae were selected for neuromuscular junction study. 
Selected larvae were collected in a glass plate containing 1xPBS to wash away the food. 
A drop of cold 1xPBS was dropped on the sylgard dissection plate and an individual 
larva was placed in it. This will keep the larvae from drying and stun the larvae to 
restrict their active movements. Larva was pinned using minuten pins between posterior 
spiracles and in the head near the mouth hooks. Larval body wall muscles were 
carefully opened in the dorsal side using surgical spring scissors. Internal organs were 
removed with the help of forceps and the fillet was carefully washed with 1xPBS buffer. 
The cuticle was laterally expanded on both sides in order to see the nerve muscle 
interactions in all muscles of each segment.  
2.10.2 Sample fixation, immunocytochemistry and mounting 
The dissections were fixed in 4% paraformaldehyde (Sigma) in PBS for 20 
minutes. The preparations were washed in PBS-0.1% Triton (PBST) for 3x5 minutes 
each. Samples were incubated for 2 hours at room temperature or overnight at 4ºC with 
neuronal marker 1:200 dilution of anti-HRP (Jackson ImmunoResearch) in PBST. After 





3x10 minutes PBST washes. The secondary anti-rabbit AlexaFlour594 (Molecular 
Probes) was incubated at 1:500 dilution in PBST for 2 hours room temperature or 4ºC 
overnight. Samples were given 3xPBST quick washes, followed by 3x10 minutes PBST 
washes. After washes all the PBST was removed and replaced with 70% 
Glycerol+30%PBS solution to remove the air bubbles. The samples were left in the 
fridge for overnight or 3-4 hours at room temperature. Dissected larvae can be stored for 
up to one week at 4°C. Lastly the samples were mounted on glass slide with mowiol 4-
88 (Sigma-Aldrich). A coverslip was placed on the top and the edges were sealed with 
nail varnish. 
2.10.3 Muscle imaging and Bouton quantification 
Bouton number and NMJ branches were acquired from longitudinal muscle 6/7 
of hemisegment A3. All the observations were made by eye under epi-fluoresence 
microscope using 63X objective. Methods used for recording and quantification were 
same as discussed by Milton et al 2011 with minor modifications. 
2.10.3.1 Normalized Bouton number 
Bouton number is determined by counting every distinct anti-HRP stained 
swollen spherical structure at the neuromuscular junction. To minimise the effect of 
reduced developmental size between various genotypes we determined the muscle 
surface area as well to normalise all the calculations to the controls. Muscle surface area 
was calculated by imaging muscle 6/7 with a 10X objective Leica DC500 digital camera 
with a Leica DMLA microscope. Muscle surface area size was measured as drawing a 
straight line across the junction of muscle 6 and 7 (X) and then drawing a straight line 
parallel to the muscle extremes in the middle of muscle 6 and 7 (Y). X refers to length 
of the muscle and Y stands for width of the muscle. X and Y were determined by using 
measure>ImageJ. Area was then calculated by multiplying X and Y. Bouton numbers 
for testing genotypes were then determined by following formula: 
Normalized bouton number for the test= actual bouton count for test/(average muscle 
surface area of test /average muscle surface area of control) 





Branch number was defined as the divergent points or extensions on the presynaptic 
motor neuron. 
2.10.3.3 Confocal imaging for mitochondrial morphology 
Z-stack images were taken using a Carl Zeiss LSM510 confocal microscope 
using Plan-Apochromat 63X NA 1.4 oil objective. Images for the cell bodies, segmental 
nerve segments and synaptic boutons were taken from the fixed larvae samples to study 
mitochondrial morphology. 
2.11 Culture S2R plus cells and incubation with EA 
2.11.1 Cell Culture conditions 
Drosophila Schneider S2 receptor plus (S2R
+
) cells were cultured in 75cm
2
 
flasks in Schneider’s medium (Invitrogen) supplemented with 10% heat inactivated 
fetal bovine serum (Sigma) and 1% Penstrep (Invitrogen-Gibco). Cells were kept in a 
25ºC incubator with 5% CO2. Cells were passaged twice a week by gently scrapping the 
adhered cells off the bottom of the flask with a sterile scrapper. Then transfer 1ml of the 






cells/well were plated into 8-well slide chambers with well surface area of 
1.8cm
2
. The cells were allowed to adhere overnight before drug treatment. The 
following day cells were stained with MitoTracker Red CMXRos (Molecular Probes) in 
DMSO with working concentration of 1.8μM diluted in fresh prewarmed MEM media 
and incubated for 3 minute at 25ºC. Cells were washed 3 times with prewarmed fresh 
media for 1 minute each at 25ºC. 
2.11.3 Drug Incubation and Imaging 
Various concentrations of ethacrynic acid (EA) were prepared in prewarmed 
Schneider’s medium and added to cells (details see section 5.10.1). Cells were then 
incubated for 4 hours in 25ºC incubator. After 4 hours cell were imaged live under the 






2.11.4 Feeding flies EA 
Drosophila standard food was made with addition of 0.1% DMSO as vehicle 
and EA test concentrations. 50ml of drug food (carrying 50µl drug) was added to the 
250ml standard bottles. The food bottles were covered with paper towels and left over 
night on the bench to settle. Following day, a thin coat of toothpaste-like suspension of 
live yeast in water containing 0.1% DMSO, or EA was added to the drug food. Flies 
were reared in the drug food bottles at 25ºC. The progeny was collected and transferred 
to the 10ml vial containing drug food. The flies were kept at 25ºC for aging. 
2.11.5 Behavioural assays 
Climbing and flight assays were carried out on EA fed 2 days and 15 days old 
flies in the same manner as discussed in section 2.9.2 and 2.9.3. 
2.12 EMS mutagenesis screen for Marf mutant 
Ethyl methane sulfonate (EMS), commercially know as methanesulfonic acid 
ethyl ester (Sigma) is a chemical mutagen which has been widely used by Drosophila 
geneticist to induce de novo DNA lesions. EMS is an alkylating agent; it introduces an 
ethyl group to O-6 position of guanine, thus creating O-6-alkylguanine. This alkylation 
leads to direct mispairing with thymine during replication and results in GC → AT 
transitions. These transitions can lead to missense or nonsense codons or may even 
destroy splice sites (Pastink et al., 1991; Bentley et al., 2000). 
2.12.1 EMS mutagenesis method 
200 newly emerged w1118 males were collected and aged separately from 
females for 1-3 days. 400-500 virgin females from Dp(1;Y)dx
+
 stock were collected and 
aged 1-3 days. For optimum mating both males and females should be same age 
preferably females should be younger. 2 layers of small circles cut out of whatman 3mm 
paper were put in the bottom of 250ml empty food bottles. 2 bottles were prepared. 
Next day, starting early in the morning 100 males flies were placed in each of the bottle. 
Males were starved for 6 hours. After the period of starvation required concentration of 





whatman filter paper fitted at the bottom of the bottles. For example, for a final EMS 
concentration of 25mM EMS, we used 12µl of EMS (Sigma) in 5ml of sucrose and then 
dripped 2ml of the solution into each bottle. After use, the syringe was filled with 10% 
sodium thiosulphate solution used as decontaminant. Any left over EMS solution was 
also decontaminated by adding 10% sodium thiosulphate to the tube. After 24 hours of 
decontamination the liquid was poured down the drain of the hood and syringe and 
tubes were placed in plastic bags. Caution: always used double layer of gloves while 
handling EMS. Also this whole procedure was done in the designated hood in the room 
for mutagenesis. All the waste material was left in sealed plastic bags and put in hazard 
yellow bin which was then removed by the department safety officer. The males were 
then left in the hood overnight. Following day, mutagenized males were carefully 
transferred to new empty bottles containing whatman filter paper layers, carried to 
experimental lab and further, males rub off their feet on the whatman papers and get 
cleaned. After and hour, the males were then transferred to the bottles containing 
standard food and were allowed to recover for 24 hours at 25ºC. EMS bottles were 
decontaminated and removed as discussed above. Next day, the Dp(1;Y)dx
+
 females 
were added to the bottles. 100 w
1118
 mutagenized males and 200-250 Dp(1;Y)dx
+
 
females. Crosses were kept at 25ºC room and flies were transferred to new bottles every 
24 hours for next 2 days. The parents were removed on 4
th
 day of the experiment to 
prevent the getting several identical mutants derived from mutagenized germline stem 
cells as a result of spermatogenesis cease in males. 
2.12.2 Isolation of EMS mutants 




 were collected (* 
denotes the presence of newly induced mutations) and aged for 2-3days. In mean time 
600-800 Df(1)Exel6239 virgins were collected. Individual crosses were set in 10ml 




 males and 2-3 Df(1)Exel6239 
females. For 25mM EMS screen normally 500 individual crosses were set to get at least 
one or two lethal mutations/chromosome. All the crosses were kept at 25ºC and parents 
were allowed to mate only for 24 hours. Please see result section for the number of 
individual crosses set for our EMS screens. Mutant lines were scored in F2 for the 
absence of adult female w
1118
*/Df(1)Exel6239 genotype. Please see result section for 






2.12.3 Identification of EMS mutants 
Mutant stocks w
1118
*/FM6 were crossed with FM7.GFP to isolate the mutant 
phenotype. Please see detail in result section. 
2.12.4 DNA isolation and PCR for sequencing 
2.12.4.1 Larvae genomic DNA extraction 
Thirty 3
rd
 instar and approximately hundred 1
st
 instar larvae were used for each 
DNA preparation. The samples were collected according to the mutant phenotype. The 
samples were collected in an eppendorf and kept on ice. 400µl of lysis buffer (1M 
TrisHCl pH 7.5, 500mM EDTA pH 8.0, 40mM NaCl, 10% SDS) made in dH2O was 
added in each tube keeping on ice. Larvae were squashed in lysis buffer using plastic 
homogenisers. The samples were then incubated for 30minutes at 65ºC. Tubes were 
replaced to the room temperature and 800µl LiCl/KAc solution (6M NiCl, 5M KAc) 
was added in each tube. Tubes were inverted several times to mix and incubated for 10 
minutes on ice. After incubation tubes were spun for 15 minutes at 14000rpm on bench 
top centrifuge at room temperature. Supernatant was transferred into a new eppendorf. 
800µl isopropanol (Fisher Scientific) was added to precipitate the DNA. The samples 
were mixed by inverting the tubes gently and then centrifuged for 10 minutes at 
14000rpm to obtain DNA pellet. Supernatant was discarded and tubes were given a 
quick spin. All the residual isopropanol was aspirated and discarded. The pellets were 
washed in 500µl of cold 70% ethanol. The samples were centrifuged at 14000rpm for 5 
minutes and the ethanol was aspirated. Tubes were then given a quick spin again and all 
the residual ethanol was removed. The pellets were air dried for 20 minutes and 
resuspended in 50µl nuclease free water overnight at room temperature. DNA preps 
were stored at -20ºC. 
2.12.4.2 PCR for Marf DNA templates 
Using the primer3 programme (http://biotools.umassmed.edu/bioapps/primer3_ 
www.cgi),  primers were designed to amplify Marf as overlapping amplicons of about 
1.6-2.2kb, based on extended gene sequence obtained from FlyBase. All the designed 





were discussed in result section. The primers used are shown in Table 2.1. 
The amplicons were amplified using Phusion DNA Polymerase (Finnzymes). 
2µl DNA template was added to 20µl of PCR mix consisting of  4μl 5xPhusion HF 
buffer, 0.4μl 10mM dNTPs, 0.6µl 50mM MgCl2, 1μl 1mM Forward primer, 1μl 1mM 
Reverse Primer, 0.2μl Phusion DNA Polymerase and 10.8μl nuclease free H2O. The 
PCR tubes were placed in a PCR machine and run on a Touchdown PCR programme 
consisting of: 
Cycle 1 (1x)                Step 1: 98ºC 2min (denaturation) 
Cycle 2 (20x)              Step 1: 98ºC 30sec (denaturation) 
                                    Step 2: 68ºC 30sec (annealing) 
Decrease temperature after cycle 1 by 0.5ºC every 1 cycle 
                                    Step 3: 72ºC 1min 40sec (extension) 
Cycle 3 (15x)              Step 1: 98ºC 30sec (denaturation) 
                                    Step 2: 58ºC 30sec (annealing) 
                                    Step 3: 72ºC 1min 40sec (extension) 









Table 2.1: Amplification and sequencing primers 
Primer ID Primer Sequence Map Distance 
relative to Marf 
Amplification Sequencing 
F1 (F1new) GGCTAGTGTGACCATTTCCAA -230 YES YES 
F2 TCAACTCGATTTACGCACACA 321 - YES 
F3(MfnEcoR1) ATGGCGGCCTACTTGAACCGC 909 YES YES 
R1(N)* GATCTGGAGCGGTGATTTGT 1133 - YES 
F11 TACCCAACAGAAGCCAATCC 1241 YES YES 
F4 GAAGTACTGCAGCGGGATCA 1494 YES YES 
R2(N)* CATTCGCCAGTTGTTTGATG 1773 YES YES 
F5(Mfn3F) AGCAAGCCGAACATCTTCAT 2038 YES YES 
F12 AGGAGTGCATCTCGCAGAGT 2797 YES YES 
F10 AGGTGGAGGAGAAGGTGTCAA 3037 YES YES 
R3(Mfn3R) AGTTCAATATGCCCTTCCATCC 3122 YES YES 
R7 GAAGCGTGAGATCAACGACA 3667 YES YES 
F7(MfnSeqQC) ATCTACCTGTACGAGCGCCTCTC 3903 YES YES 
R4(N)* AGGTCGACAATCATCTTGAGC 4009 - YES 
Xba(N)  4289 YES YES 
F8 GAAATCAGGCGAAGACAAACA 4376 - YES 
R8 TATCGTTTTGATCGGGATCAC 5141 YES YES 




To determine the amplified product was correct size, the PCR products were run 
with Hyper Ladder I (Bioline) on a 1% agarose gel at 100V for 50 minutes. DNA bands 
were visualised using ultraviolet (UV) light. 
The amplified DNA was always stored at 4°C. 
2.12.4.3 Sequencing 
The amplified genomic DNA amplicons were sent for purification and 
sequencing to the Core Genomic Facility in University of Sheffield. For sequencing 
1pmol/µl dilutions of sequencing primers were used. The sequence data obtained from 
Genomic core facility was analysed using FinchTV to see the quality of data and later 
Sequencher® was used to align the sequencing data with extended Marf reference 
sequence from Flybase to generate contigs that covered the entire gene plus 200bps 5' 
and 3' intergenic regions. 
2.12.5 Protein analysis for EMS mutants 
2.12.5.1 Larvae protein extraction 
The protein samples were collected from fifteen 3
rd
 instar and fifty 1
st
 instar 
larvae according to each mutant phenotype. The larvae were collected in an eppendorf 
tube and anaesthetised at -20°C for 10 minutes. The samples were homogenised in 75μl 
RIPA buffer (50mM Tris-HCl, 150mM NaCl, 1mM EDTA, 0.1%SDS) and 3μl Protease 
Inhibitor (11836170001, Roche). The samples were centrifuged at 13000rpm for 10 
minutes and supernatant was collected. 
2.12.5.2 Bradford Assay 
Protein concentration was determined by performing standard Bradford assay 
(Bradford, 1976). Serial dilutions of Bovine Serum Albumin (BSA) (stock 
concentration: 10mg/ml) were prepared as follows: 
1mg/ml (10μl of BSA (10mg/ml) + 90μl dH2O) 
2mg/ml (20μl of BSA (10mg/ml) + 90μl dH2O) 
4mg/ml (40μl of BSA (10mg/ml) + 90μl dH2O) 
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Reaction mixture (diluted 1:4 with water) was prepared by adding 200ml Bradford 
reagent in 800ml dH2O. 
BSA working concentrations were prepared in the reaction mix as follows: 
BSA working 
concentrations 
Volume added from BSA 
working concentration 
Reaction Mix 
1mg/ml BSA  1μl 1ml 
2mg/ml BSA 2μl 1ml 
4mg/ml BSA 4μl 1ml 
 Note: 3 tubes for each dilution concentration were prepared to make standard curve. 
1µl of the protein homogenates for each sample was added to 1ml of reaction mix. 
Tubes were incubated for 5 minutes at room temperature for colour development. 
Absorbance of each sample was measured at 595nm using UV-visible 
spectrophotometer. Standard curve was prepared using Excel and concentration of 
protein in each sample was calculated from the equation: 
y = a(x)+b. 
Here x = concentration of protein, y = absorbance at 595nm 
All the concentrations were brought to the lowest value in the sample concentrations by 
adding RIPA buffer and PI mixture to load equal volume of protein on gel. Formula to 
calculate the amount of RIPA buffer and PI mixture in each protein sample: 
Concentration of protein sample - final solution volume (e.g: 50μl) = amount of RIPA 
buffer and PI mixture 
d-50 = f 
2.12.5.2 Protein Analysis by Western Blotting 
4XSDS loading dye (0.25M Tris-HCl (pH6.8), 8% SDS, 10% β-
mercaptoethanol, 30% Glycerol, 0.02% Bromophenol blue) was added to the protein 
samples and boiled at 95ºC for 8 minutes to denature the protein and break disulphide 
bonds. The samples were replaced on ice to stop the denaturing process. The protein 
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samples were always kept at -20ºC. The denatured protein samples were separated by 8 
% SDS-PAGE.  
8% resolving gel recipe for 10ml: 
4.6ml H2O, 2.7ml 30% acrylamide, 2.5ml 1.5M TrisHCl (pH 8.8), 0.1ml 10%SDS, 
0.1ml 10% Ammonium persulphate, 0.006ml TEMED. 
Stacking gel recipe for 10ml: 
6.8ml H2O, 1.7ml 30% acrylamide, 1. 25ml 0.5M TrisHCl (pH 6.8), 0.1ml 10%SDS, 
0.1ml 10% Ammonium persulphate, 0.001ml TEMED. 
The resolving and stacking gels were casted in 1.5mm thickness glass plates. 
20µg protein/well was loaded and the gels were run in running buffer (25mM Tris, 
192mM Glycine, 0.1% (w/v) SDS, pH8.3) at 60volts for stacking gel and 120volts for 
resolving gel to obtain optimum separation. The gels were transferred to polyvinylidene 
difluoride (PVDF) membrane (162-0177, BioRad) using the transfer buffer (25mM 
Tris, 192mM Glycine, 20% Methanol, pH8.3). Transfer time was 1 hour at 100volts. 
The transferred membranes were given a quick wash with H2O and blocked in in 
5% blocking solution (PBST–0.2% Tween-20 with 5% (w/v) milk powder) for 1 hour to 
minimise the background binding of antibodies. The primary antibody used to detect 
Marf against N-terminal peptide, DTVDKSGPGSPLSRF (Ziviani et al., 2010) was used 
at 1:2000 dilutions in 5% blocking solution. Mouse anti-Complex Vα (MS507, 
MitoSciences) was used as control in 1:5000 dilutions. Membranes were incubated with 
primary antibodies at 4ºC overnight. The membrane were given 3xPBST washes each 
for 20 minutes and incubated with the HRP-conjugated secondary antibodies (1:5000) 
for 1 hour at room temperature. For Marf, anti-rabbit HRP (Jackson ImmunoResearch) 
and for Complex Vα, anti-mouse HRP (MitoScience) were used. The membranes were 
washes thoroughly with 3xPBST 10 minutes each. Proteins on the membrane were 
detected using ECL-Plus Chemiluminescence (RPN2132, GE Health) and recorded on 
















Chapter 3: Mitochondrial morphology in 















The ideal model system to study the pathological effects of Mfn2 pathogenic 
alleles are CMT2A patient derived motor or sensory neurons. However, these cells are 
not readily available but patient derived primary skin fibroblasts are easily available and 
already a well established model to study disease pathology for various common 
diseases (Connolly, 1998; Auburger et al., 2012). Skin fibroblasts present a disease 
model system where pathological mutations are expressed at physiological levels along 
with the aggregated cell damage according to the patient’s age and polygenic and 
environmental risk factors faced by the patients (Connolly, 1998; Auburger et al., 
2012). Patient skin fibroblasts have been used to study disease mechanisms in 
Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and other 
neurological diseases (Huang et al., 1994; Mortiboys et al., 2008). Mitochondrial 
function, morphology and distribution have been studied in fibroblasts derived from 
CMT2A and HMSNVI patients (Loiseau et al., 2007; Amiott et al., 2008; Guillet et al., 
2010; Chevrollier et al., 2012; Rouzier et al., 2012). 
We studied mitochondrial morphology in CMT2A and HMSNVI patients 
carrying Mfn2 mutations and observed mitochondrial morphology defects in HMSNVI 
patient fibroblasts. 
3.2 Fibroblasts used in the study 
Fibroblasts carrying Mfn2 mutations used in this project were obtained from 
Professor Frank Baas (Academic Medical Centre, Amsterdam, Netherlands). Mfn2 
mutations were also characterised in his lab. We have 2 family members (Patient 1 and 
Patient 2) with Charcot-Marie-Tooth Type 2A (CMT2A). They carry a novel point 
mutation Q674P, reported for the first time here. The other patient (Patient 3) has 
hereditary motor and sensory neuropathy type VI (HMSNVI) patient carrying a point 
mutation R364W in highly conserved R3 region of Mfn2 (Zuchner et al., 2006) (Figure 
3.1). This patient showed severe form of axonal degeneration, muscle loss and optic 
atrophy and was wheelchair bound. The onset of CMT was at the age of 1 year old and 
developed bilateral optic atrophy at the age of 10. Also fibroblasts obtained from 3 










Figure 3.1: Location of Mfn2R364W and Mfn2Q674P in the gene. Mfn2 mutations carried by 
CMT2A (Q674P present in R6 region) and HMSNVI (R364W present in R3 region) patients are 
indicated. GTPase domain: red box, HR1 domain: green box, yellow boxes: bi-partite 
transmembrane domain, HR2 domain: pink box. Blue boxes are the R regions (R1-R7) R-
regions are the highly conserved regions among species including mammals, fruit fly and 
nematodes. (Adapted from Honda et al., 2005). 
 
3.3 Mitochondrial morphology in CMT2A and HMSNVI patient 
fibroblasts 
Primary fibroblasts were cultured using standard procedures and stained with 
MitoTracker Red CMXRos for live imaging as discussed in section 2.1.3. Mitochondria 
appeared as long tubular structures and loose networks in all the three control 
fibroblasts (Figure 3.2). CMT2A derived fibroblasts from Patient 1 and Patient 2 









Figure 3.2: Mitochondrial morphology in Control fibroblasts. Primary fibroblasts were stained with MitoTracker Red (CMXRos) to visualize by fluorescence 
microscope. Control 1, Control 2 and Control 3 showed long tubular mitochondria (indicated with arrows in inset) and mitochondrial networks in perinuclear region. 





Figure 3.3: Mitochondrial morphology in CMT2A patient fibroblasts. Patient 1 and Patient 2 showed long tubular mitochondria (indicated with arrows in inset) 








Figure 3.4: Mitochondrial morphology in HMSNVI patient fibroblasts. Patient 3 fibroblasts showed different mitochondria morphologies including fibroblasts 
with fragmented spherical mitochondria (a) (indicated with arrows in inset), small tubule shaped mitochondria with few branch points (b) (indicated with arrows in 




In contrast, Patient 3 showed variable mitochondrial morphologies across the 
cell samples. Fibroblasts with fragmented spherical disconnected mitochondria were 
predominantly present along with cells harbouring small rod shaped mitochondria with 
few branch points with neighbouring mitochondria (Figure 3.4). However, fibroblasts 
with normal mitochondria carrying long tubular mitochondria and mitochondria 
forming connections with neighbouring mitochondria were also present (Figure 3.4). 
To quantify these different mitochondrial morphologies across the patients we 
carried out two different analyses; subjective analysis and a computational analysis 
using ImageJ software. 
3.3.1 Subjective analysis for mitochondrial morphology 
Images of MitoTracker Red stained cells were taken for each of the samples. 
Scoring was performed once the investigator had been blinded to the sample ID. Each 
cell was scored as one of three categories: Small and spherical shaped mitochondria 
lacking connections with neighboring mitochondria were categorized as fragmented 
mitochondria. Small rods shaped mitochondria with less frequent branching were 
categorized as small tubular mitochondria. Generally, in fibroblasts mitochondria 
appear as long filamentous tubules dispersed throughout the cytosol and mitochondrial 
networks in the perinuclear region. Such morphology was categorized as normal 
mitochondrial morphology in our subjective analyses (Figure 3.2). Mitochondrial 
morphology was scored from 50-60 cells per experiment from 3 independent 
experiments and the percentage of cells that showed normal mitochondrial morphology 
(Figure 3.2, Figure 3.3, Figure 3.4c) or fragmented mitochondria (Figure 3.4a) or 
small tubular mitochondria (Figure 3.4b) was calculated. 
Patient 1 and Patient 2 showed zero fibroblasts with fragmented mitochondria, 
however Patient 3 showed significantly high percentage of fibroblasts with fragmented 
mitochondria as compared to the controls (Figure 3.5A). Patient 3 also showed 
significantly higher percentage of fibroblasts with small tubular mitochondria. A small 
percentage of cells with small tubular mitochondria were also observed in Control 2 and 
Control 3. Patient 2 also showed few cells with small mitochondrial tubules but the 
difference was insignificant as compared to the controls (Figure 3.5B). Patient 3 










Figure 3.5: Subjective analysis for mitochondrial morphology. Fibroblasts were scored 
blindly for fragmented (A), small tubules (B) and normal mitochondrial morphologies (C). 
Control 1: black bar, Control 2: white bar, Control 3: doted bar, Patient 1: angled striped bar, 
Patient 2: vertical striped bar and Patient 3: horizontal striped bar. Data is presented as 
mean±standard error. Statistical significance was determined by one-way ANOVA followed by 





3.3.2 Mitochondrial morphology analysis using ImageJ Software 
Image analysis was done with the open-source image analysis programs ImageJ 
(developed by W. Rasband, National Institutes of Health, Bethesda, MD; 
http://rsb.info.nih.gov/ImageJ) and the plugins written by K. De Vos. To quantify 
mitochondrial morphology in fibroblasts different mitochondrial shape attributes were 
selected see section 2.2.5.1 and 2.2.5.2. 
3.3.2.1 Patient 3 fibroblasts showed reduced mitochondrial aspect ratio 
and length 
Mitochondria appear as long tubular structures and extensive networks forming 
in fibroblasts. To determine the shape of individual mitochondria segregating from the 
connected mitochondrial structures mitochondrial aspect ratio and mitochondrial length 
was determined using ImageJ software as discussed in section 2.2.5.1. Patient 1 and 
Patient 2 showed normal aspect ratios as compared to controls (Figure 3.6A). However, 
Patient 3 showed significantly reduced aspect ratio as compared to controls. Next 
mitochondrial length was measured and quantified for each sample. Mitochondrial 
length for Patient 1 and Patient 2 also appeared comparable to all three controls. Patient 
3 showed significantly smaller mitochondria with reduced mitochondrial length (Figure 
3.6B). 
3.3.2.2 Patient 3 fibroblasts showed reduced mitochondrial bifurcation 
ratio and network ratio 
Branching and network mitochondrial morphology, typical in fibroblasts was 
measured as bifurcation ratio and network complexity ratio (see section 2.2.5.2). Patient 
1 showed normal bifurcation ratio as compared to controls (Figure 3.6C). Patient 2 
showed significantly lower bifurcation ratio as compared to Control 1 and Control 2, 
however the difference was insignificant as compared to Control 3. Patient 3 showed 
significantly reduced bifurcation ratio compared to all controls (Figure 3.6C). The 
overall network complexity ratio for Patient 1 was in normal range with controls 
(Figure 3.6D). Patient 2 presented lower network complexity as compared to Control 2 















      
 
Figure 3.6: ImageJ analysis of the mitochondrial morphology. (A) Aspect Ratio. (B) Length. 
(C) Bifurcation ratio. (D) Network complexity ratio. 15 images were analysed for each 
genotype. N = 3. Data is presented as mean standard error. Statistical significance was 
determined with Kruskal-Wallis non-parametric analysis and Dunn’s pair-wise comparison 







Our results showed that fibroblasts derived from the HMSNVI patient (Patient 
3) carrying a heterozygous Mfn2
R364W
 mutation showed fragmented mitochondrial 
morphology with reduced mitochondrial aspect ratio, mitochondrial length, bifurcation 
ratio and network complexity ratio. CMT2A patients (Patient 1 and 2) harbouring 
heterozygous Mfn2
Q674P
 mutation showed normal mitochondrial morphology. However, 
computational analysis highlighted the subtle mitochondrial morphology defects in 
Patient 2, showing reduced mitochondrial bifurcation ratio and network complexity 
ratio. Due to limitation of number of HMSNVI and CMT2A patients we can not make 
conclusive result that the defected morphology we saw in this Patient 3 is typical to 
Mfn2 pathogenic mutations or is just a novel case due to some other underlying 
pathology in this patient. Furthermore, ImageJ analysis proved to be useful tool to 
quantify the mitochondrial morphology efficiently. 
Two previous studies have shown normal mitochondrial morphologies in 
CMT2A patient fibroblasts and are comparable to the normal mitochondrial 
morphology observed in our CMT2A patients (Loiseau et al., 2007; Amiott et al., 
2008). Appearance of normal mitochondrial morphology in CMT2A fibroblasts 
suggests that disease-associated Mfn2 alleles are able to form fusion competent 
complexes with Mfn1. As Mfn2 CMT2A associated alleles restore normal 
mitochondrial morphology in Mfn2 knockout mouse embryonic fibroblasts by forming 
Mfn1/Mfn1 and Mfn1/Mfn2 (CMT2A allele) hetero oligomeric complexes (Detmer and 
Chan, 2007a). 
HMSNVI patient (Patient 3) carrying a heterozygous Mfn2
R364W
 mutation was 
first discussed by Zuchner et al (Zuchner et al., 2006). According to their findings, 
Patient 3 was 10 years old and disease onset was at 1 year age (Zuchner et al., 2006). 
This individual presented severe muscular atrophy, sensory impairments, reduced visual 
acuity and was restricted to a wheelchair at an early age. The individual also presented 
with respiratory insufficiency. The severity of the clinical symptoms presented by this 
patient is consistent with significantly fragmented mitochondrial morphology observed 
in the skin fibroblast derived from this patient. The fragmented mitochondrial 
morphology seen in Patient 3 suggests defective mitochondrial fusion and inability of 
Mfn1/Mfn1 and Mfn1/Mfn2 (CMT2A allele) hetero oligomeric complexes to maintain 
a normal mitochondrial fusion. Previously, Loiseau et al also studied mitochondrial 
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morphology in a patient harbouring heterozygous Mfn2
R364W
 mutation and reported 
normal mitochondrial morphology in fibroblasts (Loiseau et al., 2007). This patient was 
a 31 years old man, who was 20 at the onset of his initial symptoms and has moderate 
ankle weakness, normal gait, normal motor conduction velocity and no optic atrophy. 
The difference seen in clinical phenotypes and mitochondrial morphology in these two 
patients carrying the same mutation highlights the degree of variability presented by the 
CMT2A and HMSNVI patients and suggests the existence of disease modifying factors. 
These factors could possibly be a mutation in other gene/genes, which can exacerbate 
the disease and result in severe early onset or reduce the effects of mutation, thereby 
reducing disease penetrance. Alternatively the modifying factor could be environmental 
such as exposure to a currently unidentified neurotoxic factor. As discussed earlier 
Mfn2 associates directly and indirectly with other cellular proteins and pathways and 
these interactions play their role in mitochondrial dynamics. Mutations in any of the 
interacting proteins can exaggerate the deleterious effects of Mfn2 mutations itself in a 
subset of patients with early onset and severe neuropathy. 
Furthermore, Patient 3 is not a novel case showing fragmented mitochondrial 
morphology as recently another study has also shown fragmentation of mitochondrial 
networks in fibroblasts carrying Mfn2 mutation D210V. However, this mutation is 
associated with Optic atrophy ‘plus’ phenotype as the patient presented with optic 
atrophy as initial clinical complication with the development of sensorineuropathy and 
muscular atrophy (Rouzier et al., 2012). This report showed reduced Mfn2 expression in 
patient fibroblasts which might lead to reduced mitochondrial fusion. In our opinion, it 
might be possible as low levels of Mfn1/Mfn2 (normal copy) and Mfn1/Mfn2 (mutation 
allele) complexes are being formed in less abundance and Mfn1/Mfn1 complexes are 
unable to fulfil the requirement for normal mitochondrial morphology. We also know 
that Mfn2 deficient MEFs and mice have shown fragmented mitochondrial morphology 
and metabolic defects and recently Mfn2
R94W
 knock-in mice showed fragmented 
mitochondria in MEFs (Chen et al., 2003; Chen et al., 2007; Strickland et al., 2014).  
Inter and intra familial variabilities in disease penetrance have been reported in 
many studies showing family members with severe, mild and asymptomatic individuals, 
individuals with early onset, rapidly progressive severe neuropathy and individuals with 
late onset, slowly progressive mild sensory neuropathy (Muglia et al., 2007; Del Bo et 
al, 2008; Klein et al., 2011). Such variabilities support the incomplete penetrance of 
Mfn2 mutations and highlight the importance of interacting gene/genes affecting the 
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disease phenotype. We could also investigate the haploinsufficiency by determining the 
expression level of Mfn2 mRNA and protein in our patient fibroblasts as compared to 
controls. In addition, heterozygous patients carrying more than one mutation are also 
reported (Polke et al., 2011). Additionally, we have recently showed that zebrafish with 
a null mutation develop symptoms consistent with CMT which supports the loss of 






















































Chapter 4: Effect and role of Ethacrynic 














Mitochondrial fusion and fission are essential for mitochondrial function and are 
also involved in fundamental cellular processes, including development, apoptosis, and 
ageing. However, the role of mitochondrial fusion and fission in cell function and 
survival is still poorly understood. Most commonly used approaches to study 
mitochondrial dynamics are either to knockdown gene expression using RNAi methods 
or use dominant-negative mutants affecting the expression of pro-fusion and pro-fission 
proteins. We know that changes in mitochondrial morphology occur within minutes to 
hours but the changes due to genetic manipulations take much longer time to be 
detected. There is a need to identify compounds that produce changes in mitochondrial 
morphology on the time scale of minutes to hours to study these cellular processes more 
conveniently and such approaches might also help to provide novel insight into these 
dynamic processes. One of the known mitochondrial fusion-inducing compounds is 
ethacrynic acid (EA) identified by Soltys and Gupta (Soltys and Gupta, 1994). 
EA is an α,β-unsaturated ketone which acts as a cysteine alkylator and is able to 
deplete cellular glutathione without an increase in reactive oxygen intermediates (ROIs) 
(Ciaccio et al., 1994; Seyfried et al., 1999; Rizzardini et al., 2003). The known cellular 
targets of EA alkylation are adenylate cyclase coupled G-proteins, sodium potassium 
chloride (Na-K-2Cl) cotransporter and ATP-dependent Cl
- 
transporter, and it was 
previously clinically tested as diuretic (Kunugi et al.,1991; Palfrey and Leung, 1993). In 
cultured cells, EA treatment induced end-to-end fusion resulting in increased 
mitochondrial length and end to side fusion to form a mitochondrial reticulum (Soltys 
and Gupta, 1994). However, in the presence of 0.5mM dithiothreitol, a sulfhydryl 
reagent, EA was unable to produce mitochondrial reticulum. This suggested that EA 
induced mitochondrial fusion could be mediated by cellular thiols (Soltys and Gupta, 
1994). However, a saturated EA analogue; Dihydro-EA which lacks the central α,β-
unsaturated ketone structure did not induce mitochondrial fusion in cells, suggesting 
that the α,β-unsaturated ketone group is responsible for EA toxicity and unique fusion 
inducing nature (Bowes and Gupta, 2005). Gupta and colleagues also tested a well-
known cysteine alkylator N-ethylmaleimide and found that it produced a similar 
mitochondrial reticulum as observed in cells treated with EA (Bowes and Gupta, 2005). 
This suggests that induction of mitochondrial fusion by EA is not due to glutathione 
depletion but could possibly be due to the cysteine alkylating nature of the compound 
(Bowes and Gupta, 2005). Thus it is possible that EA induces mitochondrial fusion by 
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modifying critical cysteine residue(s) in proteins involved in mitochondrial dynamics 
(Bowes and Gupta, 2005).  
We wanted to further characterise EA, in order to understand how it causes 
increased mitochondrial fusion in cells. I wanted to determine whether EA could be 
developed as a potential treatment for diseases where there are mutations in 
mitochondrial fusion factors such as CMT2A, or whether it would simply be a useful 
tool compound to study mitochondrial dynamics in laboratory assays. Our working 
hypothesised was that EA induce mitochondrial fusion by acting as a cysteine alkylator. 
This is possible by two distinct mechanisms: either EA is inhibiting a negative 
regulator/repressor of the fusion machinery or it is inactivating positive regulators 
important for fission (Figure 4.1). However, as this investigation is the part of larger 
drug screening project being carried out to identify the compounds affecting 
mitochondrial morphology, we included other compounds in the screen as discussed in 




Figure 4.1: Schematic of EA working hypothesis. EA is acting as a protein inactivator by 
alkylating essential cysteine residue(s) of either pro-fission proteins (Drp1, Fis1, Mff or an 




4.2 Background and initial compound screen 
Dr. Andrew Grierson in Academic Neurology, University of Sheffield carried 
out primary screen in fibroblasts derived from a hereditary motor and sensory 
neuropathy type V1 (HMSNVI) patient carrying a Mfn2
R364W
 mutation to identify 
compounds affecting mitochondrial morphology. He used 2000 compounds from the 
SPECTRUM Collection and 4 compounds identified from published work suggesting 
their involvement in mitochondrial dynamics and/or transport. He used a single dose of 
each compound and observed its effect on the mitochondrial morphology as 
mitochondrial fusion enhancer. From this primary screen 10 potential candidates were 
identified, and were further studied by me in a secondary screen carried out in CV14A 
cells (Table 4.1). 
4.2.1 Effect of candidate compounds on mitochondrial morphology in 
CV14A cells 
CV14A cells stably expressing DsRed1mito were used for the secondary screen. 
These cells normally have mitochondrial networks around the nuclear region with long 
rod shaped mitochondria reaching to the cell periphery. CV14A cells also contain few 
spherical mitochondria. Cells were plated 18-20 hours prior to incubation with test 
compounds. Serial dilutions of all the compounds were made in DMEM media. Each 
compound was tested at the concentrations shown in Table 4.1 for incubation periods of 
15 minutes, 4 hours and 24 hours on three separate occasions. Positive hits were defined 
as compounds that gave increased mitochondrial length and networks (also defined as 
mitochondrial reticulum) morphology. Mitochondrial morphology of cells was scored 
as increased fusion or no increase in fusion; however, scoring was not done blind and 
formal statistical tests were not applied. 
0.1% DMSO and 0.1% chloroform were used as vehicles. CV14A cells 
incubated with 0.1% DMSO or 0.1% chloroform showed normal mitochondrial 
morphology with perinuclear mitochondrial networks and long and small rod shaped 
mitochondria near the cell periphery designated as normal mitochondrial morphology in 
these cells (Figure 4.2). In 15 minute drug incubation experiment, cells showed 
increased mitochondrial network morphology or typical mitochondrial reticulum 
formation only with 165µM EA. However, 4 hour drug incubation showed increased 
mitochondrial fusion with EA, NEM and cycloheximide. Mitochondrial reticulum 
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formation was seen with 41µM EA, 83µM EA, 165µM EA, 2µM N-ethylmaleimide 
(NEM) and 100µM cycloheximide. However, long incubation of 24 hours proved to be 
an ideal time frame to characterise the effects of all the compounds on mitochondrial 
morphology (Table 4.1 and Figure 4.2). Cells incubated with EA (2.6-81µM) showed 
increased mitochondrial networks in a dose dependent manner. 165µM EA proved to be 
toxic as cells rounded up and detached from cover slip. NEM (0.2-2µM) and 
cycloheximide (10-100µM) also showed extensively interconnected mitochondrial 
networks after 24 hours incubation (Figure 4.2). All the mitochondria in the cell 
appeared to have joined together making continuously interconnected reticulum with 
EA and NEM. However with cycloheximide few separated mitochondria near cell 
periphery were also observed in addition to the central mitochondrial reticulum. Also, 
crinamine (10µM) showed long tubular mitochondria as compared to controls but no 
mitochondrial reticulum was seen in the cells (Figure 4.2). Podophylotoxin acetate, a 
microtubule inhibitor, showed a unique mitochondrial morphology with less branching 
or network formation but more curly large and small mitochondrial rods (Figure 4.2). 
Dopamine HCl (1-100µM), β-Sitosterol (2.5-250µM) and 12-Methoxy-4,4 bisnor-
5alpha-8,11,13-podocarpatrien-3-ol (12 Methoxy) (10µM), showed no obvious effects 
on mitochondrial morphology and mitochondria appeared similar to the controls 
(Figure 4.2). Mitochondria in dynasore (5-500µM) treated cells lack any connections 
and appeared as small rods distributed throughout the cytoplasm (Figure 4.2). MTMA 
bromide (3-300µM) showed small round and aggregated mitochondria in the entire cell 
lacking any mitochondrial branching (Figure 4.2). The secondary screen identified EA, 
NEM, cycloheximide and crinamine as positive hits for increased mitochondrial fusion 
morphology observed in CV14A cells. However, NEM and crinamine were excluded 











































Figure 4.2: Screen for mitochondrial fusion inducing compounds in CV14A cells. 
Representative images of each compound showing its effect on mitochondrial morphology after 
24 hours incubation are shown. (a) 0.1% DMSO and (b) 0.1% Chloroform used as vehicles. (c) 
Crinamine 10µM (arrows indicate long tubular mitochondria) (d) Ethacrynic Acid 41µM 
(arrows indicate mitochondrial reticulum formation, increased branching) (e) N-ethylmaleimide 
2µM (arrows indicate mitochondrial reticulum formation) (f) Cycloheximide 10µM (arrows 
indicate mitochondrial reticulum formation) (g) Dynasore 10µM, (h) Podophylotoxin acetate 
10µM, (i) MTMA bromide 10µM, (j) β-Sitosterol 25µM, (k) Dopamine HCl 10µM, (l) 12-



















4.2.2 Analysis of compound toxicity for EA, NEM and Cycloheximide 
MTT (3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was 
used to analyse cytotoxicity of the compounds. The principle of the assay is the 
reduction of MTT salt by mitochondrial succinate dehydrogenase in metabolically 
active cells (Mosmann, 1983). Mfn2
R364W
 patient fibroblasts were incubated with 
various concentrations of EA, NEM and cycloheximide for 24 hours. 0.1% DMSO was 
used as control. Cytotoxicity was calculated as cell survival with drug relative to the cell 
survival with 0.1% DMSO (vehicle). Mfn2
R364W
 patient fibroblasts treated with lower 
doses of EA showed a trend towards increased cell survival but this effect was not 
statistically significant relative to the control (Figure 4.3A). Cell survival declined at 
concentrations higher than 10µM EA with significant reduction at concentration of 
41µM, 83µM and 165µM EA (Figure 4.3A). In CV14A cells, EA showed less toxicity. 
Cell survival declined above 83µM EA but the effect was not significant as compared to 
control (Figure 4.3B). However, these cells showed significant decrease in cell survival 
with 165µM EA (Figure 4.3B). Furthermore, in Mfn2
R364W
 patient fibroblasts NEM 
showed significant decrease in relative cell survival in a dose dependent manner 
(Figure 4.3C). Also, cycloheximide showed significantly reduced cell survival relative 
to the control in Mfn2
R364W
 patient fibroblasts but this remains constant without further 

















Figure 4.3: MTT assay. (A) Relative cell survival of Mfn2R364W patient fibroblasts after 24 
hours treatment with ethacrynic acid. (B) Relative cell survival of CV14A cells after 24 hours 
treatment with ethacrynic acid. (C) Relative cell survival of Mfn2R364W patient fibroblasts after 
24 hours treatment with N-ethylmaleimide. (D) Relative cell survival of Mfn2
R364W
 patient 
fibroblasts after 24 hours treatment with cycloheximide. N = 3 independent experiments. 





4.3 PEG fusion assay for EA and Cycloheximide 
The fusion activity of EA and cycloheximide was tested in polyethylene glycol 
(PEG) mitochondrial fusion assay see section 2.5.2. In this assay, CV14A cells 
containing either DsRed1mito or GFPmito were co-cultured and PEG was transiently 
applied to fuse the cells. This is followed by incubation with the respective drug along 
with cycloheximide. Addition of cycloheximide is a part of the standard protocol to 
prevent synthesis of new fluorescent molecules in the fused cells. Cellular fusion results 
in the formation of bi or multi-nucleated cell hybrids. These hybrids allow cytoplasmic 
mixing where DsRed1mito and GFPmito labelled mitochondria interact and undergo 
fusion which can be seen as mixing of the both fluorescent tags. To quantify fusion 
activity the hybrids between the two cell lines were visually evaluated and scored. The 
scoring criteria used are shown in Figure 4.4A, with 0% fusion in cells where no 
overlapping or co-localised fluorescent DsRed and GFP signals were present. Less than 
50% fusion was scored for hybrids where less than half of the cell has shown co-
localised DsRed and GFP fluorescent. Cell hybrids showing half or more than half of 
mitochondrial population with DsRed+GFP co-localisation were scored as more than 
50% fusion activity. Full or 100% fusion was scored for cell hybrids that exhibited a 
complete overlay of mito-DsRed and mito-GFP.  
After 4 hours of incubation, CV14A cells were fixed as shown in section 2.3.1.4, 
and 50-60 cell hybrids were scored blindly for each concentration. Cells incubated with 
0.1% DMSO showed majority of cells with 0% and less than 50% fused cells and no 
cell hybrids with full fusion were observed (Figure 4.4B). Cells incubated with EA 
showed increase in cell hybrids with increased mitochondrial mixing in dose dependent 
manner (Figure 4.4B). Number of cells with more than 50% fusion and 100% fusion 
increased with the increase in EA concentration. With 165µM EA only 6% of cell 
population showed zero fusion (Figure 4.4B). The two experiments performed for EA 
are two biological replicates and statistical analysis was performed. However, we 
suggest in order to determine formal statistical significance this assay has to be repeated 
with at least 3 biological replicates which is considered as standard. Therefore, at this 
point the PEG fusion assay results are preliminary but indicate that ethacrynic acid is 








Figure 4.4: Mitochondrial fusion assay. PEG fusion of CV14A cells stably expressing mito-
DsRed1mito and GFPmito. (A) Representative images for the fusion scoring criteria. Following 
4 hours of drug incubation cells were scored for 0% fusion, less than 50% fusion, more then 
50% fusion and full or 100% fusion. Scale bar = 5µm (B) PEG fusion assay for EA. Data is 
presented as mean standard error. n = 50 cells, N = 2 independent experiments. Statistical 




Cycloheximide was excluded from the PEG assay and further characterisation 
due to specific limitations of the PEG assay protocol and additional reasons as 
mentioned in discussion section. 
4.4.1 Fis1 overexpression assay to observe the effect of EA on 
mitochondrial morphology 
Fis1 was overexpressed in CV14A cells to induce mitochondrial fragmentation 
and test whether EA can inhibit Fis1 mediated mitochondrial fission or not. Fis1 was 
chosen to overexpress rather than Drp1 because Fis1 is a mitochondrial outer membrane 
protein and acts as an anchor for cytosolic Drp1. Hence, more Fis1 on the mitochondrial 
outer membrane results in more Drp1 recruitment to fission sites. Also, overexpression 
of Fis1 has been shown to fragment mitochondrial networks suggesting increased 
mitochondrial fission (Yoon et al., 2003). 
CV14A cells stably expressing DsRed1mito were used to assess the effect of 
hFis1 overexpression on mitochondrial morphology (for details see section 2.6.5). 
Figure 4.5 demonstrates the principle of the assay. CV14A cells were transfected with 
either pCI-NEO empty vector and EGFP-C2 vector (Figure 4.5 A-D (i-iii)), or myc-
tagged hFis1 plasmid and EGFP-C2 vector (Figure 4.5 E (i-iii)). 0.5µg and 0.75µg Fis1 
were used to see the effect of increasing Fis1 expression on mitochondrial morphology. 
EGFP was used to identify the transfected cells and 1:3 ratio of EGFP: Fis1 is used to 
confirm co-transfection. 4 hours post transfection 0.1% DMSO (vehicle) or 21µM, 
41µM and 83µM EA was added to all the conditions. Figure 4.5 A-D is showing the 
effect of 0.1% DMSO or various concentrations of EA on mitochondrial morphology in 
pCI-NEO empty vector transfected cells. Figure 4.5 E is a representative image for 
0.75µg Fis1 overexpression induced fragmentation of mitochondrial network 
morphology in CV14A cells treated with 0.1% DMSO. After 24 hours cells were fixed, 
stained with Hoechst for nuclear morphology and scored for mitochondrial 
morphologies as shown in Figure 4.6. Mitochondrial morphology was classified as 
clustered, fragmented, small tubules and normal in CV14A cells. Mitochondrial 
morphology was classified as clustered if mitochondria were clustered around the 
nucleus forming small aggregates, with the presence of few fragmented mitochondria 
not spread in the cytoplasm (Figure 4.6. A). Small spherical mitochondria spread in the 























Figure 4.5: Fis1 overexpression assay for mitochondrial morphology. CV14A cells stably 
expressing DsRed1mito were transfected with EGFP-C2 vector and pCI-NEO empty vector 
(A,B,C,D) and EGFP-C2 and 0.75µg myc-tagged hFis1 (E). (i) DsRed1mito+EGFP+Hoechst 
merged (ii) DsRed1mito (iii) Hoechst staining for nuclei images. A (i-iii) CV14A cells treated 
with 0.1% DMSO showing normal mitochondria (indicated with arrow in inset) with loose 
networks (indicated with arrowhead in inset). B (i-iii) CV14A cells treated with 41µM EA for 
24 hours post transfection with empty vector show few long tubular mitochondria. (indicated 
with arrow in inset). C (i-iii) CV14A cells treated with 61µM EA for 24 hours post transfection 
show long tubular mitochondria (indicated with arrow in inset) and increased mitochondrial 
networks (indicated with arrowheads in inset). D (i-iii) CV14A cells treated with 83µM EA for 
24 hours post transfection show long tubular mitochondria (indicated with arrow in inset) and 
extensive mitochondrial reticulum morphology (indicated with arrowheads in inset). E (i-iii) 
CV14A cells treated with 0.1% DMSO for 24 hours post transfection with 0.75µg Fis1 show 





















Figure 4.6: Classification of mitochondrial morphology for Fis1 overexpression assay. 
Representative images of CV14A cells showing various mitochondrial morphologies observed 
in Fis1 assay. A (i,ii) clustered mitochondria (indicated with arrowheads in inset). B (i,ii) 
Fragmented mitochondria (indicated with arrowheads in inset). C (i,ii) small tubular 
mitochondria. (indicated with arrowheads in inset). D (i,ii), E (i,ii) normal/fused mitochondria 
(In insets arrows indicate long tubular mitochondria and arrowheads indicate mitochondrial 




















Mitochondria which were larger than fragmented mitochondria and appear as 
small rods were categorised as small tubular mitochondria (Figure 4.6 C). The 
normal/fused mitochondrial category was elaborate as it included mitochondria larger 
than small tubules and present near cell periphery and mitochondria forming loose 
network around the nucleus (Figure 4.6 D) and extensively fused mitochondrial 
reticulum morphology; a typical of EA effect (Figure 4.6E). EA effects were 
considered as normal mitochondrial morphology because the principle of the 
experiment was to see the rescue effect of EA on increased mitochondrial fission rather 
than to quantify increased mitochondrial fusion induced by EA. Fis1 overexpression 
significantly increased mitochondrial clustering and fragmentation in a dose dependent 
manner in both 0.5µg and 0.75µg Fis1 suggesting increased mitochondrial fission 
(Figure 4.7). However, EA treatments showed reduced mitochondrial clustering and 
fragmentation and increase in cells with normal/fused mitochondrial morphology, in a 
dose dependent manner (Figure 4.7).. Though, small tubular mitochondria were not 
significantly affected across the EA treatments (Figure 4.7). This assay showed that 
increased mitochondrial fission induced by Fis1 overexpression was rescued by EA 
treatment and resulted in increased number of cells with either normal mitochondrial 
morphology or enhanced mitochondrial fusion morphology. 
Overexpression of Fis1 induces mitochondrial mediated apoptosis (James et al., 
2003; Yoon et al., 2003). Hence, in Fis1 overexpression assay, nuclear morphology of 
the cell was also studied to test the effect of EA on cell toxicity. Apoptosis is 
characterised morphologically by condensation and fragmentation of nuclei and cells. 
Therefore, nuclear morphologies were categorically scored for apoptotic nuclei, mild 
condensed nuclei and normal nuclei. Cells showing completely fragmented nuclei were 
categorised as apoptotic nuclei, nuclei which were slightly condensed were scored as 
mild condensed nuclei and normal nuclei were scored for smoothly membrane bound 
nucleus. Cells with apoptotic nuclei increased with Fis1 overexpression and the 
proportion was significantly increased with 0.75µg Fis1 in the presence of 0.1% DMSO 
(Figure 4.8). Mild condensed nuclear morphology was also significantly increased with 
Fis1 overexpression and high EA doses 61µM and 83µM. However, 41µM EA did not 
show increased apoptotic and mild condensed nuclei in pCI-NEO empty vector or Fis1 
transfected cells (Figure 4.8). This assay showed that Fis1 induced apoptosis and 41µM 












Figure 4.7: Mitochondrial morphology in CV14A cells overexpressing hFis1 and incubated 
with EA. CV14A cells transfected with pCI-NEO empty vector and/or 2 concentrations of myc-
tagged hFis1 (0.5µg Fis1 and 0.75µg Fis1) for 4 hours and later incubated with 0.1% DMSO 
and 41µM, 61µM and 83µM EA for 24 hours. 200 cells were scored blindly for each condition. 
n = 200 cells, N = 3 independent experiments. Data is presented as mean standard error. 
Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple 













Figure 4.8: Nuclear morphology in in CV14A cells overexpressing hFis1 and incubated 
with EA. CV14A cells were scored for (A) apoptotic, (B) mild condensed and (C) normal 
nuclei. 200 cells were scored blindly for each condition. n = 200 cells, N = 3 independent 
experiments. Data is presented as mean standard error. Statistical significance was determined 






4.4.2 Fis1 overexpression assay to observe the effect of EA on 
peroxisome morphology 
To further investigate whether EA is acting as an inhibitor for the fission 
machinery, we took advantage of peroxisome proliferation and studied the effects of EA 
on peroxisome number. CV14A cells were transfected with either pCI-NEO empty vector 
and EGFP-peroxisome (Figure 4.9A-C(i-i')), or 0.75µg myc-tagged hFis1 plasmid and 
EGFP-peroxisome (Figure 4.9A-C(ii-ii')) as discussed in section 2.6.6 and treated with 
either 0.1% DMSO or 83µM and 124µM EA for 24 hours. The peroxisome numbers for 
all the conditions were quantified using ImageJ particle analysis plugins as discussed in 
sections 2.6.6.4. CV14A cells transfected with empty vector showed small spherical 
peroxisomes spread throughout the cytoplasm under DMSO incubation. Peroxisome 
number was significantly increased in cells overexpressing Fis1 (Figure 4.10). Particle 
analysis showed the number of peroxisomes did not change in EA treated cells 
transfected with empty vector however; peroxisome number was significantly reduced 
in cells overexpressing Fis1 and treated with 83µM EA 124µM EA (Figure 4.10).  
It is important to mention that 124µM EA was only used to investigate the 
possible dose dependent decrease of peroxisome number, since lower EA 
concentrations such as 41µM did not show any effect on peroxisome number with 
empty vector and Fis1 overexpression (data not shown). Incubation of CV14A cells 
with 124µM EA for 24 hours showed 50% cell death in MTT assays, however, to see 
the effect of EA on peroxisome numbers the higher dose was included only to 
investigate whether EA produces a stronger effect beyond 83µM. The results are 
considered preliminary as they are from one experiment and require further repetition to 
draw conclusive results. It is difficult to suggest that why peroxisome number does not 









Figure 4.9: Fis1 overexpression assay for peroxisome number. CV14A cells stably 
expressing DsRed1mito were transfected with EGFP-peroxisome and pCI-NEO empty vector 
(A,B,C i-i’) and EGFP-peroxisome and 0.75µg myc-tagged hFis1 (A,B,C ii,ii’). Panel A shows 
cells treated with 0.1% DMSO for 24 hours. Panel B shows cells treated with 83µM EA for 24 





Figure 4.10: Peroxisome number analysis in Fis1 overexpression assay. Data is presented as 
mean standard error. n = 30 cells. N = 1 Statistical significance was determined by one-way 









4.5 Effect of EA on the mitochondrial morphology in fibroblasts 
derived from Patient 3 carrying Mfn2
R364W
 mutation 
As shown in chapter 3, HMSNVI patient derived fibroblasts carrying Mfn
R364W
 
heterozygous mutation have fragmented mitochondria lacking branching and network 
morphology. This phenotype is indicative of reduced mitochondrial fusion in these 
fibroblasts. Screening for fusion inducing compounds, could identify molecules that can 
be developed into a potential treatment for mitochondrial fusion deficient disorders. As 
mentioned earlier that the primary compound screen was done on fibroblasts derived 
from patient 3 carrying Mfn2
R364W
 mutation. I further quantified the effect of EA on the 
mitochondrial morphology in these patients using subjective and ImageJ analysis 
discussed in section 2.2.5.1 and 2.2.5.2. 
Fibroblasts derived from control 1, control 2 and patient 3 carrying Mfn2
R364W
 
mutation were incubated with either 0.1% DMSO or 83µM EA for 4 hours (Figure 
4.11). Images taken from live cells were scored for fragmented, small tubules, normal 
and fused mitochondrial morphology as discussed in section 3.3.1. Fused mitochondrial 
morphology was included to evaluate the fusion inducing ability of EA on 
mitochondrial morphology in controls as well as patient fibroblasts. 
In the presence of 0.1% DMSO, control 1 and control 2 showed a comparable 
percentage of cells with normal mitochondria. Furthermore, control fibroblasts showed 
zero cells with fragmented and small tubular mitochondria under normal conditions 
(Figure 4.12). However, in the presence of 0.1% DMSO, Patient 3 fibroblasts showed 
significantly high percentage of cells with fragmented mitochondria and cells with small 
tubular mitochondria (Figure 4.12). With 83µM EA 4 hours incubation an over all 
increase in mitochondrial fusion was observed in control fibroblasts (Figure 4.12). Both 
controls showed significantly high percentage of cells with increased mitochondrial 
connections with neighbouring mitochondria producing mitochondrial reticular 
morphology also known as mitochondrial reticulum (Figure 4.12). Interestingly, with 
83µM EA incubation for 4 hours, Patient 3 fibroblasts showed a shift in the 
mitochondrial fragmented morphology spectrum to significantly increased number of 
cells with normal and fused mitochondrial morphology (Figure 4.12). Mitochondria 
appear as long filaments and often displaying the connections with neighbouring 






Figure 4.11: Mitochondrial morphology in Patient 3 Mfn2
R364W
 fibroblasts incubated with 
EA. Fibroblasts were treated with either 0.1% DMSO or 83µM EA for 4 hours. (A) Control 1 
and (B) Control 2 show long tubular mitochondria and mitochondrial loose networks in 
perinuclear region (C) Patient 3 Mfn2R364W fibroblasts show fragmented mitochondria dispearsed 
in the cytoplasm (A') Control 1 fibroblasts treated with 83µM EA. In inset arrow indicate the 
mitochondrial connections producing mitochondrial reticulum. (B’) Control 2 fibroblasts treated 
with 83µM EA. In inset arrows indicate the mitochondrial connections producing mitochondrial 
reticulum. (C’) Patient 3 fibroblasts treated with 83µM EA. In inset arrow indicate long 


















In the presence of 83µM EA percentage of cells with fragmented mitochondria 
and cells with small tubular mitochondria was also significantly reduced as compared to 
DMSO treated ones (Figure 4.12). 
ImageJ analysis for mitochondrial aspect ratio, length, bifurcation ratio and 
network complexity ratio was carried out to quantify the difference in the mitochondrial 
morphologies observed with DMSO and EA treatment (for analysis details see section 
2.2.5). Patient 3 showed significantly reduced aspect ratio as compared to controls in 
the presence of 0.1% DMSO, however in the presence of 83µM EA Patient 3 showed 
significant increase in mitochondrial aspect ratio (Figure 4.13). With 83µM EA, 
Control 1 presented slightly reduced aspect ratio and Control 2 showed significantly 
reduced mitochondrial aspect ratio, and no effect on mitochondrial length was observed 
in control fibroblasts (Figure 4.13). The reduction in aspect ratio is most likely due to 
increase in mitochondrial connectivity among the mitochondrial population which is 
shown as significant increase in bifurcation ratio and network complexity ratio in 
controls (Figure 4.13). Furthermore, with 83µM EA, Patient 3 fibroblasts showed 
significant increase in mitochondrial length, bifurcations and network complexity ratio 
(Figure 4.13).  
In conclusion, these analyses demonstrated that EA has shown an enhanced 
mitochondrial fusion effect in both controls and patient fibroblasts. We have shown that 
in the presence of EA an overall increase in the number of cells showing normal and 
fused mitochondrial network morphology was observed. Also, ImageJ analysis 
demonstrated significant increase in mitochondrial aspect ratio, length, branch 
formation and network complexity. Hence, our results suggest that EA is rescuing the 




























Figure 4.12: Subjective analysis of mitochondrial morphology in Patient 3 Mfn2R364W 
fibroblasts incubated with EA. 0.1% DMSO used as vehicle. Cnt1: control 1, Cnt2: control 2, 
Pat3: patient 3 Mfn2R364W. Data is presented as mean standard error. n = 50-60 cells, N = 3 
independent experiments. Statistical significance was determined by one-way ANOVA 





















Figure 4.13: ImageJ analysis of mitochondrial morphology in Patient 3 Mfn2
R364W
 
fibroblasts incubated with EA. 0.1% DMSO used as vehicle. Cnt1: control 1, Cnt2: control 2, 
Pat3: patient 3 Mfn2
R364W
. Data is presented as mean standard error. n = 50-60 cells, N = 3 
independent experiments. Statistical significance was determined with Kruskal-Wallis non-







Primary drug screen including 2000 compounds from the Spectrum Collection 
and 4 compounds from literature search were tested for their ability to affect 
mitochondrial morphology in skin fibroblasts obtained from HMSNVI patient carrying 
heterozygous Mfn2
R364W
 mutation. Following the primary screen, positive compounds 
were tested for their ability to increase mitochondrial fusion in CV14A cells. The 
scoring for the effect of each dose of the compounds with the 3 incubation periods (15 
mins, 4 hours and 24 hours) on mitochondrial morphology was done once, however, the 
scoring was not done blind. Hence, the results are considered preliminary for the 
secondary screen. However, the increase in mitochondrial fusion morphology was 
strong enough for us to continue with the compounds that scored as positive candidates 
in the initial results. Nevertheless, the results need to be improved by replicating the 
incubations times with blind scoring of mitochondrial fusion. From the secondary 
screen EA, NEM, cycloheximide and crinamine came out as positive hits for the 
increased mitochondrial fusion in cells, however, NEM and crinamine were excluded 
from further analysis. NEM was excluded because it is well-known non-specific 
cysteine alkylator with cellular targets in various cellular pathways (Glick and 
Rothman, 1987; Mseeh et al., 2002). The effect of NEM on mitochondrial morphology 
might be non-specific as it may be interacting with other pathways not directly involved 
in mitochondrial dynamics and the increased mitochondrial fusion observed in cells 
might refelect the secondary effects of such interactions. Also, NEM was included in 
the study as a comparison with EA to see how it behaves in our cells since Bowes and 
Gupta used NEM as another cysteine alkylator to see its effect on mitochondria along 
with EA (Bowes and Gupta, 2005). Crinamine is a natural product and was obtained at 
the standard concentration of 10µM from Spectrum library. Crinamine was excluded 
from further characterisation due to the lack of availability of the compound and also 
because another group in Canada communicated with us that they are already working 
on the effects of this compound on mitochondrial dynamics. Cycloheximide also 
showed increased mitochondrial fusion in CV14A cells but was dropped from further 
validation because of various reasons as discussed later in the text. As a result, from 
secondary screen EA was considered as candidate compound for studying its effect on 
mitochondrial morphology and further characterisation for how it is increasing 
mitochondrial fusion in cells. 
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MTT assay was performed to determine cytotoxicity and cell viability for EA, 
NEM and cycloheximide. The rationale for testing toxic effects of positive hits on cell 
survival was to determine drug doses that can be used in further cell based assays to 
characterise the compounds without toxic effects. In MTT assay EA showed an increase 
in cell survival in Mfn2
R364W
 patient fibroblasts and 50% inhibitory concentration (IC50) 
was in between 41µM and 83µM for 24 hours incubation. However, CV14A cells 
showed much less toxicity with EA. The difference in the toxicity of EA in patient 
fibroblasts and CV14A cell is presumed to be the sensitivity of patient cells. It might be 
because patient fibroblasts may perhaps be under stress which makes than more 
sensitive to cytotoxicity of EA. Also, EA showed a typical dose dependent decrease in 
cell survival in both patient and CV14A cells that is supportive to consider it as 
potential drug. The toxic levels of EA found in CV14A cells were in concordance with 
Gupta and colleagues who showed that short exposure (2 hours) had no toxic effect in 
Chinese hamster cells with higher EA concentrations (Soltys and Gupta, 1994). 
However, long term exposure of EA (6-7days) showed adverse effects on colony 
formation by showing IC50 at approximately 40µM EA (Soltys and Gupta, 1994). In 
MTT assay NEM showed high toxicity level and 50% cells were dead past 1.75µM 
NEM after 24 hours incubation. Furthermore, cycloheximide did not show high toxicity 
with higher concentrations but it failed to produce a drug like response in MTT assay. 
This suggests that increasing the concentration of cycloheximde in the assays would not 
influence its effect on cells and therefore it would be difficult to establish a reliable 
concentration for the optimal effect to be studied. We know that the MTT assay 
involves the reduction of MTT salt by mitochondrial succinate dehydrogenase in 
metabolically active cells (Mosmann, 1983). There are various other tests such as the 
lactate dehydrogenase (LDH) assay and ATP quantification to analyse compound/drug 
toxicity and effect on cell viability. However, we used MTT assay because it was 
already in use in our lab to test the toxicity and cell survival. Though, one question that 
arises is, whether the effect of compounds on cell survival could be due to effects on 
mitochondria? It is ought to be considered that the drugs screened in this project were 
selected because they modify mitochondrial morphology and we do not expect such 
changes in morphology to lead to toxicity. However, it could be that toxicity causes 
changes in mitochondrial morphology but such change is typically pro-fission not pro-
fusion (DeVos et al., 2005). 
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The PEG fusion assay was performed to test the ability of EA and 
cycloheximide to induce mitochondrial fusion in cells in-vitro. The rationale was to 
investigate whether the increase in mitochondrial fusion is the primary effect of the 
compounds and not a phenomenon that occur secondary to some other process in the 
cell. The PEG fusion assay protocol included addition of 107µM cycloheximide to 
inhibit new protein synthesis before the addition of compounds being tested for fusion 
induction (Chen et al., 2003). It is an important step as it prevents the synthesis of new 
mitochondrially targeted DsRed1 and GFP fluorophores in the fused cells and makes it 
possible to show that the increased fusion is the result of drug action on mitochondrial 
dynamics rather than production of more DsRed1mito and GFPmito in the cells. For EA 
our results have shown a significant increase in mitochondrial fusion in a dose 
dependant manner. As stated in result section, this assay needs further replication. 
However, data from the two biological replicates suggests that EA is able to induce 
mitochondrial fusion in-vitro and the increase in mitochondrial fusion is not a result of 
any other process going on in cells under EA exposure. These are novel findings as 
previous work done on characterisation of EA has not measured its ability to induce 
mitochondrial fusion in in-vitro conditions.  
However, testing cycloheximide for its ability to induce fusion in PEG fusion 
assay was problematic because of the addition of cycloheximide in initial steps to 
inhibit protein synthesis. Therefore, we decided to exclude cycloheximide from further 
characterisation. Also, cycloheximide is a known protein synthesis inhibitor; therefore 
its broad activity would make it a hard choice to be developed into a potential drug as 
well as a bench tool to study the mitochondrial dynamics specifically. There is a report 
in the published literature suggesting that stress as a result of protein inhibition by 
cylcoheximide results in the activation of SLP2, which in turn leads to mitochondrial 
hyperfusion (Tondera et al., 2009). SLP2 is believed to stabilize the OPA1-L isoform 
under stress facilitating the hyper fusion of mitochondria and increased production of 
ATP (Merkwirth et al., 2008; Tondera et al., 2009). This process is thought to be cell’s 
resistance response to the stress. However, they did not show the effect on 
mitochondrial morphology in longer incubations with cycloheximide. Similarly, such 
findings are also not performed in my studies but it is suggested that longer exposure on 
mitochondrial morphology with cycloheximide is necessary to see what happens in long 
term stress conditions. Does mitochondrial fragmentation render cells unable to cope 
with continued stress exposure? Normally, mitochondrial fission is the result of any 
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stress a cell is experiencing; however, elongated mitochondria were seen in tobacco 
cells in hypoxic conditions and in Hela cells generating ATP by oxidative 
phosphorylation instead of glycolysis (Van Gestel and Verbelen, 2002; Rossignol et al., 
2003). Furthermore, our MTT assay results also support the idea of excluding 
cycloheximide from further investigation as it resulted in 50% loss of cell viability at all 
the tested concentrations. 
To investigate how EA is able to increase mitochondrial fusion in cells we 
followed our working hypothesis that EA is acting by either inactivating the essential 
cysteine residue/s in mitochondrial fission machinery or in mitochondrial fusion 
repressor factor. For this, we used an easy approach to manipulate normal mitochondrial 
dynamics by increasing mitochondrial fission by overexpressing Fis1. EA showed 
significant increase in mitochondrial fusion in cells overexpressing Fis1 as compared to 
control cells. Fis1 overexpression assay was an alternative readout assay to show that 
EA increases mitochondrial fusion, however this assay does not reveal whether EA is 
pro fusion or anti fission. Possible assays that could give an unbiased answer for 
identifying EA cellular targets are seeing the effect of EA in fission machinery 
knockout models (Drp1 knockout) or fusion machinery knockouts (Mfn1 and Mfn2 
knockout and Opa1 knockout models). Based on the hypothesis that EA is inactivating a 
fission factor, we can assume that in cells lacking Drp1 EA will be unable to show 
increased mitochondrial fusion and possibly the fusion level would be same as in 
DMSO (vehicle) treated cells. The emphasis of our discussion is more on Drp1 as a 
major candidate for EA action because it is the main GTP protein involved in 
membrane scission using GTP hydrolysis (Smirnova et al., 1998; Mozdy et al., 2000; 
Smirnova et al., 2001). Other members of fission machinery such as Fis1 and Mff are 
the anchoring proteins for Drp1 and facilitate the dimerization of Drp1 at fission sites. 
These anchoring proteins are not involved in the membrane severing in mitochondrial 
fission and their expression in Drp1 mutant backgrounds does not rescue mitochondrial 
fission (Breckenridge et al., 2008; Otera et al., 2010).  In addition to Fis1 and Mff other 
anchoring proteins MiD49 or MiD51 mediate Drp1 recruitment to the fission sites in the 
absence of Fis1 and Mff (Loson et al., 2013). Cells expressing dominant-negative Drp1 
mutant Drp1
K38A
, which is GTPase dead form, have shown increased mitochondrial 
network morphology (Smirnova et al., 1998; Smirnova et al., 2001). We assume that 
EA inactivates its target by alkylating the functional cysteine residue(s). Drp1 has in 
total 9 cysteines; N-terminal GTP-binding domain has one cysteine, middle domain has 
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6 cysteines, insert B has 1 cysteine and the C-terminal GTPase effector (GED) domain 
also has 1 cysteine. The GED domain is involved in mediating GTPase activity to sever 
the mitochondrial membranes (Pitts et al., 2004; Zhu et al., 2004). Additionally, an 
intra-molecular association has been identified between the GED domain folding back 
to interact in cis as well as in trans with the GTP-middle domains of Drp1 (Zhu et al., 
2004). These intra- and inter-molecular associations have been thought to promote Drp1 
dimerization and enhance its GTPase activity (Pitts et al., 2004; Zhu et al., 2004). More 
to the point, S-nitrosylation of cysteine 644 in the GED domain enhances the 
dimerization of Drp1, increased GTPase activity and showed fragmented neuronal 
mitochondria and neurotoxicity (Cho et al., 2009). A similar report to our study has also 
shown increased mitochondrial network morphology in cells when incubated with 15 
deoxy-Δ
12,14
-prostaglandin J2 (15d-PGJ2) peptide for 2 hours. It is believed that 15 
deoxy-Δ
12,14
-prostaglandin J2 (15d-PGJ2) peptide acts by thiol modification of 
cysteines in target proteins (Mishra et al., 2010). Based on our hypothesis, the second 
possibility is that EA is inactivating an anti-fusion factor or fusion repressor. There 
could be various candidates which are involved in negative regulation of mitochondrial 
fusion either acting directly or indirectly. It is known that Drp1 undergoes various post-
translational modifications for its activation and translocation from the cytoplasm to the 
mitochondrial outer membrane to start mitochondrial fission (Chang and Blackstone, 
2007; Karbowski et al., 2007). Hence, any of the kinases involved in its activation could 
possibly be inactivated by EA. Additionally; another interesting side to the story would 
be if EA is acting on components of the PINK1/Parkin pathway. We know that Mfn1 
and Mfn2 are targets for Parkin mediated degradation upon dissipation of membrane 
potential (Ziviani et al., 2010). In order to investigate whether EA may be acting on the 
PINK1/Parkin pathway, it could be tested in cells overexpressing Parkin or PINK1 to 
look for effects on expression levels of normal and ubiquitinated forms of Mfn1 and 
Mfn2. 
Furthermore, Fis1 overexpression induced mitochondrial fission morphology 
could primarily be rescued by expressing mitochondrial fusion factors such as Mfn1, 
Mfn2 and OPA1. It is suggested that in future, it would be interesting to add these 
conditions in parallel to EA treatment of cells overexpressing Fis1. Also, it would be 
interesting to see the effect of EA in Drp1 knockout cells and in Mfn1 and Mfn2 double 
knockout and Opa1 knockout cells. Such studies would help further dissect the pathway 
EA is acting to promote mitochondrial fusion in cells. However, it is difficult to 
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separate out whether EA is inhibiting fission machinery or it is inactivating a fusion 
inhibitor or repressor. Therefore, it is suggested to take a direct approach and see the 
effect of EA on Drp1 GTPase activity if EA is alkytaing cysteine residue/s in Drp1 and 
rendering it inactive. 





 is a heterozygous mutation giving 
one mutated allele and one wild type allele. It is clear from previous studies that 
pathogenic Mfn2 alleles can make fusion competent complexes with the wild type 
alleles and with Mfn1 (Detmer and Chan, 2007a). Our results indicate an increase in 
mitochondrial fusion in Mfn2
R364W
 patient cells when treated with EA. Therefore, it can 
be assumed that EA might be blocking fission, and as a result fusion continues to take 
place, this leads to an increased number of cells with normal and branched 
mitochondrial morphology. Although 100% rescue of the fragmented mitochondrial 
morphology of Mfn2
R364W
 cells was not observed, however, a significant number of cells 
with increased mitochondrial aspect ratio, length and branching were present after EA 
treatment. This suggests the occurrence of fusion might be facilitated by the formation 











 mutation has not been tested for its 
ability to be fusion competent, therefore at this point we can not be sure of its 
mitochondrial fusion competence and testing the fusion ability was beyond the scope of 
present study. However, fusion competency can be analysed with the PEG fusion assay 
co-culturing Dsred1mito and GFPmito cells expressing Mfn2
R364W
 heterozygous 
mutation. This would be a valuable assay for the characterization of this mutation. 
Furthermore, peroxisomes use the same mitochondrial fission machinery 
including primarily Drp1, Fis1 and Mff for division and multiplication (Kobayashi et 
al., 2007; Gandre-Babbe and van der Bliek, 2008). Our preliminary results have shown 
significant increase in peroxisome number in Fis1 overexpressing cells and are 
presumably due to increased proliferation of peroxisomes. After EA incubation for 24 
hours the peroxisome number was significantly decreased in cells overexpressing Fis1. 
Peroxisome number did not change in mock treated cells (empty vector) and no larger 
or bloated peroxisomes were seen, suggesting the non-fusing nature of peroxisome. 
Peroxisome fusion is still a grey area and the majority of scientific evidence suggests 
that peroxisomes do not fuse to form larger structures (Motley and Hettema, 2007). Like 
fission machinery components, mitochondrial fusion factors such as Mfn1, Mfn2 and 
 
 126
OPA1 were not identified to be present on peroxisomes, however, it has been reported 
that moving peroxisomes interact with each other while motile and form transient 
contacts but such connections are not considered as fusion events (Schrader et al., 
2000). For division and proliferation peroxisomes form elongated tubular structures 
with constrictions which look like beads on a string (Schrader et al., 1998; Kobayashi et 
al., 2007). Pex11 has the major role in elongation and tubulation of peroxisomes 
(Schrader et al., 1998). The beads on a string like morphology represent the elongation 
of single peroxisomes and not the fusion of neighbouring peroxisomes to form longer 
structures. Drp1 is recruited to the constriction sites on the elongated peroxisome to 
initiate membrane scission (Kobayashi et al., 2007). Drp1 knockdown cells showed 
peroxisomes with beads on a string like morphology showing failure of membrane 
scission (Koch et al., 2004). We did not see bloated peroxisomes or beads on a string 
like morphology with EA treatment; we only observed reduction in peroxisome number. 
It is difficult to make conclusion from one experiment about how EA is causing the 
reduction in number without giving bloated peroxisomes or beads on string like 
morphology. However, it could be suggested that EA action does not occur to a 
detectable level unless increased number of Drp1 is present on peroxisomes as a result 
of Fis1 overexpression. Hence for this reason, EA was unable to show obvious effect on 
peroxisome number under basal levels of fission machinery. Moreover, failure to see the 
beads on string like morphology could be due to limitations of microscopy, or because 
the effects of EA on Drp1 are not equivalent to the effects seen in Drp1 knockout cells. 
Therefore, in future studies it would be helpful to use 3D confocal imaging techniques 
to study the peroxiomal morphology more carefully. Finally, due to limitations of our 
data we cannot make any conclusion about how EA is acting on peroxisomes and why 
we only see an effect of EA in Fis1 overexpressing cells.  
To conclude, we have shown that EA is able to increase mitochondrial fusion in 
CV14A cells and Mfn2
R364W
 patient fibroblasts. We have also shown that EA is able to 
induce mitochondrial fusion in PEG fusion assay. EA has shown increased 
mitochondrial fusion in cells overexpressing Fis1 and preliminary assays show that EA 
is able to reduce the number of peroxisomes in cells overexpressing Fis1. Mitochondrial 
fusion and fission are highly regulated processes and many factors have indirect link to 
the actual process. Consequently, there are number of candidates and their inactivation 
could result in increase in mitochondrial fusion. Hence, it is an interesting avenue for 
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further research in order to progress our understanding of how EA is increasing 





































Chapter 5a: Characterisation of 














Drosophila melanogaster has been used as a successful animal model for 
various common neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s 
disease, amyotrophic lateral sclerosis and Huntington’s disease (Wittmann et al., 2001; 
Auluck et al., 2002; Gunawardena et al., 2003; Iijima et al., 2004; Clark et al., 2006; 
Park et al., 2006). Modelling a human neurodegenerative disease in Drosophila 
melanogaster allows several advantages for studying molecular and cellular pathology 
of the disease. In this respect, fruit fly offers researchers a system to analyse neuronal 
structure and physiology in an intact animal. Mfn2 is a profusion factor present in the 
outer mitochondrial membrane and is associated with common inherited 
neurodegenerative diseases such as CMT2A and HMSNVI (Zuchner et al., 2004; 
Verhoeven et al., 2006). Drosophila has Fzo and Marf for mitochondrial outer 
membrane fusion. However, fzo expression is restricted to male testis only (Hales and 
Fuller, 1997). Marf is considered as the main profusion factor as it is expressed 
ubiquitously and shares a higher percentage of sequence homology to mammalian Mfn1 
and Mfn2 (Hwa et al., 2002). In this project, GAL4/UAS system was used in conjunction 
with inducible RNA interference (RNAi) to knockdown Marf expression in different fly 
tissues and study the effect on fly development, locomotion and mitochondrial 
morphology. RNAi is cell-autonomous in Drosophila and targeted expression of RNAi 
using the GAL4-UAS system can be achieved for cell or tissue specific gene knockdown 
(Gunsalus and Piano, 2005). The method of RNAi knockdown involves the expression 
of an interfering RNA containing inverted repeat sequences (>200bps) that form hairpin 
double-stranded RNAs (dsRNA) homologous to sequences of the target transcript. 
These hairpin dsRNAs are processed by the enzyme Dicer into short interfering RNA 
(siRNA) (21-23bps). These siRNAs are then incorporated into a group of proteins called 
the RISC (RNA-Inducing Silencing Complex) that uses the antisense strand of the 
siRNA to bind to and degrade the corresponding mRNA. GAL4-UAS is a bipartite 
system in flies involving separate transgenic stocks for GAL4-driver flies and UAS-IR 
flies. The GAL4-driver fly carries a promoter controlling the expression of yeast 
transcription factor GAL4, which allows tissue specific expression. The UAS-IR fly 
holds a transgene containing inverted repeat sequences (IR) of the target gene under the 
control of the GAL4 upstream activating sequence (UAS). A cross between these two 
transgenic lines results in a tissue specific binding of GAL4 on the promoter region of 
 
 130
UAS to activate the formation of hairpin dsRNA, which results in sequence specific 
gene silencing.  
5.2. Characterisation of Marf and its role in Drosophila melanogaster 
development, locomotion and mitochondrial dynamics 
5.2.1 Marf RNAi lines 
Two UAS-RNAi lines designed to knockdown Marf were obtained from Vienna 
Drosophila RNAi Centre (VDRC). P-element generated RNAi line: Marf
RNAiGD
, (UAS-
Marf-IR(GD) (ID40478)) was the first line used. The inverted repeat sequence to 
generate the short hairpin formation targets the exon 6 (Figure 5.1A). This RNAi line 
has one predicted off target Dmel/CG3188, a protein with unknown function, and low to 
moderate expression in larval and adult midgut, hindgut, malphigian tubules, adult 
heart, adult spermathecae and adult carcass. The 2
nd
 RNAi line: Marf
RNAiKK
 , (UAS-
Marf-IR(KK) (ID105261)), was from a library of newly generated RNAi lines using site 
specific integration of transgene with phiC31 integrase. Marf
RNAiKK
 targets exon 2 and 3 
of Marf and has no predicted off target effects (Figure 5.1B). 
5.2.2 Characterisation of lethal phase of Marf knockdown in basic 
tissues 
To characterise the lethal phase for Marf knockdown we drove the RNAi 
expression in all tissues using ubiquitous da-GAL4 driver, in muscles using Dmef-GAL4 
driver, in all neurons using elav-GAL4 driver and in motor neurons using D42-GAL4 
driver (Table 5.1). A benign RNAi control; y-RNAi was used in the assays for 
comparison for non-specific effects of RNAi. y-RNAi control showed normal 
developmental cycle under ubiquitous-GAL4-driven y knockdown, muscles-GAL4-
driven y knockdown, neuronal-GAL4-driven y knockdown and motor neuron-GAL4-
driven y knockdown flies (Figure 5.2). Ubiquitous-GAL4-driven Marf
RNAiGD
 showed 
developmental failure arresting at 3
rd
 instar larval stage (Figure 5.2). These larvae were 
smaller than control larvae (data not shown) and had life span up to 28-30 days post 
embryonic stage (Table 5.1). Similarly, ubiquitous-GAL4-driven Marf
RNAiKK
 also 
presented developmental arrest by 3
rd











Figure 5.1: RNAi lines. GD line: UAS-Marf-IR(GD) and KK line: UAS-Marf-IR(KK) used in 
this study. GBrowse indicating the targeting sequences for the short hairpin sequences. (A) 
UAS-Marf-IR(GD) has inverted repeat sequences for hairpin formation targeting the exon 6 of 
Marf. (B) UAS-Marf-IR(KK) has inverted repeat sequences for hairpin formation targeting the 













Figure 5.2: Lethal phase of Marf knockdowns. da: da-GAL4: ubiquitous expression, Dmef: 
Dmef-GAL4: muscle expression, elav: elav-GAL4: all neurons expression, D42: D42-GAL4: 
motor neurons expression. ctrl: UAS-y-IR; used as control. GD: UAS-Marf-IR(GD). KK: UAS-
Marf-IR(KK). Marf OE: UAS-Marf overexpression. UAS-Marf transgenic lines; UAS-Marf-
IR(GD),UAS-Marf(1) have UAS-Marf  transgene on chromosome 1 and UAS-Marf-





To verify that these phenotypes were due to loss of Marf function and not an off-
target effect, Marf was re-expressed using a UAS-Marf overexpression transgene, 
although this transgene may also be affected by the RNAi. As expected, re-expression 
of Marf in ubiquitous-GAL4-driven Marf knockdown was sufficient to almost 
completely rescue the developmental arrest for both GD and KK lines (Figure 5.2). 
Importantly, as a control for the dilution effect of RNAi in the presence of two UAS 
transgenes we also tested development in fly line carrying Marf
RNAi
 in combination with 
UAS-mitochondrial green fluorescent protein (GFP) reporter transgene. Ubiquitous-
GAL4 driven Marf down regulation for both GD and KK lines carrying UAS-
mitochondrial GFP showed similar developmental arrests as seen in the presence of 
single UAS transgene (Figure 5.2). This suggests that halted developmental defect was 
likely due to Marf knock down and Marf plays a vital role in Drosophila normal 
developmental process.  
Subsequently, we explored the affect of Marf
RNAi
 in muscles on Drosophila 
development. Muscle-GAL4-driven Marf knockdown showed normal development up 
to pupal stage but fail to develop further and showed pupal lethality (Table 5.1, Figure 
5.2). The majority of animals showed pupal lethality, however, a few escapers were 
seen in KK line (Figure 5.2). Again, the pupal lethality was rescued by muscle-GAL4 
re-expression of Marf in muscle-GAL4-driven Marf
RNAi
 in both GD and KK lines 
(Figure 5.2). These findings also suggested that the developmental defects were due to 
the down regulation of Marf in fly muscles and optimum levels of Marf in muscles are 
significant for normal developmental cycle. Subsequently, we wanted to assess the 
relative effect of Marf
RNAi 
in nervous system and independently in motor neurons only. 
Neuronal-GAL4-driven Marf knockdown for both GD and KK lines showed viable 
adults, however, the flies were weak and immotile (Table 5.1, Figure 5.2). In contrast, 





 lines (Table 5.1, Figure 5.2). The rescue experiments were 
not performed in these assays since the knockdowns did not affect viability. 
Nevertheless, our results suggest that Marf is important for normal developmental 
process for Drosophila and its ubiquitous loss is lethal. Also, these results are consistent 





5.2.3 Western blot analysis for Marf RNAi effectiveness 
The effectiveness of the RNAi to knockdown Marf was analysed by western 
blots against Marf protein. At the beginning of the project no suitable antibodies for 
Marf were available, therefore we begun by raising an antibody to the protein. This was 
done through a commercial outsource. Anti-Marf was raised in rabbit against N-
terminal peptide, DTVDKSGPGSPLSRF (Ziviani et al., 2010). Protein expression 
analysis was done to analyse the effectiveness of ubiquitous-GAL4-driven Marf
RNAi
, 
Marf rescue lines and Marf
overexpression
. Control larvae showed predicted size Marf band 
(91.4-94.1 kDa), which was absent in ubiquitous-GAL4-driven Marf knockdown larvae 
for both GD and KK lines (Figure 5.3A). This band was also absent in larvae carrying 
ubiquitous-GAL4-driven Marf
RNAi 
and UAS-mitochondrial GFP but reappeared upon the 
re-expression of UAS-Marf (Figure 5.3A). Interestingly, the Marf band appeared more 









 (Figure 5.3A). At the 
present it can be suggested that this difference of band intensity could probably be due 
to different levels of Marf expression in both lines. Additionally, the Marf band 
appeared similar in intensity in ubiquitous-GAL4-driven Marf
overexpression
 for both line 1 





 lines to attenuate Marf expression.  
We also wanted to see the expression levels of Marf throughout fly 
developmental stages, therefore, protein samples were extracted from embryo, early 




 larval instar, pupae and adult flies. In the control 
blot, predicted size Marf band (91.4-94.1kDa) was present in all the developmental 
stages (Figure 5.3B). Blots showed moderate Marf expression in embryonic and early 
larval stages and high Marf expression in late larval stage, pupae and adults in control 
(Figure 5.3B). In addition, Marf expression in ubiquitous-GAL4-driven Marf
RNAi
 during 
the early stages of development to the arrested 3
rd
 instar larval stages was also analysed. 
Early and late ubiquitous-GAL4-driven Marf
RNAiGD
 larvae showed absence of the Marf 
band (Figure 5.3B), Marf band was present in embryonic stages for both ubiquitous-
GAL4-driven Marf
RNAiGD
 and ubiquitous-GAL4-driven Marf
RNAiKK
. Appearance of Marf 
in embryonic stages is possibly due to the known ineffiency of RNAi in embryonic 
stages. In the case of ubiquitous-GAL4-driven Marf
RNAiKK 
, very weak Marf band was 
present during early larval stages but the band disappeared in 3
rd








Figure 5.3: Western blot analysis for Marf RNAi effectiveness. (A) Expression analysis for 
Marf ubiquitous knockdown, rescue and overexpression. da-GAL4>UAS-Rh4-IR used as control 
(lane 1). Marf band (91.4-94.1kDa) (indicated with arrow) is absent in da-GAL4>UAS-Marf-
IR(GD) (lane 2) and da-GAL4>UAS-Marf-IR(KK) (lane 3). Marf band is present in da-
GAL4>UAS-Marf-IR(GD);UAS-Marf(1) (lane 4) da-GAL4>UAS-Marf-IR(KK);UAS-Marf(3) 
(lane 5). Marf band is absent in da-GAL4>UAS-Marf-IR(GD),UAS-mitoGFP (lane 6) and da-
GAL4>UAS-Marf-IR(KK),UAS-mitoGFP  (lane 7). Intense Marf band present in Marf 
overexpression lines: da-GAL4>UAS-Marf(1) (lane 8) and da-GAL4>UAS-Marf(3) (lane 9).  
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(B) Western blot analysis for Marf expression during development. (Blot 1) da-GAL4>UAS-
Rh4-IR controls (Lane 1: embryo, Lane 2: early larval stages (1 and 2), Lane 3: 3rd instar larval 
stage, Lane 4: pupal stage, Lane 5: adult stage). Marf band present in all lanes at 91.4-94.1 kDa 
(indicated with arrow) with an increase in band intensity through the later developmental stages. 
da-GAL4>UAS-Marf-IR(GD); Marf band is present in embryonic stage (Lane 1, indicated with 
arrow), and not visible in larval stages (Lane 2 and 3). da-GAL4>UAS-Marf-IR(KK); Marf band 
is present in embryonic stage (Lane 1, indicated with arrow), faint Marf band present in early 
larval stages (Lane 2), Marf band disappeared in 3rd instar larval stage (Lane 3). ns: non specific 



















5.2.4 Locomotion defects in Marf ubiquitous knockdown larvae 
Drosophila larvae exhibit forward movement by contracting the body wall 
muscles in successive segments from posterior to anterior creating a peristaltic wave 
pushing the body forward. Such movement has been extensively studied to detect 
locomotory defects in larvae (Feiguin et al., 2009). To find motility defects in the Marf 
ubiquitous knockdown larvae, the numbers of peristaltic waves for every 2 minutes 
were recorded for 3
rd





larvae showed significantly reduced peristaltic movement as compared to the 
controls (Figure 5.4). Larvae obtained from cross between ubiquitous-GAL4-driver line 
and transgenic line carrying Marf
RNAiGD
 and UAS-mitochondrial GFP, also showed 
significantly reduced peristaltic movements (Figure 5.4). Interestingly, the defective 
larval locomotion was rescued in the rescue line where Marf was re-expressed in 
ubiquitous-GAL4-driven Marf
RNAi
 (Figure 5.4). These results suggest that loss of Marf 







is absent therefore this data should be interpreted cautiously. 
5.2.5 Survival rate for Marf nervous system and motor neuron 
knockdowns 
The longevity assay was performed to establish the role of Marf in adult 
survival. 0-24 hour old flies were collected, kept in food vials in humidified chamber at 
25ºC and survival was recorded for 30 days. Neuronal-GAL4-driven Marf knockdown 
flies showed significantly reduced survival (Figure 5.5A). Neuronal-GAL4-driven 
Marf
RNAiGD
 adult flies were severely affected and showed a median life of 2 days 
(Figure 5.5A), whereas Marf
RNAiKK
 adult flies showed slightly longer life span with a 
median survival of 12 days (Figure 5.5A). However, motor neuron-GAL4-driven Marf 
knockdown flies showed relatively variable survival rates (Figure 5.5B). Motor neuron-
GAL4-driven Marf
RNAiGD
 adult flies presented median survival of 15 days (Figure 
5.5B), and motor neuron-GAL4-driven Marf
RNAiKK
 adult flies showed normal survival 











Figure 5.4: Larval locomotion assay for Marf ubiquitous knockdowns. n = 20 for each 
genotype. Controls out crossed with w
1118
. Black control bar: da-GAL4/+, dark grey control bar: 
UAS-Marf-IR(GD)/+, light grey control bar: UAS-Marf-IR(KK)/+, white control bar: UAS-
Marf-IR(GD),UAS-mitoGFP/+. Data is presented as mean standard error. Significance was 












Figure 5.5: Survival curves for Marf nervous system and motor neuron knockdown flies. 
The number of flies scored from each cross was >100. (A) elav-GAL4>UAS-Marf-IR(GD) and 
elav-GAL4>UAS-Marf-IR(KK) showed significantly reduced life span. (B) D42-GAL4>UAS-
Marf-IR(GD) showed reduced survival. D42-GAL4>UAS-Marf-IR(KK) showed normal 
survival. Each data point represents percent survival. All statistical analyses were performed by 





The difference in survival observed between the GD and KK lines for motor 
neuron Marf knockdowns is difficult to explain. One possible suggestion can be an off 
target effect associated with Marf
RNAiGD
 transgene and/or possibly reduced expression of 
Marf
RNAiKK
 transgene in motor neurons. Future work could test for off-target effects by 
assessing whether re-expression of Marf can rescue these phenotypes. Our results 
suggest that Marf expression have an effect on fly survival but the limitation of the data 
to draw conclusion is the absence of benign RNAi as control in this assay. The effect of 
Marf down regulation in nervous system and motor neurons on fly survival could be a 
false positive effect of UAS-RNAi it self. Hence we are unable to distinguish between 
the effect of UAS-RNAi on fly survival and the effect due to ablation of a necessary 
gene such as Marf on fly survival. 
5.2.6 Locomotion defects in Marf nervous system knockdown and 
motor neuron knockdown flies 
Climbing and flight ability of the flies were tested to assess locomotion defects 
in nervous system and motor neuron knockdown adult flies. 100 flies for each genotype 
in cohorts of 20 flies (approximately equal proportion of males and females) were tested 
in climbing assays followed by flight assays. Nervous system-GAL4-driven Marf
RNAiGD
 
flies were unable to perform in the climbing test and showed 0.00 climbing index 
(Figure 5.6). Similarly, nervous system-GAL4-driven Marf
RNAiKK
 flies also showed poor 
climbing with significantly reduced climbing index as compared to the controls (Figure 
5.6). The climbing deficit was successfully rescued in nervous system-GAL4-driven 
Marf
RNAiGD
 flies with the re-expression of Marf (Figure 5.6) (Data for locomotion 
assays for Marf overexpression flies is presented in Appendix A). Re-expression of 
Marf increased the climbing ability of nervous system-GAL4-driven Marf
RNAiKK
 flies but 
the effect was significantly lower than control flies (Figure 5.6). Motor neuron-GAL4-
driven Marf
RNAi 
flies also showed significantly reduced climbing as compared to the 
control flies (Figure 5.6). However, the climbing defect was significantly rescued in 
these flies with re-expression of Marf in motor neurons (Figure 5.6). Moreover, flies 
carrying both Marf
RNAi
 and UAS-mitochondrial GFP transgene were also included in the 
assays as transgene dilution test sample. These flies showed similar climbing defects as 
seen in nervous system and motor neuron Marf
RNAi
 flies (Figure 5.6). 





flies showed significantly reduced flight ability as compared to the control (Figure 5.7). 
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The flight defect was significantly rescued for both GD and KK lines with re-expression 





 flies showed significantly reduced flight ability (Figure 5.7) and was 
significantly rescued with Marf re-expression (Figure 5.7). Flies carrying both 
Marf
RNAiGD
 and UAS-mitochondrial GFP also showed significantly reduced flight 
ability. However, flies with motor neuron-GAL4-driven Marf
RNAiKK 
and UAS-
mitochondrial GFP transgene showed normal flight ability (Figure 5.7). Also, the 
difference between the flight ability of GD and KK lines was statistically significant. 
The difference in flight ability of these two transgenic lines is difficult to rationalise but 
could possibly be due to the consistently weaker effect of the Marf
RNAiKK
 being further 
titrated by the presence of a second UAS transgene. 
In conclusion, our data indicate that Marf plays a role in Drosophila locomotion 
and that down regulation of Marf, either in nervous system or in motor neurons 






















Figure 5.6: Climbing assay for Marf knockdown flies. n = 100 for each genotype. RNAi: 
UAS-Marf-IR. Marf-OE: UAS-Marf. ctrl: UAS-y-IR. mitoGFP: UAS-Marf-IR,UAS-mitoGFP. 
ctrl: UAS-y-IR. GD: UAS-Marf-IR(GD). KK: UAS-Marf-IR(KK). Data is presented as mean
standard error. Significance was determined with Kruskal-Wallis non-parametric analysis and 














Figure 5.7: Flight assay for Marf knockdown flies. n = 100 for each genotype. RNAi: UAS-
Marf-IR. Marf-OE: UAS-Marf. ctrl: UAS-y-IR. mitoGFP: UAS-Marf-IR,UAS-mitoGFP. ctrl: 
UAS-y-IR. GD: UAS-Marf-IR(GD). KK: UAS-Marf-IR(KK). Data is presented as mean standard 
error. Significance was determined with Kruskal-Wallis non-parametric analysis and Dunn’s 






5.2.7 Mitochondrial morphology and neuromuscular junction 
structure analysis in Marf motor neuron knockdown and Marf motor 
neuron overexpression larvae 
Mitochondrial morphology in motor neurons of Drosophila was analysed to gain 
insight into the effect of Marf knockdown in motor neurons. Mitochondrial morphology 
was observed in the cell bodies of the motor neurons present in the ventral ganglion, in 
axonal part of segmental nerves in abdominal segment A2 and in the boutons of the 
neuromuscular junctions innervating muscle 6/7 in abdominal segment A3. Anti-HRP 
was used to stain the motor neuron membranes and UAS-mitochondrial GFP transgene 
under the control of motor neuron-GAL4 driver was used as mitochondrial marker. 
Motor neuron-GAL4-driven Marf
RNAiGD
 larvae showed heterogeneous mitochondrial 
morphology in cell bodies. Mitochondria appeared fragmented in various cell bodies 
unlike filamentous and loose mitochondrial networks present in control cell bodies 
(Figure 5.8b). Cell bodies of motor neuron-GAL4-driven Marf
overexpression
 larvae showed 
elongated mitochondria forming tangles of highly interconnected mitochondrial mass 
(Figure 5.8c). Axons projecting from the ventral ganglion of motor neuron-GAL4-
driven Marf
RNAiGD
 larvae showed increased population of small mitochondria as 
compared to control (Figure 5.9b). Motor neuron-GAL4-driven Marf
overexpression
 larvae 
showed various elongated thread like- mitochondria in addition to normal mitochondrial 
population in axons (Figure 5.9c). The last part of the motor neuron studied for 
mitochondrial morphology was the neuromuscular junction (NMJ) where motor neurons 
innervate the muscles (Figure 5.10). Typical NMJ has several spherical structures 
called boutons which are the sites where neurotransmitters are released to induce muscle 
contraction. Each bouton harbours a number of small mitochondria to meet the energy 
requirement during synaptic transmission. We noticed no difference in the 
mitochondrial morphology in boutons of motor neuron-GAL4-driven Marf
RNAiGD
 larvae 
(Figure 5.11c,c',d,d'). However, noticeably few mitochondria were present in the 
boutons of motor neuron-GAL4-driven Marf
overexpression
 (Figure 5.11e,e',f,f'). These 
findings suggest a possible mitochondrial morphology defects in these larvae. The 
confocal images are representative of many analysed samples, but the changes were not 
able to be quantified satisfactorily. Nevertheless, we feel that this qualitative assessment 







Figure 5.8: Mitochondrial morphology in cell bodies of Drosophila larvae motor neurons. 
Representative confocal images from cell bodies of motor neurons present in ventral ganglion of 
3
rd
 instar larvae. (a) In D42-GAL4,UAS-mitoGFP/+ (control) larvae showed typical loose 
mitochondrial networks morphology (indicated with arrows in the inset). (b) D42-GAL4,UAS-
mitoGFP>UAS-Marf-IR(GD) larvae showed fragmented (indicated with arrowheads in inset) 
mitochondria and longer mitochondria. (c) D42-GAL4,UAS-mitoGFP>UAS-Marf(1) larvae 
showed elongated mitochondria and extensive mitochondrial networks (indicated with arrow in 





















Figure 5.9: Mitochondrial morphology in axons of Drosophila larvae motor neurons. Representative confocal images from the axonal part of segmental nerve 
of 3rd instar larvae. Axonal membranes were labelled with HRP (red) and mitoGFP (green) to label the mitochondria. (a,a') Mitochondria appeared as small tubules 
and spheres in D42-GAL4,UAS-mitoGFP/+. (b,b') D42-GAL4,UAS-mitoGFP>UAS-Marf-IR(GD) larvae showed large number of fragmented mitochondria 
(indicated with arrowheads). (c,c') D42-GAL4,UAS-mitoGFP>UAS-Marf(1) mitochondria appeared elongated and form long thread-like structures (indicated with 








Figure 5.10: Drosophila melanogaster neuromuscular junctions. (A) Image showing various 
neuromuscular junctions in body wall muscles of 3rd instar larvae. Magnified inset image 
showing the neuromuscular junction of muscle 6/7. Neuromuscular junctions were stained with 
anti-HRP. (B) Typical structure of neuromuscular junction innervating muscle 6/7 in abdominal 
segment A3 of 3
rd
 instar larvae. Boutons appear as round structure containing small spherical 







Figure 5.11: Mitochondrial morphology in neuromuscular junctions of Drosophila larvae 
motor neurons. Representative confocal images of synaptic boutons at muscles 6 and 7 
(abdominal segment A3) in 3
rd
 instar larvae. Two representative confocal images for each 
genotype are shown.  Neuronal membranes stained with anti-HRP and mitochondria tagged 
with mitoGFP. (a,a',b,b') D42-GAL4,UAS-mitoGFP/+ larvae showed small spherical 
mitochondria in the boutons. (c,c',d,d') D42-GAL4,UAS-mitoGFP>UAS-Marf-IR(GD) larvae 
also showed small spherical mitochondria. (e,e',f,f') D42-GAL4,UAS-mitoGFP>UAS-Marf (1) 
larvae showed few mitochondria in the boutons and majority appeared devoid of any 
mitochondria (indicated with arrows), mitochondria showed occasional clumps (indicated with 


















Bouton number and synapse branching are the two common measurements of 
neuromuscular junction development in the Drosophila larvae (Verstreken et al., 2005). 
The number of boutons was assessed as percentage of bouton count normalized to 
muscle surface area relative to controls (see section 2.10.3). Motor neuron-GAL4-driven 
Marf
RNAiGD
 larvae showed no increase in bouton count compared to controls while 
motor neuron-GAL4-driven Marf
overexpression
 larvae presented a significant increase in 
relative bouton count (Figure 5.12A). Branch count per synapse was unaffected in 
motor neuron-GAL4-driven Marf
RNAiGD
 larvae. In addition, motor neuron-GAL4-driven 
Marf
overexpression
 larvae showed small increase in branch count per synapse, however the 
difference was not statistically significant as compared to control (Figure 5.12B). Due 
to the absence of benign UAS RNAi control from the data we have limitations in 
extracting the conclusion from the results. Still, considering the results presented in 
thesis as preliminary, it is suggested that Marf is important for the normal mitochondrial 
morphology and for the development of neuromuscular structure in flies. The affect 
seen on NMJ structure could be secondary to the disruptive mitochondrial dynamics as 




Figure 5.12: Structure analysis of neuromuscular junctions in Drosophila larvae. (A) 
Percent bouton count for motor neuron MarfRNAiGD and motor neuron Marfoverexpression 3rd instar 
larvae. (B) The number of branches per synapse for motor neuron Marf
RNAiGD
 and motor neuron 
Marf




5.2.8 Effects of Ethacrynic acid on Marf knockdown flies 
We hypothesised that the locomotory deficit observed in Marf knockdown flies 
may be due to reduced mitochondrial fusion occurring in these flies. Since treatment 
with Ethacrynic acid (EA) showed increased mitochondrial fusion in CV14A cells and 
also reduced the increased mitochondrial fragmentation in Fis1 overexpressing CV14A 
cells and Mfn2
R364W
 patient fibroblasts (Chapter 4). Hence, we assumed that feeding EA 
to Marf knockdown flies might reduce the observed locomotory deficit. 




Drosophila S2R plus (S2R
+
) cells were incubated with EA to see whether EA 
can produce similar effects as seen in CV14A cells and in patient fibroblasts. It was 
done primarily to determine that the mechanism through which EA increases the 
mitochondrial fusion in mammalian cells is conserved in flies or not. S2R
+
 cells were 
incubated with 0.1% DMSO as vehicle and 3 concentrations of EA; 21µM, 41µM and 
83µM for 4 hours. In the presence of 0.1% DMSO S2R
+
 cells showed small tubular 
mitochondria with occasional connections with neighbouring mitochondria (Figure 
5.13a). Interestingly, EA showed a dose dependent increase in mitochondria fusion in 
S2R
+
 cells. With 21µM EA mitochondrial morphology appeared similar to cells in 0.1% 
DMSO (Figure 5.13b) but in presence of 41µM EA cells showed longer mitochondria 
with increased connection and networks (Figure 5.13c). Additionally, mitochondria 
appeared as aggregated clumps with 83µM EA (Figure 5.13d), a phenotype very 
similar to that observed in Drp1 RNAi S2R
+
 cells (Ziviani et al., 2010; Pogson et al., 
2014). Since this assay was performed to verify the conserved mechanism of EA, and a 
consistent pattern emerged, these effects were not quantified. Hence, these are 
qualitative observations on a limited number of cells, and while representative, without 











Figure 5.13: Mitochondrial morphology in S2R
+
 cells incubated with EA. Representative 
confocal images with magnified insets. MitoTracker was used to visualize mitochondrial 
morphology in live cells. (a) 0.1% DMSO treated S2R
+ 
cells showed small tubular mitochondria 
(indicated with arrowheads). (b) 21µM EA showed small tubular mitochondria (indicated with 
arrowhead) and long tubular mitochondria (indicated with arrow). (c) 41µM EA showed long 
tubular mitochondria (indicated with arrow). (d) 83µM EA showed highly fused aggregated 
mitochondria (indicated with arrow) mostly with perinuclear location. Scale bar = 5µm. 
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5.2.8.2 Effect of Ethacrynic acid on Marf nervous system knockdown 
and Marf motor neuron knockdown 
Flies were raised on normal food supplemented with 0.1% DMSO or 0.33mM 
EA and 1.65mM EA. These high concentrations of EA were used to ensure an optimal 
uptake of drug by the flies as no effect was observed with lower concentrations (data 
not shown). Additionally, EA reached its maximum solubility in DMSO with 1.65mM 
concentration. In 2 days old flies, EA failed to rescue the reduced climbing and flight 
ability in nervous system-GAL4-driven Marf
RNAi
 flies (Figure 5.14). In contrast, 
increase in climbing ability of motor neuron-GAL4-driven Marf
RNAi
 flies in a dose 
dependent manner was observed, with a significant increase in presence of 1.65mM EA 
(Figure 5.14A). However, increase in climbing was also observed in control flies 
treated with EA. Therefore, it cannot be concluded as rescue effect of EA on the 
climbing deficit of motor neuron-GAL4-driven Marf
RNAi
 flies, but simply increase in the 
locomotory activity of flies. Furthermore, EA treated motor neuron-GAL4-driven 
Marf
RNAi
 flies did not show significant increase in flight (Figure 5.14B). Moreover, 15 
days old motor neuron-GAL4-driven Marf
RNAiGD 
flies raised and aged on EA 
supplemented food tend to show slightly better climbing as well as flight in the presence 
of EA as compared to flies kept on DMSO food, but the difference was non-significant 
as compared to control (Figure 5.14B). 15 days old motor neuron-GAL4-driven 
Marf
RNAiKK 
flies raised and aged on EA supplemented food failed to show obvious 












Figure 5.14: Locomotion assays for 2 days old and 15 days old MarfRNAi flies fed on EA. (A) 
Climbing assay. (B) Flight assay. 0.1% DMSO was used as vehicle and 0.33mM and 1.65mM 
EA used. ctrl: UAS-Rh4-IR, GD: UAS-Marf-IR(GD), KK: UAS-Marf-IR(KK). n = 100 flies for 
each genotype per condition except 15 days old D42-GAL4>UAS-Marf-IR(GD). n = 30-50 flies. 
Data is presented as mean standard error. Significance was determined by one-way ANOVA 




To characterise the role of Marf on Drosophila development and locomotion we 
took advantage of down regulating Marf by RNAi using spatially controlled GAL4 
drivers. The data presented in the thesis showed that ubiquitous Marf
RNAi
 and muscle 
specific Marf
RNAi
 is lethal. Our data further demonstrated that Marf is essential for 
Drosophila locomotion, as nervous system Marf
RNAi 
and motor neuron Marf
RNAi
 flies 
showed severe mobility deficits. In addition, preliminary results suggested that normal 
levels of Marf in motor neurons are important for maintaining the typical mitochondrial 





 showed mitochondrial morphology and distribution 
defects and reduced bouton count in Marf
overexpression
 larvae. Also, we showed that 
mitochondrial fusion inducing compound EA has no effect on mobility deficits of 
nervous system Marf
RNAi 
and motor neuron Marf
RNAi
. 
Drosophila melanogaster larvae spend most of their time foraging inside the 
food substrate. In the late third instar stage, they leave the food and start to wander in 
search of adequate place to pupariate and undergo metamorphosis (Truman et al., 1994). 
However, ubiquitous-GAL4-driven Marf
RNAi
 larvae never entered into wandering stage 
remained inside or on top of the food, showed slow locomotion and the majority died at 
this forging stage. We have shown that these larvae presented an extended time at 3
rd
 
instar stage. Previously, a similar delayed developmental phenotype with prolonged 
larval stages were reported in genes encoding other mitochondrial proteins including 
mitochondrial transcription factor B2 (TFB2M) (Adan et al., 2008), polymerase gamma 
subunit β gene (pol γ-β) (Iyengar et al., 2002) and polymerase gamma subunit α gene 
(tamas) (Iyengar et al., 1999). Ubiquitous TFB2 RNAi and tamas mutant larvae both 
showed larval forging stage for 30 days and more. This phenotype is similar to what we 
observed in ubiquitous Marf
RNAi
 larvae. Pol γ-β mutant larvae enter normally into the 
wandering larval stage but pupariation was delayed by 2-3 days and larvae died before 
eclosion (Iyengar et al., 2002). Also, ubiquitous TFB2
RNAi
, tamas and Pol γ-β larvae 
were smaller in size as observed in ubiquitous Marf
RNAi
 larvae. Recently, two new 
reports have shown similar 3
rd
 instar larval arrest in ubiquitous Marf knockdowns and in 
Marf genetic mutants obtained by EMS mutagenesis (Debattisti et al., 2014; Sandoval et 
al., 2014). Possible reasons for prolonged larval feeding stage and smaller larval size 
could be reduced cell growth and cell proliferation during larval stages. During the 





stage (Mirth et al., 2005). At this point larvae juvenile hormone levels decline and 
prothoracicotropic hormone (PTTH) levels are increased in hemolymph. PTTH acts on 
the prothoracic gland and triggers the synthesis of the molting hormone ecdysone. 
Ecdysone and its active metabolite 20-hydroxyecdysone (20E) (collectively known as 
ecdysteroid) allow transition from the feeding stage to the wandering stage and then 
pupation and metamorphosis. Reduced levels of ecdysteroid were found in 
experimentally delayed pupariation (Berreur et al., 1979). Interestingly, Sandoval and 
colleagues have shown that Marf is critical for cholesterol storage and ecdysone 
synthesis in the ring gland of Drosophila and further reported reduced levels of 20E in 
Marf genetic mutants (Sandoval et al., 2014). Thus, the larval arrested phenotype of 
ubiquitous-GAL4-driven Marf
RNAi
 larvae reported here could possibly be the outcome of 
lower 20E levels in ring glands of these larvae. Now, if Marf is critical for fly 
development then why does growth halt at a late larval stage and not earlier? One 
possible explanation could be the maternal contribution for Marf gene product which 
would likely be sufficient to continue development through zygotic, embryonic and 
larval stages. Furthermore, we know the polytene nature of all larval tissues except 
nervous system and imaginal tissues during fly development. The polytene cells have 
only G and S phase and do not divide but the diploid cells of imaginal tissues that later 
develop into adult fly divide continuously and rigorously throughout the larval stages to 
achieve critical weight (Fain and Stevens, 1982). Interestingly, reduced cell number of 
imaginal discs prevents the release of ecdysone at the beginning of wandering 3
rd
 instar. 
Furthermore, arrested larval phenotype is typical to many mitochondrial proteins thus it 
also suggests failure of cells to cope with metabolic demand due to OXPHOS 
impairments (Iyengar et al., 2002; Adan et al., 2008). Also, Mfn2 knockout mice have 
shown reduced number of cells and endo-replication cycles in polyploid trophoblast 
giant cells of placenta resulting in midgestation lethality (Chen et al., 2003). The high 
metabolic activities of trophoblast cells make them particularly vulnerable to defective 
mitochondrial fusion, which is responsible for maintaining a healthy population of 
mitochondria that are efficient in oxidative phosphorylation (Chen et al., 2003). 
Recently, Sandoval et al showed that Marf is involved in storage of free cholesterol in 
lipid droplets and suggested an inter-organellar interaction between endoplasmic 
reticulum and mitochondria for lipid vacuole formation. They further reported 
OXPHOS impairment in the Marf genetic mutants however they did not show that this 
defect is a secondary defect due to defective cholesterol storage or is due to some other 
factors (Sandoval et al., 2014).   
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Our data showed that Marf is critical for fly locomotion as both nervous system 
Marf knockdown flies and motor neuron Marf knockdown flies presented reduced 
climbing and flight which were rescued with the re-expression of Marf. These findings 
suggest that Marf is required in neuronal tissues and its loss induces motility deficits of 
neurological origin. Other mitochondrial shaping factors such as OPA1 and Drp1 
mutants and mitochondrial trafficking factors such as Miro and Milton mutants also 
showed locomotive defects (Stowers et al., 2002; Guo et al., 2005). In addition, 
zebrafish carrying pathogenic Mfn2 mutations showed slower swimming ability and 
defects in axonal transport of mitochondria (Chapman et al., 2013).  
Furthermore, we saw mitochondrial fragmented morphology in neuronal cell 
bodies of motor-neuron-GAL4-driven Marf
RNAiGD
 larvae but the mitochondrial 
morphology defect was not clear in axonal segments and in boutons and might be due to 
the low expression of D42-GAL4 driver. Debattisti and colleagues have reported 
prominent mitochondrial morphology defects in motor neurons, however, they reported 
these defects in strong Marf knockdown mutants such as ubiquitous-GAL4-driven 
Marf
RNAi
 and nervous system-GAL4 driven Marf
RNAi
 larvae (Debattisti et al., 2014). 
Besides, Marf
RNAiKK
 line was not included in our data presented in this thesis rendering 
the data presented here as preliminary. However, it is suggested to include it in future 
work to make a comparison between the lines. In addition, elongated and highly fused 
mitochondrial morphology in motor neuron cell bodies in motor neuron-GAL4-driven 
Marf
overexpression
 larvae suggests increased mitochondrial fusion in these cells. The 
absence of mitochondria in boutons of these larvae imply that excess fusion is possibly 
disrupting transport of elongated mitochondria as mitochondrial transport machinery is 
unable to move large mitochondria. We know that Drp1 mutants also showed few 
mitochondria in boutons (Verstreken et al., 2005). Additionally, mitochondrial 
transporting protein Milton and Miro also lack mitochondrial population in axons and 
boutons of the mutant larvae suggesting loss of mitochondrial transport (Stowers et al., 
2002; Guo et al., 2005). It was shown in chick peripheral axons that either 
overexpressing Mfn1 or inhibiting Drp1 by RNAi resulted in long immotile 
mitochondria (Amiri and Hollenbeck, 2008).  
In addition, we did not see any NMJ structure defect with Marf knockdown in 
motor neurons but we saw increase in bouton count in Marf overexpression larvae. 
Sandoval et al have reported few mitochondria in neuromuscular junction boutons of 
Marf mutants and severe reduction in size of boutons and doubling in the number of 
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boutons (Sandoval et al., 2014). Marf genetic mutant larvae also presented quick 
running down of neurotransmission in the motor neurons depicting a reserve pool 
mobilization defect and reduced local ATP levels (Sandoval et al., 2014). This defect 
was also reported in Drp1 mutants that show normal bouton morphology (Verstreken et 
al., 2005). Sandoval and colleagues have suggested that this defect might be due to 
reduced number of mitochondria in distal regions of axons resulting in local energy 
deficiency due to reduced ATP production and increased ROS in their motor neurons 
(Sandoval et al., 2014). The increased bouton number in our motor neuron Marf 
overexpression larvae might also be due to increased oxidative stress as we have 
observed few mitochondria in the boutons but it needs to be shown. It has been reported 
previously that the reduced number of mitochondria present in neuromuscular junction 
could lead to Ca
2+
 homeostasis impairment leading to enhanced oxidative stress, which 
then results in activation of synapse growth pathways resulting in synaptic overgrowth 
(Milton et al., 2011; Vincent et al., 2012). However, motor neuron Marf overexpression 
flies showed normal climbing and flight (see appendix) which is different from drp1, 
milton or miro mutants that showed locomotion defects. A possible explanation could 
be that the adult flies may have sufficient ATP supply from few mitochondria present in 
synapses together with up-regulation of local glycolysis under oxidative stress to 
perform normal locomotion activities (Hansson et al., 2004, Adan et al., 2008). 
However, this question needs to be further addressed in depth by measuring the 





Also, live imaging to study the axonal transport of mitochondria in Marf knockdown, 
and overexpression could provide a more precise view on mitochondrial defects. To 
conclude our data is still preliminary as it lacks the benign RNAi control and Marf
RNAiKK
 
line. Also, ideally the mitochondrial morphology seen in motor neuron cell bodies, 
axons and boutons needs to be quantified to obtain conclusive results, however, 
technical and time constraints precluded further study to complete this. 
Lastly, the effect of mitochondrial fusion inducing compound EA on the 
locomotory defects in nervous system and motor neuron Marf RNAi flies was assessed. 
While the effect of EA improved the climbing defect, we cannot conclude that this was 
due to a reversal of the loss of Marf since it also enhanced climbing in control as well 
by an unknown mechanism. This effect to climbing ability is difficult to explain, but 
possible reasons can be that EA is somehow providing more energy and/or EA is 
interacting with other cellular processes in addition to enhancing mitochondrial fusion. 
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Moreover, we have not monitored how much drug gets into the fly’s system, so further 
assays using colour dyes in the food can be done to see how much food along with EA 
is taken up by the larvae. Although we failed to see any clear improvement of Marf
RNAi 
flies with EA it would be interesting to see the mitochondrial morphology in the motor 
neurons of Marf
RNAi
 larvae and see whether EA is able to increase mitochondrial fusion 
in vivo. 
In conclusion, in concordance with the recently published reports by Debattisti 
et al and Sandoval et al on Marf mutants, the data in this thesis support that Marf is 
important for Drosophila normal development, its absence resulting in severe 


























Chapter 5b: : EMS genetic screen for 













Drosophila melanogaster provides an excellent genetic model organism for the 
generation, recovery and identification of new mutations. Over the years, various 
approaches have been used to induce de novo mutations in fly genome but Ethyl 
methane sulfonate (EMS) mutagenesis has become established as a successful approach 
providing low toxicity and high mutagenesis efficiency (Bentley et al., 2000). EMS is 
an alkylating agent which adds an ethyl group to O
6
 position of guanine, thus creating 
O
6
-alkylguanine which mispairs with thymine during replication and results in GC → 
AT transitions in DNA (Pastink et al., 1991). 75-100% EMS induced lesions result in 
missense or nonsense mutations or may even destroy splice sites (Pastink et al., 1991; 
Bentley et al., 2000). Occasionally small deletions, transversions and frame shift 
mutations can also be recovered but in small proportions (Vogel and Natarajan, 1979). 
DNA alkylation is linearly dependent on the EMS dose used in a screen (Aaron and 
Lee, 1978; Ayaki et al., 1985). For a typical mutagenesis protocol using 25-50mM 
EMS, it is predicted that a new mutation is induced every 150-300kb of the genome 
(Greenspan, 2004; Bokel, 2008). EMS treatment induces mutations in all chromosomes; 
it only produces lesions in one chromosomal strand (Ashburner and Bergman et al., 
2005; Bokel, 2008). Additionally, with the availability of the Drosophila genome 
sequence it has become easier to accurately map and identify the mutations generated in 
EMS screen. 
Drosophila Marf is present on the X chromosome. To isolate new mutation on a 
locus on X chromosome is not straight forward and requires additional genetic 
manipulations to a conventional EMS screen. Being hemizygotic Drosophila males 
carry only one copy of X chromosome, therefore male flies carrying a mutation in a 
vital gene on X chromosome cannot survive unless there is a wild-type copy of the gene 
duplicated elsewhere in the genome (Greenspan, 2004). Advancements in fly genetics 
provide us with a unique tool known as compound X chromosomes. Compound X-
chromosomes also known as attached X
^
X chromosomes have both arms of X 
chromosome attached to one centromere. X
^
X stocks are kept as both males and females 
carrying a Y chromosome which during segregation is inherited by the sons from their 
mothers only (Greenspan, 2004; Bokel, 2008). To rescue the male flies bearing a lethal 
mutation on the X chromosome, a duplication of the region of interest on X-
chromosome must be present in the genome, for example may be on Y chromosome of 
the X
^
X chromosome stock. As a result of which, during meiosis this duplication 
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carrying Y chromosome segregates away from the attached X of the mother and the 
sons bearing lethal mutations can be recovered in next generation (Cook et al., 2010). 
Bloomington Drosophila Stock Centre has an on going project to construct 
interchromosomal duplications of the X chromosome called Bloomington Duplication 
Project (http://flystocks.bio.indiana.edu/Browse/dp/BDSC-Dps.php). The approach 
taken to generate these duplications is by translocation of large segments of the X 
chromosome on to the tips of Y chromosomes (Cook et al., 2010). Another useful 
advancement for mapping and characterising new mutations are the available deficiency 
chromosomes from Bloomington Drosophila Stock Center (http://www.drosdel.org.uk/) 
(Parks et al., 2004; Ryder et al., 2007). The deficiency chromosomes can be used in 
trans with newly induced mutation to identify interacting loci and characterizing 
complementing alleles. 
The main disadvantages of RNAi are off-target effects and it does not 
completely eliminate a protein expression. So, to study the knockout effect of Marf in 
Drosophila we aimed to isolate a genetic mutant through EMS mutagenesis. Ideally, 
from such mutagenesis an allelic series may be isolated. This would generate a number 
of genetic mutants which could be useful for comparison and complementation among 
the mutants. It is known that EMS generally results in missense or nonsense mutations 
and occasionally it may even destroy splice sites, therefore we aimed at isolating either 
missense or nonsense mutations for Marf. 
5.4.1 Forward Genetic screen for Marf using EMS mutagenesis 
5.4.1.1 Complementation test for Df(1)Exel6239 used in EMS screen 
Df(1)Exel6239 was used to map the mutations on the EMS mutagenized chromosome. 
The chromosomal break points for Df(1)Exel6239 are at 5F2-6B2 on Drosophila X 
chromosome (Figure 5.15). It completely deletes 21 genes including Marf (Table 5.3). 
Before starting the EMS screen we wanted to verify that the Df(1)Exel6239 is 
approximately mapping the same region and true to the position by performing 
complementation with another deficiency chromosome overlapping the same region. 
Df(1)G4e[L]H24i[R] is a cytologically mapped deficiency for 5E3-5E8;6B. 
Complementation assay showed that both the deficiencies fail to complement each other 






Figure 5.15: Genomic map for the Df(1)Exel6239 deficiency chromosome showing the deleted 180kb region and the genes in the region. The deficiency maps to 
5F2-6B2 on X-Chromosome. Duplicated region spanning from 5A7-6B2 is also indicated. This overlay also shows that duplication covers the deleted region in the 



















Figure 5.16: Crossing scheme for deficiency chromosomes complementation assay. 




+ males from F1 progeny were crossed with 
Df(1)G4e[L]H24i[R]/FM7c females. FM7c is a balancer chromosome. In F2 absence of 







5.4.1.2 Isolation of EMS mutants 
To isolate a genetic mutant for Marf we conducted F3 EMS screen targeting the 
X chromosome. Males were collected from a w
1118
 stock (previously isogenised) and 
aged for 1-3 days, see section 2.12.1. These males were exposed to certain 
concentration of EMS for 24 hours. After recovery mutagenized w
1118
 males were 
crossed with X^X/Dp(1;Y)dx+ females (Go). This Dp(1;Y)dx
+
 duplication stock carries an 




spans the Marf region as Marf is mapped to cytological region 5F4-5F4 on X 
chromosome (Figure 5.15) (http://flybase.org/reports/FBgn0029870.html). Dp(1;Y) 
chromosome show typical Y-linked inheritance by behaving as normal Y chromosome 




 males were 
recovered in F1 progeny (Note: * indicates newly induced mutations). The F1 
mutagenized X chromosomes were tested against Df(1)Exel6239 deficiency of the X 




 males with 3-4 
Df(1)Exel6239/FM6 females (Figure 5.17). 
Since characterisation of the Marf
RNAi
 showed loss of Marf is lethal, we 
predicted that genetic mutations in Marf would also be lethal. Therefore, F2 progeny 
was scored for the absence of w
1118
*/Df(1)Exel6239 adult females which could 
potentially uncover a lethal Marf mutation. The lethality of w
1118
*/Df(1)Exel6239 was 
scored by the absence of females lacking the FM6 balancer which carries the B
1
 (bar 
eye/kidney shaped eye) marker or mutation (Figure 5.17). F2 included females 
w
1118
*/Df(1)Exel6239 which did not show red bar eye and female flies w
1118
*/FM6 with 
bar shaped eye and red eye colour. The heterozygous females were then backcrossed 
with FM6 males to generate a stable stock. The other progeny in F2 cross include 
FM6/Dp(1;Y)dx
+
 males and Df(1)Exel6239/Dp(1;Y)dx
+










Figure 5.17: Crossing scheme for EMS mutagenesis. w
1118 males were fed with EMS in 1% 
sucrose. These mutagenized w
1118








+ males from F1 were set up in individual crosses with Df(1)Exel6239/FM6 
females. F2 progeny contains homozygous mutation bearing genotype w
1118
*/Df(1)Exel6239 
females and heterozygous  w1118*/FM6 females along with other genotypes including 
FM6/Dp(1;Y)dx
+
 males and Df(1)Exel6239/Dp(1;Y)dx
+
 males. Stable stocks for mutants were 
generated by crossing w1118*/FM6 females with FM6 males. 
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We performed 5 rounds of EMS screening (Table 5.4). In first EMS 
mutagenesis screen, 25mM EMS was used to mutagenize w
1118
 males from a previously 
isogenised stock. In F1, 349 individual crosses with Df(1)Exel6239 females were set up. 
This screen gave 85% viable crosses but recovered no lethal mutations over 
Df(1)Exel6239. During such random mutagenesis scheme it can be useful, though not 
essential, to monitor the mutagenesis rate. Since we were aiming for mutagenesis 
targeting the X chromosome, we can also monitor the incidental occurrence of mutants 
for known X chromosome genes such as yellow (y). However, we did not observe any 
obvious y mutants (data not shown), suggesting that the mutation rate was very low. As 
the effect of EMS increases linearly with increase in concentration, we doubled the 
concentration in next 2 rounds of the screen. In the first 50mM EMS screen, 500 
individual crosses for F1 were set up. This gave 69.2% cross viability with no screen hit. 
In the second 50mM EMS screen, with 500 individual crosses for F1, the cross viability 
was slightly lower 68.4%. However, in this screen line 112 came up as a potential hit. 
To achieve less male lethality and more viable crosses, in the fourth screen we used 
40mM EMS for mutagenesis. In this screen we set up 550 individual crosses and 
achieved 63.6% viable crosses. This screen was more successful as 5 hits, namely line 
52, line 91, line 149, line 189 and line 407, were obtained. We repeated the 40mM EMS 
for the fifth screen and set up 546 individual crosses but the percentage of viable crosses 
was lower 60.1%. Unfortunately, this screen failed to achieve any hits. 
5.4.1.3 Characterisation of EMS screen hits 
To characterise the mutant phenotype we needed to distinguish the homozygous 
mutant in early developmental stages from the siblings. In order to achieve this we used 
FM7.GFP balancer. Heterozygous w
1118
*/FM6 females were crossed with FM7.GFP 
males to bring in the FM7.GFP balancer in place of FM6 in F1 progeny. Males and 
females carrying FM7.GFP were then crossed to generate a stable stock and isolate the 
w
1118
* mutant males (Fig 5.18A). Mutant lines were characterised according to the 
phenotypes presented by the hemizygous males (Fig 5.18B). Line 112 showed 3
rd
 instar 
larval lethality for the majority, however, a few pupate but die before eclosion. Line 52 
and line 91 both showed embryonic lethality as we were unable to locate any non-GFP 
1
st
 instar larvae. Line 149 showed 3
rd
 instar larval lethality. Line 189 and line 407 both 







Table 5.4: EMS mutagenesis screens results. 
 
 
5 EMS screens were carried out. 3
rd
 screen using 50mM EMS gave one potential hit: line 112. 













Figure 5.18: Characterisation of EMS screen hits. (A) Crossing scheme to identify mutant 
phenotypes. w1118*/FM6 females from the stable stocks were crossed with FM7.GFP males. F1 
w
1118
*/FM7.GFP females were crossed with FM7.GFP males to generate a stable stock. (B) The 
non-GFP w1118*/Y males phenotypes for each of the mutant line were observed from embryonic 




5.5 Complementation assay for EMS mutants 
To establish whether the mutations are allelic, we performed complementation 
tests based on female lethality where two mutated X chromosomes appear together in 
F1. Crosses were set between males of each mutant line carrying the Dp(1:Y)dx
+
 
duplication with females of other mutant lines as shown in Figure 5.19. 
Complementation was scored on the basis of presence of non-balancer adult female 
flies. Three complementation groups were identified. Lines 112 and 149 failed to 
complement each other. Similarly, lines 52 and 91, and lines 189 and 407 also proved to 
be alleles of same gene by not complementing each other (Table 5.5). 
 
 
Figure 5.19: Crossing scheme for mutant lines complementation assay. w1118*X/FM7.GFP 






 males from F1 





female flies showed the deficiency chromosomes do not complement. In cases where two 
mutations complement each other adult female flies with both mutagenized X chromosomes 








Table 5.5: Complementation Table for EMS mutant lines. 
 










5.6 Sequencing of Marf in EMS mutants 









 instar for line 189 




 instar larvae as detailed in section 2.12.5. Genomic DNA 
was amplified as amplicons of 2kb for F1-R2, 1.6kb for F4-R3 and 2.2kb for F10-R5, 
2.4kb for F11-R7, 1.6kb for F12-Xba and 1.24kb for MfnSeqQC(F7)-R8 (Fig 5.20, 
Figure 5.21). Wild-type w
1118
 genomic DNA was used as control and analysed first. 
Polymorphisms from the reference sequence were identified in the progenitor stock and 
so were ignored. Analysing the sequence data for lines 112, 149, 189 and 407, no 
additional base change was observed in Marf gene sequence apart from the pre-existing 
polymorphism observed in wild-type larvae. It can be presumed that EMS may have hit 
other vital genes in the deficiency region 5F2-6B2. CG42340, kdn and dx could be an 
easy target to be hit by EMS because of there large sizes. The deleted region also 
contain a tRNA:CR32748 gene which despite its very small size is an important gene 
involved in protein translation. However, a mutation in any of the other genes in the 
deficiency region is also possible. 
5.7 Protein analysis of Marf in EMS mutants 
Protein samples from control and mutant larvae were isolated to see protein 
quantity in mutants. Western blot analysis showed correct banding pattern for Marf in 
all the mutant lines (Figure 5.22). However, it showed reduced Marf levels in all 
mutant lines. It is presumed that may be the mutations in the mutant lines are somehow 
affecting the protein levels of Marf. However, more likely chances are the limitation of 
presented data as it is produced from one blot due to time constraint. Therefore, for 
conclusive results to see that the mutations are affecting the protein level or not could 













Figure 5.20: Marf overlapping amplicons PCRs strategy. Amplicon F1-R2 is 2kb, F11-R7 is 











Figure 5.21: Sequencher® generated contig showing the sequencing coverage of control w
1118











Figure 5.22: Western blot for EMS mutants. 20µg protein samples were loaded in each lane. 
Marf band about 91.4-94.1kDa was observed in all the lanes. w
1118
 is the wild type control. 











EMS mutagenesis is advantageous as it generates irreversible mutations in the 
genome and can generate a range of mutations including nonsense and missense 
mutations. However, EMS mutagenesis is laborious and the random nature of the 
mutagenesis makes it unpredictable in isolating desired mutations. 
The EMS screens performed in this project were intended to be a small scale 
pilot screen to explore feasibility but in the end it was decided that it would take too 
much time investment to achieve the goal. Therefore, we did not proceed on further to 
achieve the statistically calculated number of flies needed to be screened to achieve the 
1:1000 lethal mutation rates. Also, as EMS causes mutations throughout the genome, 
this can complicate subsequent analysis. It is beneficial for the starter stock for any 
genetic screen to be isogenized before hand to ensure that identified base changes are a 
result of EMS mutagenesis. Isogenization results in identical homologous chromosome 
pairs. The starter w
1118
 stock that we used in EMS screens was a previously isogenised 
stock obtained from Bloomington Drosophila Stock Center; however, over time it may 
have acquired additional polymorphisms. These may even be present heterogeneously 
in the stock. Indeed, we found a number of polymorphisms present in Marf nucleotide 
sequence as compared to the reference sequence from Flybase. While we did not 
identify any putative coding mutations in our screens, the possibility that the starting 
stock may contain heterogeneous polymorphisms may have confounded subsequent 
analysis of putative Marf mutants. Moreover, while these polymorphisms are clearly 
benign to the animal, as the starting stock was fully viable and fertile, it is possible that 
other such polymorphisms in the genome combined with the Marf mutations caused by 
EMS could be non-viable. This could be one possible explanation for the failure to 
obtain a genetic mutant for Marf in our screens. Furthermore, we obtained less viable F1 
crosses with higher EMS concentration such as 40mM and 50mM EMS. The major 
possibility is EMS toxicity and male sterility due to higher EMS concentrations (Bokel, 
2008). For an EMS screen it is always better to start with a large number of males flies 
as EMS toxicity kills around 10% of G0 males and many surviving suffer sterility as 
well. Recently, Sandoval et al, have reported the allelic series of Marf generated by 
EMS mutagenesis (Sandoval et al., 2014; Yamamoto et al., 2014). It was a large screen 
for generating chemically induced mutations in X-chromosome (Yamamoto et al., 
2014). They looked at 33887 lines and identified 5857 lethal stock with 165 genes 




performed over a smaller region of deficiency chromosome. Additionally, they used 
lower EMS concentrations 7.5-10mM to avoid additional mutations in the genome 
(Yamamoto et al., 2014). Therefore, presumably the possible reasons for the failure of 
getting any Marf mutant in our EMS screen could be higher concentrations of EMS (25-
50mM) used to mutagenize wild type males and less number of individual crosses (F1). 
We characterised the mutant phenotype from hemizygous w
1118
* males. 
Drosophila males carry only one X chromosome therefore a lethal mutation in a gene 
would exert its effect in similar manner as in homozygotic females. However, the 
disadvantage is that the mutant phenotype seen in hemizygous w
1118
* males would be 
due to the ‘most severe’ mutation and so may mask other mutations/phenotypes of 
interest. Here we only made a brief assessment of hemizygous males since we were 
specifically searching for coding mutations in Marf which we did not find in our limited 
screen. If a more extensive screen would be planned, it would indeed be advantageous 
to characterise isolated mutants in trans to a deficiency. In addition to nonsense 
mutations, EMS also generates missense mutations and small deletions. Such mutations 
could be interesting as loss of function mutations. The majority of Mfn2 mutations 
associated with CMT2A are missense mutations leading to disease pathology. Most of 
these mutations are unable to restore fusion suggesting a loss of function or 
haploinsufficiency (Zuchner et al., 2006; Detmer and Chan, 2007a). However, the 
moderate size of Marf and the presence of few codons mutable to stop codons make it a 
hard target for our small scale screening strategy, though by scaling up the screening 
genomes and using lower EMS concentrations may be useful for further screens. 
EMS is a classic mutagenesis method to obtain missense and null mutations, 
however, several site specific mutagenesis techniques, such as P-element mobilisation, 
homologous recombination, transcription activator-like effector nucleases (TALENs), 
zinc finger nucleases (Zfns) and clustered regularly interspaced short palindromic 
repeats (CRISPR)/CRISPR-associated (Cas) system, have evolved in past few years 
(Liao et al., 2000; Bibikova et al., 2002; Liu et al., 2012; Bassett et al., 2013;). These 
newer mutagenesis systems provide highly efficient methods to generate loss-of-
function mutations in desired locations in genome, if one intends to generate genetic 





























The dynamic processes of mitochondrial fusion and fission result in 
mitochondria as long tubular mitocondria and interconnected mitochondrial networks or 
small fragmented units or a combination of both morphologies present in a cell. A 
balance between mitochondrial fusion and fission in the cell regulates the steady state 
level of mitochondrial morphology. Mitochondrial fusion allows maintenance of 
mtDNA and mixing of essential proteins and nutrients, whilst mitochondrial fission is 
permissive for selective removal of damaged mitochondria through mitophagy and 
allows distribution of mitochondria within the cell. A cell can show different 
mitochondrial morphologies at various stages of the cell cycle and cell processes to 
meet the diverse energy demands. Long and interconnected mitochondrial networks 
provide easy access of energy to various neighbouring cellular components such as 
endoplasmic reticulum to maintain Ca
2+
 homeostasis and to Golgi complex for the 
synthesis of membranes, to liposomes for liposynthesis. Whereas, small mitochondria 
are motile energy units that are easily transported to the distant regions of the cell to 
meet the local energy demand or can be transported back to the cell soma for recovery 
or degradation in case of damage. 
Primarily three large GTPases are involved in mitochondrial fusion; namely 
Mfn1 and Mfn2 which mediate outer mitochondrial membrane fusion which is followed 
by inner mitochondrial fusion mediated by OPA1. These fusion processes are carried 
out in a SNARE-like mechanism involving GTP hydrolysis. Unlike Mfn1, Mfn2 plays a 
part in various other cellular functions such as apoptosis, cell oxidative metabolism, cell 
cycle regulation, axonal mitochondrial transport, mitochondrial and endoplasmic 
reticulum tethering, Ca
2+
 uptake by mitochondria and endoplasmic reticulum stress 
(Neuspiel et al., 2005; de Brito and Scorrano, 2008; Sebastian et al., 2012; Debattisti et 
al., 2014). Mitochondrial fission also requires a cytosolic GTPase from the dynamin 
family, Drp1, which is recruited to the fission sites to initiate the membrane severing 
process. The association of mutations in mitochondrial fusion and fission proteins with 
neurodegenerative diseases highlight the importance of these mitochondrial processes in 
cell function. The pathological mechanisms for neurodegeneration linked to effective 
mitochondrial dynamics are still not clear. Oxidative stress due to impaired OXPHOS, 
enhanced excitability of glutamate receptors or enhanced intracellular Ca
2+
 levels pose a 
high risk for neurodegeneration. One way or other mitochondria are either directly or 
indirectly involved in maintenance of these cellular processes. Therefore, defective 




types. Neurons are particularly sensitive to imbalanced mitochondrial dynamics as it 
affects the intracellular distribution of mitochondria. The cell transport machinery is 
unable to transport larger mitochondria to synapses leading to loss of synaptic 
mitochondria, low ATP production and impaired Ca
2+
 buffering (Verstreken et al., 
2005). Loss of fusion results in complications such as accumulation of damaged 
mitochondria with impaired OXPHOS and also increases ER stress (Debattisti et al., 
2014).  
Mutations in Mfn2 are associated with peripheral axonal neuropathy CMT2A 
and its subtype HMSNVI (Zuchner et al., 2004; Zuchner et al., 2006). The disease 
mechanisms by which these mutations are causing the neurons to die are still unclear, 
and variability in disease severity has been reported in patients. It is important to 
establish how these mutations alter the normal function of Mfn2, for example whether 
the resulting protein is partially active or completely non-functional, and what effect 
such mutations actually have on mitochondrial morphology and functioning. The 
occurrence of CMT2A patients with compound heterozygous mutations supports loss of 
function as a possible mechanism. There are varying reports from patient data and from 
mouse models for CMT2A in relation to Mfn2 expression levels, mitochondrial fusion 
capacity and ATP production (Detmer and Chan, 2007a; Amiott et al., 2008; Rouzier et 
al., 2012). Mfn2 knockout MEFs show fragmented and aggregated mitochondrial 
morphology which was rescued by the expression of CMT2A pathogenic mutation 
Mfn2
R94Q
. However, it failed to rescue fragmented mitochondrial morphology in Mfn1 
knockout MEFs indicating CMT2A-associated Mfn2 alleles (here Mfn2
R94Q
 which is 
unable to initiate fusion on its own) are able to form fusion capable complexes with 
Mfn1 (Mfn1/Mfn2 (CMT2A allele)
 
complexes) and not with wild-type Mfn2 (Detmer 
and Chan, 2007a). However, in a PEG fusion assay CMT2A mutations had different 




















showed normal fusion activity (Detmer and Chan, 2007a). It is difficult to say from the 
cellular assays that CMT2A mutations are all non functional but they appear to have 
variable capacity of being fusion efficient. In the case of transgenic mouse models, mice 
carrying Mfn2
T105M
 mutations showed gait defects and neurodegeneration with 
mitochondrial accumulation in axons of motor neurons (Detmer et al., 2008). Also, 
transgenic mice overexpressing Mfn2
R94Q
 in neurons develop late-onset neuropathy and 




Recently, knock-in homozygous Mfn2
R94W
 mice die prematurely and showed 
fragmented mitochondria in MEFs, however heterozygous pups showed mild peripheral 
neuropathy (Strickland et al., 2014). Due to lack of other CMT2A genetic mouse 
models it is still not easy to interpret the pathophysiology of Mfn2 heterozygous 
mutation scenario of human disease in transgenic mice overexpressing the mutations. 
On the other hand patient skin cells carrying the pathogenic mutations at endogenous 
levels also have reported contradictory results regarding mitochondrial morphology 
defects (Amiott et al., 2008; Chevrollier et al., 2012; Rouzier et al., 2012). This might 
be because patients carry heterozygous mutations, the effect of which is subtle and most 
pronounced in the primary affected cells, which are peripheral motor and sensory 
neurons. 
The most widely used tools to study the pathophysiology of any disease are 
animal and cellular models. These systems provide insights into disease mechanisms 
but the physiological expression levels of pathogenic mutations are difficult to achieve 
in a model animal. Also, the endogenous cellular damage due to environmental factors 
exposure, other affected genes and individual’s age are not easily represented in model 
organisms hence limiting the translation of a disease in a model system. The ideal 
scenario is to study the disease in affected cells but sometimes the affected cells such as 
neurons, glia, heart cells, are not easily accessible to study disease pathology. Hence, 
readily available patient skin fibroblasts have been used extensively in the past decade 
to study disease mechanisms as they are easily available to study and are exposed to the 
same genetic and environmental factors as the affected cells. In this thesis we have 
reported mitochondrial morphology defects in HMSNVI patient fibroblasts carrying 
Mfn2
R364W
 mutation. Fibroblasts from this patient showed significantly reduced 
mitochondrial aspect ratio, length, bifurcation ratio and network complexity. However, 
cells from two other CMT2A patients with Mfn2
Q674P
 mutation showed normal 
mitochondrial morphology (Chapter 3). The reasons for using patient fibroblasts to 
study the mitochondrial morphology was easy availability, robust culturing and 
established assays with significant number of published data using them as successful 
cellular system to study mitochondrial morphology for CMT2A and other neurological 
disorders (Huang et al., 1994; Amiott et al., 2008; Mortiboys et al., 2008). The effect on 
mitochondrial morphology we observed in the HMSNVI patient is quite pronounced; 
however, one should be cautious about drawing firm conclusions as this data from only 




some other factor influencing the fragmented mitochondrial morphology in fibroblasts. 
The question still remains as to whether the mitochondrial morphology we saw in 
patient fibroblasts is typical of what is happening in the affected motor and sensory 
neurons or not. Interestingly, now researchers are developing new techniques to study 
the issues of disease pathology in the affected cells (Saporta et al., 2011). The 
successful generation of motor neurons from patient derived fibroblasts to study ALS 
using induced pluripotent stem cell (iPSC) technology is an excellent example of such 
developments (Dimos et al., 2008). This technology involves reprogramming of skin 
fibroblasts obtained from patients into pluripotent stem cells (Saporta et al., 2011). 
These pluripotent stem cells are then differentiated into various lineages including 
neurons and glia (Dimos et al., 2008; Ebert et al., 2009; Liu et al., 2010; Ogawa et al., 
2011). Recently, motor neurons derived from fibroblasts of 45 years old CMT2A 
patient carrying Mfn2
R364W
 heterozygous mutation have shown normal mitochondrial 
morphology but slower mitochondrial axonal movement (Saporta et al., 2015). Here one 
can suggest that the reduction in mitochondrial transport could be independent of 
mitochondrial fusion defect and is due to the pathology of disease. However, Saporta 
and colleagues have reported that these defects are subtle compared to what has been 
shown in motor neurons of mice expressing Mfn2 disease alleles. The possible reason 
might be heterozygous expression of Mfn2 mutation in patients (Saporta et al., 2015). 
Moreover, CMT2A patient iPSC-derived motor neurons were in a hyperexcitable state 
and had higher sodium current densities. They suggested that hyperexcitability of motor 
neurons might be causing axonal degeneration due to failure of sodium potassium 
channels and increased intracellular Ca
2+
, however this still needs to be shown in 
affected neurons. Nevertheless, it is an intriguing and growing area for model systems; 
therefore a suggestion for the future is to reprogram CMT2A and HMSNVI patient 
fibroblasts used in this thesis into motor neurons to further investigate what is 
happening in neurons. In addition, axonal transport studies can be done to find out any 
defective mitochondrial axonal transport in patient cells. Such studies in iPSC-derived 
motor neurons should be based on a large cohort of patient derived samples to allow 
comparison of several different Mfn2 mutations. 
Furthermore, it would be interesting to perform genetic studies in Mfn2
R364W
 
fibroblasts to see whether over-expressing Mfn2 rescues the fragmented mitochondrial 
morphology. Also, reducing Drp1 levels using RNAi in these cells might reduce the 




mitochondrial morphology is due to the pathogenic Mfn2 allele making Mfn2 inactive 
and giving fragmented mitochondria through over-active mitochondrial fission genes. 
Such experiments would give insight into the cause of defective mitochondrial 
dynamics as previous studies on fibroblasts from CMT2A patients have not reported 
such genetic interactions. 
We also undertook a drug screen to find potent fusion inducing compounds. The 
objective was to either develop a drug for cases where mitochondrial fusion appears 
affected, such as patients with Mfn2 mutations or OPA1 mutations, or to characterise a 
bench tool to study mitochondrial dynamics in cellular assays. We have shown that EA 
increases mitochondrial fusion in different cultured cell lines (Chapter 4). However, we 
were unable to characterise the cellular target of EA due to time constraints. It is worth 
mentioning that performing a drug discovery screen based on phenotypic analysis is 
useful however it could also be that the particular phenotype we are looking at is not 
due to the activation or deactivation of only one protein. We have shown that EA is able 
to promote mitochondrial fusion in the presence of Fis1 overexpression suggesting it 
might be acting on mitochondrial fission machinery factor and rendering it inactive. 
Therefore in future work, we suggest measurement of Drp1 GTPase activity under EA 
treatment to test for Drp1 function. Drp1 is major fission mediator and requires its 
GTPase activity to sever the mitochondrial membranes. Therefore, this assay will give 
us insight into the possibility that EA acts on Drp1 and renders it non-functional. 
Furthermore, we suggest using proteomic approaches to identify the binding partners of 
EA. Such advancements have been widely used by biochemists and biologists to 
identify the molecular targets for the small molecules and drugs. 
Drosophila has been widely used as an animal model to study various 
neurological diseases. Despite the fact that there are obvious limitations of modelling a 
human disease in Drosophila, various functional studies can be done in flies as 
biological processes are well conserved between vertebrates and invertebrates. In this 
thesis, we studied the role of Marf, the orthologue of mammalian Mfn2, in fly 
development and locomotion. We have shown that Marf is vital for Drosophila viability 
and locomotion (Chapter 5). Recently, two other studies have also reported that Marf is 
important for fly development and Marf depletion showed larval lethality (Debattisti et 
al., 2014; Sandoval et al., 2014). These studies have also reported intriguing new 
functions for Marf in the maintenance of endoplasmic reticulum morphology and 




al., 2014). Debattisti and colleagues have shown that Marf
RNAi
 caused endoplasmic 
reticulum and mitochondrial fragmentation, and hMfn2 but not hMfn1 rescued ER 
morphology suggesting fly Marf has both functions in maintenance of ER as well as 
mitochondrial morphology. Sandoval and colleagues showed that larval lethality is 
probably due to the defective ecdysone synthesis which is necessary for larval 
development into pupae in flies. Ecdysone is specific for insects but these findings 
suggest that Mfn2 could possibly be involved in steroid synthesis in vertebrates. 
Additionally, Sandoval and colleagues have proposed a model suggesting that Marf has 
an active role in lipid droplet formation and steroidogenesis. The reduced lipid droplets 
and ecdysone levels seen in ring glands of Marf mutants was partially rescued by 
expression of hMfn2 as cells showed normal lipid droplet formation but reduced 
ecdysone levels in ring glands (Sandoval et al., 2014). However, coexpression of hMfn1 
and hMfn2 rescues the defects completely but not Mfn1 alone. Sandoval and colleagues 
suggested that in flies Marf may interact with some other factor to promote steroid 
synthesis which is accomplished by hMfn1 and hMfn2 complex together. However, 
such findings need to be verified in mammalian systems as it would help to figure out 
how Marf is acting differently in fly ring glands and why its function was not solely 
rescued by either hMfn1 or hMfn2. 
It is clear that Mfn2 has diverse functions as mutations in this gene resulted in 
reduced mitochondrial fusion, mitochondrial axonal transport disruption, mitochondrial-
ER interaction failure, ER fragmentation and defective steroid (ecdysone in flies) 
synthesis (Detmer and Chan 2007; de Brito and Scorrano, 2008; Misko et al., 2010; 
Sandoval et al., 2014). However, it still remains unclear how Mfn2 mutations result in 
selective degeneration of long axons of motor and sensory neurons in peripheral 
nervous system. Mfn2 is a ubiquitously expressed protein, however high levels have 
been reported in heart cells, neurons and skeletal muscles. There are various models 
suggesting the degeneration or ‘dying back’ of long axons is possibly due to energy 
deficiency in distal axonal regions and synapses. This lack of energy might possibly be 
due to lack of mitochondrial population in those regions. In human motor nerves these 
axons are about a meter long and require highly organised and efficient mitochondrial 
transport machinery. CMT2A patient biopsies have shown clustering of small spherical 
mitochondria in the distal regions of axons (Vallat et al., 2008; Calvo et al., 2009). 
Similarly, cultured sensory neurons expressing CMT2A associated Mfn2 mutations 
and/or loss of Mfn2 (Mfn2
-/-




segments, reduced density of mitochondria in distal regions, slower anterograde and 
retrograde mitochondrial mobility with prolonged pauses in axons (Baloh et al., 2007; 
Misko et al., 2010). This suggests that the possible reason for axonal degeneration in 
CMT2A and HMSNVI might be mitochondrial distribution defect rather than 
mitochondrial fusion defect. Additionally, various morphology analysis done on 
CMT2A derived fibroblasts including our data showed no obvious and dramatic 
mitochondrial fusion deficiency in these patients (Loiseau et al., 2007; Amiott et al., 
2008; Guillet et al., 2009; Chevrollier et al., 2012; Rouzier et al., 2012). Also, reduced 
levels of OPA1 result in defective fusion and no affect on mitochondrial transport in 
cultured neurons (Chen et al., 2005; Misko et al., 2010). Therefore one can speculate 
that it might be Mfn2’s role promoting axonal mitochondrial transport as being majorly 
affected in axonal neuropathies rather than its role as pro-fusion factor. It has been 
shown that Mfn2 interacts with Miro 2 and Milton 1 and mediates mitochondrial 
transport in axons (Misko et al., 2010). It is suggested that Mfn2:Miro2:Milton1 





showed mitochondria spend increased time paused in the axons (Misko et al., 2010). 
This study has claimed that disruption in transport does not appear to be a consequence 
of attenuated fusion thus suggesting a fusion independent role for Mfn2 in the 
regulation of mitochondrial motility (Misko et al., 2010). A recent study by the same 
group has shown axonal degeneration in neurons expressing disease associated Mfn2 
mutations due to improper distribution of mitochondria in the axons (Misko et al., 
2012). This defect was partially rescued by either expressing Mfn1 or treatment with 
sodium channel blocker; tetrodotoxin (Misko et al., 2012). One can suggest the low 
expression of Mfn1 in these cells could potentially be the reason that peripheral motor 
and sensory neurons are specifically sensitive. Additionally, previously our group has 
also reported significantly reduced axonal transport of mitochondria in a zebrafish Mfn2 
loss of function model (Chapman et al., 2013). These findings support the essential role 
of Mfn2 in axonal transport of mitochondria and implicate a possible mechanism that is 
disrupted in CMT2A patients leading to motor and sensory neuronal loss. At the present 
it still needs to be shown that how Mfn2 pathogenic mutations disrupt the 
Mfn2:Miro:Milton complex in the axons. It has been reported that Mfn2 mutant alleles 
lose their ability to maintain the tethering of mitochondria and endoplasmic reticulum 
(de Brito and Scorrano, 2009). The increased local Ca
2+
 levels due to fragmented ER 
and lost mitochondrial bridging might be playing a role in stopping of 




and Scorrano, 2009; Misko et al., 2012). However, expression of Mfn1 in neurons 
resulted in rescue of Ca
2+
 homeostasis and mitochondrial axonal transport (Misko et al., 
2012). Further, the stoppage of mitochondria might result in hypoxic conditions in distal 
regions where synapse is taking place and resulting in local energy deficiency due to 
absence or late arrival of mitochondria (Misko et al., 2012). The recent study done on 
motor neurons derived from CMT2A patient fibroblasts have shown normal 
mitochondrial morphology but slower mitochondrial axonal movement supporting the 
idea of mitochondrial axonal transport impairments (Saporta et al., 2015). However, the 
precise mechanism of how these pathogenic mutations are halting mitochondrial 
movement remains unclear.  
Moreover, a simple in vivo model such as Drosophila would allow the rapid 
testing of potential drugs. However, in this study Drosophila has proved to be a difficult 
model. The reasons for our inability to see EA effect in adult flies are unclear but could 
indicate that there might be less drug entering the animal system or drug being not 
metabolised into its active form to act on its target(s). We have seen similar effect on 
mitochondrial morphology in fly cells as seen in mammalian cells, which suggests that 
the protein target sites are conserved in flies, however, why we were unable to see the 
effect on fly phenotype is unclear. If time had allowed we could have dissected the 
larvae and looked at the mitochondrial morphology in motor neurons to assess whether 
EA had affected mitochondrial morphology in vivo. It is also suggested that zebrafish 
Mfn2 mutants should be fed EA and see the affect of drug on their swimming defects. 
As an advantage, Mfn2 fish mutants develop normally into adult and most functional 
studies including axonal transport of mitochondria and effect of EA on it can be studied 
easily. 
In summary, in this thesis we have shown that Marf is essential for Drosophila 
development and locomotion. Additionally, CMT2A patients showed normal 
mitochondrial morphology and HMSNVI patient showed severely fragmented 
mitochondria. The reason for the different effects remains unknown and needs to be 
studied in large cohorts for a clearer overall picture. Analysing mitochondrial 
morphology and axonal transport in the patient iPSC-derived motor and sensory 
neurons would also be informative for effects in the disease-relevant cell type. We have 
also successfully tested EA fusion ability in various cellular assays, however, despite 
showing increased mitochondrial fusion morphology in patient fibroblasts EA was not 




transport, not mitochondrial fusion, is the most important process that is defective in 
these mutants. Further work is needed to elucidate the role of Marf/Mfn2 in 





























Figure A1: Locomotion assays for Marf overexpression. (A) Climbing assay. (B) Flight 
assay. Marf overexpression in nervous system elav-GAL4>UAS-Marf(1) and elav-GAL4>UAS-
Marf(3) resulted in adult flies with reduced climbing and flight ability. Marf overexpression in 
motor neurons D42-GAL4>UAS-Marf(1) and D42-GAL4>UAS-Marf(3) flies showed normal 
climbing and flight. All controls were out crossed with w1118 flies. n = 100 for each genotype 
Data is presented as mean standard error. Significance was determined with Kruskal-Wallis 
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